var title_f7_37_7760="Karmen cannula";
var content_f7_37_7760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Karmen uterine cannula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Karmen cannula used for menstrual evacuation. Note curved tip of cannula (insert).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7760=[""].join("\n");
var outline_f7_37_7760=null;
var title_f7_37_7761="Ivabradine: International drug information";
var content_f7_37_7761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ivabradine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2528297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Ivabradine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2676306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cardiovascular Agent, Other",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2528298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance for beta-blockers",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2528300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose: 5 mg twice daily; may increase dose after 3-4 weeks to 7.5 mg twice daily depending on response; may decrease dose to 2.5 mg twice daily if heart rate decreases below 50 bpm at rest or if patient experiences symptoms of bradychardia; discontinue if decreased heart rate and/or bradycardia persist",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2528301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride: 5 mg, 7.5 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10467 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7761=[""].join("\n");
var outline_f7_37_7761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528297\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676306\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528298\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528300\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821245\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528301\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_37_7762="Lichen sclerosis et atrophicus";
var content_f7_37_7762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosis et atrophicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAUIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDOb5X5xjPOB0NRyMcc5B9KJGCt8xPHTmoZGIwAcHPWvPPvmroSVjk/3u/NZmoOAMmrrn5SS3zdxWTeP2Iz9aaZNjMuW+X39ax7hssR3/lV+8cbiOvvWZINzFSaDGpohLdCzZIPtW3YrtxweO3c1Ts4Qzgfqa14ETdz1zyc4/KqRhYuwKiksAY+QNx7j2qdsqWAy+OhI/mabalt20DAAyVqe7jCzRpj5pBuGDwB70paiSsyfStqNJK43xxIWZiM4wP8T1q14U+TfIwxuO5ncgKPUn/PWqDfutOEDF42uHycdox3/E1uWtsPJjjVF2s20tgZK8U4rUwqtJO/UxfFQWXVSYpS8ZwCcEE/nVyG0ZLdYLYDe+CST0I9/SpJrEm9ijAGQxYnPQcD/CujttmYY7QecV+VmxlWPoK1jHU5qta0Ukc6dIMVn5rnncFGPz49x/KnafDIt0kSl1MigKFwOvrXQCSKKf52Eiq/COmQ2f5VXMUgEUsQPnbiBCCSQg6HPfFJpJmftZSVmMu5prMJEWEMqd4/vN6nI6ZrFjRWuY2ckAnJLJkZ7/UZqxcrtNwVmBMhOwuuWbHr9fWlhtpGQicq2zCYBJ28k1nOWprTioxGiCW5m8pwV6MpAA6989h7VtwS/KsSsXlT5Bt5zjPT2qC2ijVwCoCkE5A7+9W7CzkHzbVwWOXwB+A/Os0rsJSTWpoWrtFLG6QBiiksVPDN7+n4VdWNvs7pcIVlfBwBlQD0zUlraqE2cBTgvuyFH+NXY4QskqRIGRhgkD7vsK15GcMpofZ2jBPJjKBImz5mOH9/pViXTpmYlvmKxhjtfcUHqf5Vo291HDiRLcvlTGyBvlGRU1kX+y3TzO6yKM4bqMDgjH6D1rot0OXmd7mXLYRm1DpGS4OwM3AbB5rKnsoBBK0hZHRiFUgggevv6fhXWaSl/eS3EVuxWRgMqQBtGByT2PNYpjjZgkMglkJ3E5569SamWxvBtHEahZTxM5jkDLnb069D0/GuZurW5e6Ksvysf4Tnj616df2Wx1SSNohJna5B2t9D61jXlkI1md51SWBsGGWPB7dxxXPLQ76Vc85k0uWWT96xEedwJPGBzgfXFL9kjt7gGI5mRVJC9/Uk1197b+YXntm87yyT5Y5+XHJ59OeK5mKeR7xEQL5aA5wNoPHfHWo5jp5nNXMyz0yBp3ndEVGy2eSBntWldQNdW16VniQQIgCqeG7ce4qyhE8MlvHNt2tvIQcucevUAd6ecQIXaIFccg4K7R2PpzSlLSwop3uzP06SCKZEKhlLYy4/mPeqmp53SRRIfKUkLheQPT6D3rS1cWkh+0JH5e5wfLBGVyPukAfj+NM1Ri8W4wqm5FVtnOcL1qaemhq9WpWI/D+0qjg/fGMg13OnKCMgjBwATXnfh+UC6MLuRt4GfSvQbEu8PTC8bQRyfeuiD1OPFRaZV1KZjPhc7VPIJ5psDYUIFxkcnHT/AOvT9TO2dmA+RsBsr6VNbQrMiebj2UDjrSluTGyjcmsYvmEjuC6j5nI6t/n0qZZZVcvtMhkwxCc4zTpTGrxwxBjEOXKnBY/X0qY4jT7oLBtu0dCP88UbAtdRvlx/xvhu4K9DRUDSXe47Psu3PGd+ce/NFHuheXmcM8hfO05C9PpUUjHcSTjt9aQZBJzhj3xxTXfOcgfX1rM+kkrEFzIyLgj5fUmsu8mz/L8Kt3rN7kVjXcg28H3pkNlG5YHqDVeLBJx60sz5bk0kAywA6mmjmqO7saNkQpBK5Xp9a1o0yV6YPOPSqFugEa/Ly3IPY1fify1HOHyQcDPtVdCLFyy3B90bFJV5yeMf/Xq3dusEuJwjShFG3J/Tmn6WoNyqNNGhI5ZuMlumSe/vVK+ikurmVmB2hs5A60iG1zal2GR9T3yvCDKhRVAH3UXPP+fStMXTI52ESRk/d6lPfA6Vl6aWWNbZWARcneeufrjpS8B5QHZUHynZ0I9KqJz1EnoXLOKa+vJHXjGFwTjOfXiu5+yLDbwwWufLQqXK8D3J4GKwPCUG/wAtoI2LM4wMZwOuT37V3TqktvJK80k77QJVCFNpzgd+eCeTW0Foebianvcq2OeugUkkmZP3IwiluceuBVC5uDajzrZXfy1Chz0BPQGtC9miS2ZpiuwYO3dk9ewrl9Tm+1XBMYaC0J3CIHqelZzbT0NKMObcBt3JLKwkOTjafmJ/wqzEGRIy0e1ie464449ahtLYRLvBG9/mBxwKvRAxurvIXYEggjhR6jmsbNs6JNItWwaNVAhAk65boR3rSs4WlkWNSQuSTJ6+1VY5Ekxg/NjCbu1aemDaVUEgbj05Jz/k1pGOpyzloXYl3xsAG4UjOa3NL+SV5J4UmSOHkfcAkP061Ws/KhnXOI+oI64BBBqUXcIu0g2GONTlyzEZ9+fat0uXdnE5OWiESaeacsojHGCkaYC81quPLM0i3MG0xEFpcoC2OVHPPpWdaSGaQx2KOwaTKIo5lxyc+mBUmoxRRxiK5TzWSMMFHHlnPJ9iaak7aD5VfUqnU57eKUW9w8DSqAdmRkfXqOMYwRiqptYEt/Ot0mWYgvuOWD8/3mOe54p0jySSx24hWSSMFsBh0984yaz3uL6GVklVZLbJaSMvhgBx36fhWE5O2p20opppafqW/wC2pUtzFOIpYuQ0Miblj9Cvp19j0qhc6ZPbQyNNE8kUgBBBA3Z5GOp7elTK4h3XKL5p6CIJvJ7ksB1+tUrgahL5YhtisyAujgkkqee5P6Vm5cyuyox100OT1UGEAKN7OpATpgnI/Osmyt7iS0YuRiaQpGrN3Hf6AVsXKRX96sFxMQI1Zv3XLZ9OT1zTbmBTdRCcNFEnAAXkcfnnHvXMpXfKtz0FotSGytvLngZ4x8wbK55c9seo+tVppEMMICpwMqqnJfP8WMfyqxczi3lmjjt1dnjJUOckgdxjoDWcuVmEiI6JGgRDgn5j1xjp7VTvGNgSv7zFsI7ecSbisdwcFMscE1G0YMLqIl80McqCTtNTwCYgSMBhsqW2jjnjPpmtCVZpLl8xoshHzBByQBjntnryPWtYO6FKVmcdGrWuog92B5J4zxXcabetNbJj5WQYKY6/5zXJ6vCYWJlGAp3DnOR2xWposztakruLZHOe/Y1pHcVaPPBSOgudrZyeD97HUVMFaMqyI7IBwCc/0qtpjK9yxKrg8HcM4z1FbUMTMjYO142zvA6r6f8A66Hqcm2g20kVkP70kk4AA5x/gKkuwYoykoOE4Yk+n86baxv9ocx+WW2sWHTJ+mOCKjkmjnDgOMglCvUgjtS6FWsyISswBVwFPIyTmipViUAA7cjr85/xop2KuefSoo4AIHfniq85CABj+dX3RUG4cHHrWTfMGzyQR1PrUH0DlcqXUw8vGaw52yT1q3dOcge3rWbOx7UbmU9ERHn1xVuzyHGwbieMGq0cZJO49O1bFijIF2Lgp8xIHT61aOTfUljVi5EhA9BVuCHoD8wbkk8c/nUaKTgYIyOTngH/APVmr1so8wecGKnjceAD2zTKJYNzStM6qyDoF74FD3mLbaCQH44HX2qOVlO5MgHJ5Jx1plvbI9wqyzKqqpJbnC+5/kKE+hEoJ6s19PTbGyGUhzjKKuc98VEzLDK8RCsW5AwcVFp4ljlZpt4hIy+OpH+NNutxu1ljykYHAIyTz3oTsYyg27Ho3w4VPtRYxh224Qb9uGPv+fXH4V22sGNNFu2klQM0hG8qMvnGckHjHavIPDN5LbNPl8Fl2bmX5Vz7/TJzWprfieR7KLTLWQtArFpCRyxxwM9x7VtGqowseZVwc51boh1e5+0XMrsqx+adwVPugegqik+1wxIbK7V+hqCd5pIwzRsxc4VI/wCE1Fcq9raK+ATJ0H8Qz7Vg27nbGKS5TSS9QOwiAyOPXj2qxFPvYMWGw4Ueua4u5uWjYR7sODyc81dtLl5JI9rZwRx6Gs3I1eGurnoVpZLIu3dkgZyOfxrQsHWKdJM5YHgdPocf57Vy1lfAt5fmbs8HH5nPv/gauzapBkW4V1c4wxxkg+voKuM7anFKhJ6HXCSH95KEknmByuBhQfWrqWMmoRkSTxLKgMj+bnk46Ad/b+VcVBqEkkqiSbEYBLYPC4BAI9RzXS281sIPMVlkdsDfIxwMc5z/AJxW0ZKW5y1KUqfqX4rm50+JoN5QIuUVW2t1+baRk9O5qxb7lkimaWOZnUZ5yRxnpnkfXFcs7XL3DqXzlgCVGAM9MA/Nj8BWxbLC5jkXKTABtwPXnpgfrRGQpQ0NFUg+0Stc3UccQU4dEJZ/Zc/1xWdcu6q8qQlU4VSwyOg5P8/xrZu4XlETwxrggEk4wx64FQTS3DRgS7NqOVEh4Xtxjv0xRJXeooOy0MpnEB8m1ZDO64a4IxsBHIGD36Y/lWXqt08EPlWk8kybNoYKQVJ4xz/Stq7SOB2MRbEg3BdvT1/CsW4Tzbsyyq7Ahm+Xrwp/+sfwrCd1ojppNN3ZiWmnw29xIjyEx5DOY0BYMOepOaqXtxvnuo5VWfauVcqSHPuex71qSMv2ZzcR7d5Dx4+8oHb8feslbKRWLuQh24kABJweMY/EVzWV7o74tv4jHCyCIDy90zEEsR0HZff6Vc0YG7nhimnZIYzkkg/N9Bj8M1C1yzXUzorly+FLdAe/HY+9aeiK1vtLQtIHUys69WHc+mKqLk5eRpUfu+ZYuYYo7pvKV1id95RlwRnndjJ45qea1hHlorlkHGIzlgB1BxV27sXNvbuJvOaXISSYgfuwBnJz17fhTYxD5tuUh8tAAXGMA56ZrpVjgcrrQ5rXNLBg3KQTjJBHbPT9RVDSAtvczRFioC4AK5OP8jrXf3UCzwn5QQcnCjAGD0z9K5WazittQWWdC0exg2O3XBH44pyVjalV5o8rNWzhcxqu1FbqPlIGfQmtWBJJ4wy4K7shF6jjpVWwaOJ3Cj5ZGJjA/iHHGD+P0NXn22zhlMhUgHJGCV/vUkZtEcx2ZJRVbPzAknJ6fyrFjgZ5zKQcZP3faty5Uzqeq54yMkH3BrIt5PKkEIBYk/exk/jWcmdFNaEm5hwoOO2VFFSFoQcEnPs//wBaijmQW8jzue5JQEc9+ayrlzg5yauuCucHBIzyazb1tq/eyB2qj2JtLYybmQ55zmqeCWJLZB7cDH+NTzPliP61HGjO4RQSzHAAPemkctWV3Ymt0GVPQA9a1oQRGqAscnPXvis63BU8ghgSNuMkGtG1znGCzc4C8H34qkQy3Gq7fmyXORkDA9iKtW7xoyA7d3TI7/1FRrKBhs8jBJ9h1pWUNhCxZCdzbW/Dk+vvTYLXcbM+b53iYDABPG3Pr1q3bQHKljuY8ZJxnJNLbWzzXUXlJiYgKRnOOOvNaMESpCGKbw3VifvDGT/+upBy6CIhBxhS4zgdMdOnrT5IQ7hpsK27A47d/r3/ACqW2V/MEhIQZ3Egfd+v6VqxkR+UqgvtdpNjADhgA354pGTlymcyfZ1/dbCxGQWQHAweg7dutZtzEUiDoWa4kyWHoMY+g61vXBUy91jVgS3GVGR0+nasy7KTSySNI75J4YfN+OKm44ENjfyW8jmZhhTuC5yAf9qsjUdVuLmUqDEUU5BWPg067dt4jhLKwAMhB4BqJYVUoQpJz1JxmndspUoKXM0QWyNczqZgz4IBA9K14bRIyWIJUDAycZb0GPz+hpsVriZtiJ8xHzeg/pWxY6XK+FL5XBO32/xxipKnUSKqxyKhWM/O5GQDjAHqa2LLSJpVaS4BcsCWCjJYAY79eDj/APVWxY6MiyKxDYGNxXkgHOAffius0yALOgkUJG4MeDyMcZxVwhd2OCti+Ve6jH0/QbiKG2upbcwRGMSRlvmBByFyPXryfQVfNrBKsa+fMtxht8j42k44A9Pc10csy2du7M4uYFIQ2ykqhA5yx/AVS1a2kUmTy47NM/u4EYMU4zyO2evPWtXFRWh5rqyqO8jPu0EV+D9pF9GiBUl24Dr3Uj26VqzpeF0hvIGs7eWT5QUypAGNwI6nHXFRLDafaAcXRg8sNNDGd3PcbjzgnvUUtxdardxzkLwNrYISOJf7vvU3sLf5E4afT40leVZY3GwOrblbnHPcdK0Li8t7nTI4XZcxn5S2Nq55LHHUe3vWZFAyyRQ6oJFhli3/ACt0HRWwOg44pGgSYNBjzFjY7ip7n379KalK1hNRbuZ2sCIWSzbpvNeQrhFHlgcd/U88CsG4vHiWYCPDKPKKsc8Ec/p/Ort/PHNMnnGTbEdqRqe/Tj0rJu4wiErHIJELO6gYK8jAP6muaUm3c9KjTSirkEUkWbuNxJ5Q/dpEGxzj3+tVngkMg/dugmjBA3ctz8rA96JLiZ4JGJCEMrqwGCT7VoQWn2i8PCbHXeuV+7yM8eme1C8jd+7qc9cWkiSFDhFU72I5Kj0OKv2Tm3uFlL5UReURn5cbecH096sXdtL/AGhdy+XEkaEhm4K7vQg9qrR/6W0krt8zRFwEAG0j7ox2H0oT10HKXMtS/EGeJGRzKYwdqAZ4Oe39K0tN2HSWjaEtOjBwxIU4AAx+PpVOF57eGEW0QnZH8wK3LMR1B9jXQXEralqJuZxDG8/l+XDCfljAGCv/AOr0rWKv6nJUl9w2GMyjfs2P9548Dj0yOvSua8RWfz7gNik8jsCc/wD1q7m7guY9n2l1kVhjcDzs3d/bg8e1YOsWyhJU3bgylv14H8q1knsY0alpXMHR3iu7cR3IAliH389fQ/mBW3bsdke8qWAIYMfbvmsK3Ybi+QJYgEwRnI9/xxWoJkkwV3hgCSAM8+9YNnbKN2OmdrdP3jHb0GDgqKouYvtGY3UvjcFLAAeuf8avskMqBXKgMpO7aSD+VZ8iLBsRSWjK8ccipbNIdiYzOTnMn60UxWhCjFtkY/vUVd0T/XQ82lctk+nrWXfthDk4x1rRmkG0kLkeg7Vjai424HOT2qmelN63M9uRycfWlGc5HIB+lNwc8Cp0B2ZX5cHgGgw3HQglVUAZznrWhbHjKswUnb61ShVQDliD3AHSr0eQxLcgg9Oc8U7BvoaFvD8gDspUMGzk/Lk4ya1bKHEhVTknGDnggdBisy1kSN0BywyAcDnFbNmVLbmKgY+Rs9P8aZDuKIlyqlX3/wBwLlsZ/wAK0bKDfOpeFnBG0gc7h1PJ6Hp0qMNtWWWGVmwqs5YlDuI5C47A5FEdxvI82QnD/LuHTPoPX+lSxNtocFJfepbduLbg2B07nr6inEqS20iRTjcudoXjP6c/nT5/3V06BmYhiFOOPqPSo7ONCSSSHbIKMmQTkYzzwDz+VTYzcupO6gRMXjxEQpZnAyG5x9BjP+cVl3cYhiDO3lzNz8xIA5/I8VtzXCuzOyMAvOBk7G4HGeT261zWrCWWYfZ1Uowy2T09MikVSbe5Tt/30rrGgIbo27pWxHaLlfMGRjAGKr6ZbvGywgZ7sx/St1IZU2s4I3g7T6j1ob0HUn7wn9kLFpi3nmrGS20RkgYHYn61r6eqCFFBDORuKrn5R6n1rFlM9xDGHZ2iByEP3Se2fU10GniS2tt2z94+ASegA6j8sVKZhUTtqzbgWPyzFCN8juAMEYz7/rW/HGkdo9x96WLEaknpyQRj/Dt9awNNgUWrAL+8Y5VVP3ie30GO2K2Ybm3hdeAyCPIUP1Ydc/jxW8H3PNqrXQ1ItLkuNP8AJEgizOo+UDaxPcn9AKh1O08m9cY8vysNjPVh0OfWqsd40aJcE4SQfKAM7O4H6fpVu6uJNRtrW38sxqnJdQep7kdq10aMLSTKVwrSQWrCQNvVyWUAMCD1c9T7ZpzyXNvK1u0iSxqAEA+ZTjoR7+tal7bpc/ZQixQPGGV8nCkZ+XaD/k1M+pRQahFcQRbpSgQu+ecDbjHT3ocVfV2FzO2iMzUbAXNjJdC6AuNuJ4twUrgfmefSoNDheFI7+8TyRCuY04y8nbjuByfyq9c6RdyR3M0ewY/eZZgBtyTlv8KrtuOnxui7SHLZxy2QOntxWbjaV7Fp3jZM5q5gSSa8mnZmkOXckfeJP8yayXt5DsEZTa2cEHnkd/1/OuhkG+R1fcEDZfj/ADmqV/DEkKmOMb5iRvLY2jpknsKwsd9ObWhhGUxKS0FshBAZiuc46/hiqU88/mxzD5lGVXa37sZPX2rZewjO0zTxu2GUhF/dg44xVK6tMyvHHGEiwAcnOMj7xocWbwnG+hUt0kld0O1oipDhUUPz1OCPWrNtaW0cj2+95JQm1lHA2g9j2NX7O3S2EaOxkIG52cZKN7GoI4DDezyH95G24BmGMkDjNJRUdSHJtsjMo2q8UZZon2hG45I+9z3rUsnMU8MhY4UKyjaOSCc5/OqohedreS4jjEmON6j5l6A/pT5o5pFwfljcBAycAZOacW1qTJpqzOh1OWU3I8o/u9v3M8jnP+NYOo3rGSUoTtKkNz/StYOi2ELo/wA0bNFNg98cH6EVhTmJ7d2+bnIww71tLXYxoxV9UZdo3nK64XOQenJ4J7dqtRMIhj+It9zqT7VlWdw0atyfmXCsR0PT+Rq1GwMuI8nI4XP51g9j0OXU05Jx5KktgjoDx/kVXcFs5ON2SOCf85pmPmTdIBtUcdc+4oicSLvXPlrkZz0J9qjoGzCK4nMaFNwQgEDngUUiglQcqMjpk0VVpdirQPLZpBtIHWsa8YGT5jkLzz2rQun6+9ZYbfMxPJrbqdUwALbW6ggEcdamU4VSORnnFOVQWA+b6f5/zzT9uFCAAAH71MzGwj95gdPf+VXkUbVxgFjyO+fpVSMgyccjg4PWrltEJXOHC8ZXJ70IGaVvEVcHg8ZO0Zx/9ety2jhZlY5bnb6DNYUEoibGCD/dBxwByc+tbNu2Ybd8gtxggYBOfu+57U9yJXRLcMGiOflA525yPwHUfnVcyFn8w5bnLBuMN+FOcNJAWcBgM5YEcdz9etRfLG8avhC5y2eoH+fxqR6WL3mKbuKIn53TB5wASPfn/wDXWjBbEZM6SxzjDKuc78Z4747f55rmJpJJr5rgLvihxuBHoehrtdOkt79fOtSI2YNuWUkgtwRyPYY/HtTSuctaTgtDK1OZv+WbkyNySBj04x7f59qOmxrOkvmMc54yCc+wp+oia+vfJgjZjHk7V9OP/rj8av2tiYJEAISVSBsJwQT3xUta6BzcsLdSSG2CRrJ8uWYBV/iPuB6VYVySNgdiBgDHSrKYicHJDoSgI557mkjYI2du7nk5xuqJaEJt6j7Ozfcm5TlzhRg4PtitpIVjYpN820ABQep9/as2KV/lkDhRG2QCeSPata3VkQ3EwZlkOIz64qkiJt9TUso0Mss8sZFuilIwvGW7flVy0t7WTTraG8hUzO5KTAkEDgliB14BA+tYs8zsQhKkFgMJuPA/i6Y/z0rZsro27wyWsKPO0RQbm3Yyep7ZIx+ZrSLT0OWomtR807vewWdiGZFKLFGQOTnqeMfia3Y5l0bUJnfy3eRssiEgJ6rznJ61BAYzItpZoqTfM7ADo23OPXFRTuyaPKsrL500gYx9SCO+a25XFNnK5KTUbE+oPPrd00oENsIEA+c/wN/X6VBZ3ltFcrGyJJaoxwr5DZHcc8Z+tVUb/Q0jRysjT7mc8g8cAYq9dCz065ktEiEpIxNJKhy/fI56D2qL9TS1lYYJJNPMrsPMhuo2w23I2ZPXHcdO1VmKDTIpBuGyTBIb75PQAelTRXV5FZperhRk28hVPkYYBGeMY5xx6etZMo+zXkgLrLGcPEiE+XyT93IBBzwfpWcpWKjC5ae7FpFJ5KDc7FO/PHPX3rMWOFgY5FXDDLMpySe2MnH1+lJqdz5NrKXIe5DfLtzx6gfX+lc1DqM9xelGCeUB8jLnH+RWcp2djrpUW43R0IsoWRwZMMqbgv3g/I49uM1W8lo5WVoywI8skc59BTJZY4wPKLCPd+dPt5DaslxIN0LAt1I2nsaOZX0Q+VxRd0wGW1uLbMKupzGHQsZmJ5Ax0I69D6VnBFEQj2gRS44PrnBI/GnWs80ksTW5ML+YHWfoFI59eTWg+25ZJn2SSICREFJHHORj1PJpxfMjJ+7Iw47faTDI2QGZCGGcr2OTVqEsluwVN8rkOrA7goGc8dM8/hViG3QRK8kgYjOUHO7k4H0p89vw62r4lI3CIAEBuh/QCmo9QlJPQoT3DRCaVvLBfGUXp0/+tVGZRJbxlicuuW5+v+Io1XzIJPKuEEZXaMMPr1x3OR61Wu3Ms6KpZYlxjAx9f50r2Z0QjZJmHKzW5VC2TnDYHT6f/rqRJOMjG8Nycduowas6nalJFyp5BJKnvWcwDDyRjLDJKntUNWZ3wtJXLi3B3hgpKtwufT1qaSYxyvGFUdecZyelUWZAqnaykcH3/CoZJjFIGRtwU8E/rSsJK7Lf22cceZ046UVnvFIXY5c89fWinqPkieeXTnHUVXiQKrNkbienepLliCRgE96htnO8EdfzrTY1m7svhMx7sZPWmZ3lmYnd2qVVYx46D0NMkRlVWx1P50CCA84wM8HJ9a0I8FeCCeASBnPtWahJ6rnHcdK2dNiL+ZghAFLHPsMg/XOOaqO5MtNSFUBc7wV4yT1rorRlm063XajtHg4Q7TvxgZz3I9OlZcFm8hBY5QEbvVsnHH51p6falWYp8rhwyc4J9QT6dvWmKTTRLa5d/IVlGW2I4GBnGOc98dvSqV27GW5lQiQxARLnlW+nvjGKuXU1vBHcb8BnXaoBzjsR7/X1rGtT5izQgnzHcOv90HHp6dqV0Sk3qGnXBindmj8yNxghzgnvXbaTFPpNrctPCzQyp5kZxkEnsD+P6e1cBDERc7FR3kDYIJ4FeiWsc2p6bbvPL5cKSpA23PC4PQdh6nvxRE5sW0rdihp0JllSebcoly5Ze1XFhi+0edM2HKnaT1PoT9aW4X7JcS+SQEJ2f7vvj8M1Rlk3Fm81SB056/8A1qHoYRTk7l6SdWCsi5EX3yP0NN8zc20EhMZ5rOLyqGCEqHPzj1q3bSf6RGeiAjp3rJ67HQo2NdZVguMuoEb4IX8O1bmnh5li2bvkz5a1y+o36X0kFvFEYtrmSWQ8cdgK6S3ut1rFncZGQsMLtKBQFGT6cVUXcyqQ91XWpburnzJVRI1QbcYTqxz1rotMtIItM2h1e5DZlA6oeowfzzXJWEnmpDIgJYBnck/fx6Cup0yC0W0jknuNpLklg2C+QDgCtoO+rOKsuXRGvBPAik5zfBMkgjvwQW9celUpbq1ecWckYwG+Zy2GB/vdOntVlhpt5BJCMQXQZUE6dZM9j26cVQt0TUYrmOJIraSIgmZgWc4PQmtHJ7HNGKvdlpJkDKEiWK3hyYcqSA3TJPrQsN9O3mwss+1WILsB+7zgkg9vahr6Ozc2gCyRRffLjcrt1JI7Z6Yqtfvb38c81uRb3O5VjhVTsYY5xjoMc1MvUuKbexBNcNcXP9nW7eXCeAFOUA7Af5zVcSmzTz7q3xOBhVZc7T0P05zUUVvbS6jDFFKIoQCDKRgtycNj1qO+uXgMcU7rOiFvYNnuO/Tn61i31Z0qKvyopy2DXWmzXc10YXiO2NQuS45J56ccUaDpNnd2BnWa4tuoErqCJWPQKDj/AGsnoMU9ohcLA0pf7OowiL1Kjk9frT0R5ZJUCFyRtQKfur2x7YzUJRvqjVzlaydjPNjcKQgYBUcLhueSeta9vptrcmO0mYqjNsJbjP8A9aprizkt3RZT8zqHJPOAe9OiihtWFw7R3WQdgY4GR6iqjHleqInVc0tSjb2KRSi0JIhVyPXB7VoaCjLewBcRtErFG9c+vpxVHUd8bGTe2913sm7ofer9lpsq6b9tnukgL/uljI3E84JbH3faiGkrJEVH7t29ys1j9l2zTFSg3AIcMCD9P/rUllbTQRSqW8s+UQsh58wE5z9elWBbNHG0c+2cyY2qh3BsdKrztPJaxhHCPuIMbDGwD/8AXWkdDNty0OV8UCVpLZJ2Erg4LqfvHA9elSaXaiRDGzsjY6k5J/zmotb3OdpYFhJxnoT61q2NtHGizScS52gA8Lx/XNZx1k7nbJ8tJIXVLeNoRuQHK4aQDp61g2mkNNKZDEFDsQDjBGOoHtium1S1mgeOMiRUIyyN6Yz1qexIEqrlURicKcnHHaqaTlqYxrShD3TCbRIkinUxlhGQM7sZIrH1HQpprRJYQm3ktzyO9eiTwLCkbSKxkZjs44kB7+9R3dobWSN440YTdd38Cj61Tpip4uUXc8hZr1GKie5ULxhW4H04or0s6XE53mJctycPRWXJI6vrdP8AlPm68OBjAqK1GSOn40y5YnOBTrPkrxn8aZ3t+8acKkgYA56UtycRqSoAzjNOjUbQe46mm3TZRlDdvTinbQL6jLdhuIIBz681vafH5ifJ8i46MTx7iufs1LOAoJ7kZ68V02lj5GGEZtu3+ufqKaFM1dNgSR41kAIfKgDoSeBz65NPsYd925ZUKx4yq8ZbHJx9P1qSKEmQPsVQCGAYn7pOP/r1aZlj1QOkQEe4MpPI/wD10NmN9dDDvppJNSdJXwyx4Iz8qsRxj6Vns6wwSJDEp82RVjuTn5CvPH4EVZ1ID7RkAlnDHBG7LdACD29ajHnvbmznby1jffsxkqx6/T0pLU22RZsIFhh3SYZ2JZmPXrmvQ9KtrWHwnFKpeS6dy7oCOD2GD19c+n0rhFKhm24BZep/hHoK73wpaxjSUm3u0ysdwI6Ajt39citqa1seVi5aXM2/t5ooAJYvLklAkXnOF569uorAG7lyy5z8oPOOen1rs9cheaKNpsRNt2onOAo7/jn9KwLqJPOYQKY0THB5/Gs6isx4epeJkzSeUQuDu5JNT20pE6pwCcAdsZqC8jdsqrFiCTuPJqXTYCUWUjLZ49qxsd11y3Na0gWUHJHD7t7flW9pkLgPA3zpvIwg++Ooz7cn9Kx7EbWjj3bmbJk9R/8AWrsvCmowWNvcTPbo6A7RkA5YdR/KrglfU5K03bREFrAkTR26hUSRDHuboTx0Pbqfyq6th9vnwl4sXlttdnO5dgXjB9cj9acHikdbmUCFizHb12Z64H+etW7DTppwXWE/ZXyjlmwzcgg4/KtVG/mccp28jZu44bmws5o98sVtwNnTI559OQP1qC/iSfTYLlpltdvyyw7Sck5wQfXGetQCVIYha2bFucHDE/NRa3ELIbWZI5oU++0g+8T/AC+vtWt09zBRa2NK8vdHlgtzPbybm/eAD24zz61gXbBTFJZx+QJMqqZ3Ec4/Nq15brS91o/2RDMqbcPzGB6Y9KpStbG8gvY/kQY3QhRhGHHy/wCzWcncun7pem8PWy6VdRRSrBexz72BIORgcfTqRXNz+RaahIIR5sY/d+byob0NXXnkhjlErAzS8RktnvyzD6VBL5UOmXccaCZjKuWblgOegqZNdEXC63dyhbW0l1KZbhvKt4iCxJwG9B7k+ntUj313cspWNQss3lrGMKowOOO3FWtktx5UDxCBE+ZTs+6cDJz3zxUd1awx2yeVLM5LEvFIcLkY6Y+tZtNLQ1jJX1HajY3kMC3QdZVT5GA48s9lOaqWN6sd3bLdRiWNHGEPHvjPpWh501zA1hHGZbxBn5By6jkA9yBU4sRYzW9rdW8bzysHlXdxknAA91B5p2u7oV7Lllv+hV16CS+uYL5P3VtcDGwtuZccbcfyrXQNq+NLtwkQ2jY2OBt7kVXkEaX+bu3LWMnywQ7iTtB4Jx2q7qN3YafbJJoq/v5JMyS4ORjoP/rVqkleTMJybSivkQ3ltcabeRoyebb26hnOc5x1zWZLCZb+SVpD5BTzFkz8oz6k+mCPwrZmt4dS1N7wSq1sygNEBzkDB5/DP41HZafdTwXEXym2AJZcduox3HBHFaOJnGdvU4HxLEmA0RVg2AGVuT75q14flX7EpwGkR1wGPfnNT6wkTmOJQoiRduCc9yaz9BkUXpTIChs4B/WuZfGei/eo+h0us3K3N3tESgJgFjyf8aF00vC5DAuWB2/xYPSoYnjubqUlQik5U91A7it1olmdHgO1ZGUE54Bzmtox5rtnBOfLZIZ5O63gjBGY4sDIyxPcj2phtFuxbpIxGxf3jY61JJHJHe+ZhTk7GHXaKp3KiO4eFZnxgguoxjj09K0vboZpPozLmWNZpFSbChiAMDpmiot83Z2x2waKwOk+Xbg8nHT1qW12lgMg+wwTVeVgW6fhU1siLKGEaB/7yqM/nUHuX942Iz8h/wAear3B+bjAp+/5OM57EVXl+Y7sEYz0oLXcmsh+9B9/1rqdPj3JvJAZVGGAzjP9a5aw/hx94nGa6HTHC3MZBBBPIfpx0poU9TdBkYIcqhzgtu+92J9zVu8iCSWiFcl1bIGVB5yen9Oe/JqO2hjcqDwjFSecbQPf/wCtTtVeVBauXRgjEl0yCVx169MdMYNJtIwveSRm6mv2i7h83aqAgAgkL7fT1qtKspmllxmVssSxJz2rRuoJ5oEmC7RIfNJJPJ7Y9T7dBUEUMt3dKC2+eUAptP3vaiOpblZFe1ldpFRhuYjCk9vWvS/CsHmaY8XmFdu5yoOAQAuM/n/nmuE06GJr9lkQy4l2lUPzEjIwPx/lXa6MDDDNb3H7qQtl8HJAxwP1yfrW0NGebi3zKyLWtTF1E0yq+U8sEnC4A7Y9OK5iS4fzMKoRQq5Cfxle5ro9b3W4hYlCShKr19PmI6ZwK4y6ukid1SQPjHOO9Z1Pi1Fhoe7oOu33XALnKqSTnqataXIRHOnlKd6kKTk+WPbHftWIkslzOTH0C4LY7Vt6YoCBUyzE4IHGBWa1O2aUY2NO2R/mPVhgZPAxnBNa9jAsdvn5t+8q319T6VTRkiGMFAkeQSOW5yPxNaRZZLeJVbEzgySktzg89PWq5TmlIvRLHFYpK+9lyWKhuuCRj/d9/et60u7oWdukqeWLhS8kzjjZzwB7DHrn8KwC8k9qsTMCPlCcD5vqe4z/ACNaiJIolmKSs8Y2qkgyEHGcdvXArVNo45pPc0LQpcXKw2cEcKbPv4y248ck5A4/nVUC1hB+0ZuLiUlnCkqq84AwOp9asWck628kNzmG2KgtuUKWPVScde9Rswi1CFGAEMBU+btBLep9/pQ9tSY6N2KrC0LqGQxgYVQZD8x7E/8A1qkuIUS4WGRAu0jc0YIUj196je3+z30c0rB4wxIBAOSOemKS+cSgFJnNqjbAzngH0HpU6FpNtdikJoIp5ZSomQZCK/8A9ai2ZAq7pjGzHcx+9gfSpljjdclFOWwVA5dfaolCSx+XHAcliC4BGc9B+FS0zS5YiaS8mFnHMHJPyyP8qqO+70FSp50MqxRLDcOgJURjK9D83P41E80SxxxPHHGEBQmP5Scd2J/GpUZ7eK3RI3WSYZ3Dkvk4B57VICxSMiq88T+aTnLYz7c+1NtrkwmSF/m8w7mkAPynHY1pW1i017At++zyGGUPBfvxx0qlqEb21zeGWTczA7EDY2FvX/CtLNK5nzKWhHJeJFIilVk/ukj5l9s0/wCeNI47XLRMx8znj8anhspLbT4r65hFwQwCEHgc8A1o6W9jpd9JB5TXLSMGJbGIzjoPU+9XFN7mUmkroyceTbPb25YEndk8EHt+lFtcyLviSRw5G055yAP/AK9XteMEFw9zFIHaNgkm3uw79fw/CqSTQ/a1Elrse5XIkI59QQew/wAactGKOquYV0olDtjEx4A6dP8A61c9bsIdREQYJuGQxOAucg5P5V1eoR+cJCARknpj5enp+NcjerCl625cKD2JOfxrmno0enh2pRaOu0+5aQAgHy4Y9nT+HPX8a2HjjMdqC+2JD+Zz2rJ0RVNq0jtmZ1AQDpxWnKomt8tJuaHiQ7cZ+lbxeh51T4tCxJifzBMjIQ25StQS36TecbVvN+UR4aP71SiZiltclfLtS22T1J9PyqO+hhgCXtsVRNwxCjZbnpiru9yFbYj+1bflNpYgjjHlDj9KKDeROS5cgtyQQBj9KKrXuKy7Hxz5n7xeefrVmF9pHPT071mmTMiEA9cDir65HY1ynuwldsvpLxgMccc54psj/j1/CoY2wec092G/jp60G9y/ZpuwD+XpXT6VEke5nBD4AjYrwD/n1rnNNwWHbHeuqs+VQHLREfMqjOff86EFRs0bR2mDmQnb2yMDOMZPPTP+T0qzqUCvZeUFUhG7cnk+tRQKF+csBwSeOFOO/bPfHtVl4RJdopWOTeAwVc7SAMgn2x+VJmSSvcZcBBB5PnOqhhuKnjYOmM8g/gOKr2gjsZ471gY/Lk3Yz90dscfhWxd2f/EvaCNHYll87BUlgvI5+mOmc1k6lceaDaMoXaBEmQSQAcnA+pPNNOwl7ysWLScxX0t2dsUzztMMDBy3I/Pk1pDUVVBGm3zvNMkkh64/u+mM1zRnRA2EzOcBDnaExznvmqNletPfJZwBQs8oJkJyfetOZpHPKhzNs9J8QvBb6JZ3RY+fPE25mGPy5PFeY3V0bm4aNcDnkjt610njnU1iljt1YvDHH5cant7/AOfSuGtg+9n59RWdR3Ztg6VoXZ0umXMcUjW5IJbHPtn1rrfDflCG6kl2qI0zknhhnn9K88sYpTL5oYZRc812NhqqR6KkO0ZebLEHrgfdxjpSg7BiKba901IZDcmJGiYkSqWZW+6n93H/ANetqaxjTUmltmYo7eWgI6ZGSR+Oa5vS7sq6oPlBfzTzwAO/rW2dRDtFj5QjAqP7mf61Satqck4zvoa9msYkIQlkjYAe7Z/pXayXE9+ZYViCeSAzPx8x7f59q4HSpWNxtQLhsuXboMH+prore6vbiOGEo62nKZxjknjn6mtIzsjlqU9TXdIm01knn3LG29W7gnjHsOTVSWSLyLclI13v8mTnHv8ASoGk+z2s1qm6eZ3wzcd/5dKh2ok1pMhyE6huQ5Hb6U+bXQlQ6ssawFuLqd4QGfep/d5CntjHbn3qGBkWOeILG7K5kl4ynA4HPp+tR3Eyxo0aNguuWCnqxqr9knQRuVCrKBt5HzAfxEVDb5rotL3bMmmIcRSby1y7BVUDGD7Y455rVtIXgsTE5OXk5BOBuB6D9PyqhaxJY6mFuHDkZ2lc4Rj0Y8VbtLSfVLkpAxFvGpaRmOdnXntycHpRF29Qla3kNjiENxO9wizZyyZAIznuPStK31DzLSK8uEVkibZH8m0EH39Bim20tvZWO6NDcyRHl3HQn19uKrRXcs07yysr2xPzQjtxxkDt0qvhM37yehJMdTvFZo+VeQbFUDgEHBz/AJ+lVtXhVCTsEr/aNjbQSDt7nvmp5NVuLOyRIn3SsxzKgOAvYDiqcF28EUhjYvMZAwbGce/vTunoxRUlqW7i4ubuOPTYfL2TJudm4EbY556AfWodGubCIOy26+ZEgzcOxPPfirGi3Vk092k4Mckq5ZyM4OeRj3qr9p0z7JLbIoiDbt0rPyw7f/qxVrpJsh63jYozG2s5VZm87e/y5OOBzgjv1qW3nbY7XLbpT8yBhkgeg9BVPzIDIklmHZSCuXXJAx1xToR5gU8llUdef5VHNroacmmpJN5YWYx5wPnKjjnrXOQ2UV2WlkJXcSc4x/nrW7OEjgkyGEj8ZzwOf/11DpsYXCOd6tkucZwO2KxfvSszqpvkg2iXSwGiTcxEqSAMMYyBXU2NrGIZpF5TcVI67eMgmuVtZfs0zOse4E5APOMdzW9p0k8ce6Jy0EituGMbmPataTtucdeLYsssI8qyubfMYBOSSBnrnisSJIZVkWDzBvkyCcYVc8V0ttdrLEEmKCZVO4EY4qsscCTxxnapcFzjpWvLzasyU+VNCpptvtH7iQ8dfWiqZ1ckkpDcFexD8YoquaHYztUPidyQQe/qa1YjnGPxrInOFz2+laFnIGgQ/wBa5D36UveaLqjIGc/WklDLGr4GCSuQRn8vxFKCCAaZcN8y9etI6TX0pgX56jGa6uwl2qwbBB65Nclpq4YAg89PSuusCgVSQu49MdVPr+eKCpGvEGYDL7mk5+9jIHQ/l3/pzWkonIhf/VyISFyMIp7r/wDWrKtpUZ0DDEfAJKjPAPAPbIyK2DJ5cTsxTO0Yweo6YH4UMzbexFbXGI5UZFwpYhSenbOfX0NZuswxojSyAK75IeNsjAJIcEcHryOtWL1Shjw+7gIDtJOR2zTIrlHSQTjMg+bacEZyfz96lF2t7yOXmguGR/MwkrEHczY2qOv4HI5q54etAlxLeMC3lN+6bONx55A/A1oSgyyKu5RIrZ38AbMDOB7Yxn3q/JcLZWM5gRwDlIgFAyThtw+g/n71SJnUdrLqcl4mlM+qys7MQxGBnpxUcGxYEyxEmScbeo7c/nVq2t1utb2eaw8rBLYOWbqR65/+vTpoMu0wbd8205A+Xvj68VNuprFpJREtGaNSXyJWXIUg9PpT9J8zDO0gWME/ePPFSBTKQWIUnA3Gl0y382d4wGAjbuMY/wAKFuOT91m/YG5j8wwxJG0h2/Pxtxz/ACNVZp/s8siznc5TcNrc7j0zj/PNapaPToisM6wusJYuRkknqM9M/SsLT1kv9SYkyshbe5P3m9amRlTs7yex2Phoma3R3MjzthBtOAPx6fnXYx3TQKYRKzKi5YkgDPtzXJ6ezQqpOGeN+E38Z7e3TH61qRMJC/2iTYEyS3UO2eg/UVtF2WhwVo80rmwt2fLVEGRgliOCSaa7okMSIx+RS7YOc+n0rK8x3PzqVMmMAHGQAanJDXYIZRkYI5IpKVzFxsXBdhQ0jxqkki5jDH7nfp3Jq2kheRp5mO0AAbR3xwKxJ7hlu3fhlQ8nqM+1XWnM9qGkz524nPrk96pT3RnOnsye3vhHcNLNGZHAYYB5YnvWnHIbPT1G4J9qUsobpjoD9a5czQyuPMHYk4GcH0rRn1V7gxKqRJKvC7Ryff6VMZXvc0lS2saunG7mkC28flKjYkKjoO5Y/SrFsEWS5ksGllulfIZgANv+QKz9FNybwpMxRHBVh1LH/Oa0r3y9NhksbHc91MRukY8g9lH6/nWqWlznk1fl/r5jLyCRAz3FwSrpwq8Yc8YPpWfDN5BVYE81mbyiNuQR7e+aum3DWUhaZkZEwRnjI559+KqWUtnaXCxtF5gcBjlsEHHY+3Wlsx307mlb6WJluJoHMTj76MQc461n39lGbd5Su3C5Bx29aoJdXiXmTIzeaGjTY2Tg+oq9DDBAhh1W4KFwzSKjYORwBzVXUlaxFpRe5mBVW2ZLZ3J4DM3UZ7AVJIDYoUjdmlYHfjpg+lUvNPmBmBQcsAR+Qp11eh4N+7a7kg5b8vpWTklsdcabb1LF3IPKWE4DgZyf8+9S2U0SdeoXDDHX2rDlmLy7e+04OePX+lJBc7X3DGMY/GsYzSkdUsM3E3Lx4g6oqEKeE9z7+tLp2rf2a7RzZKlsgqeh71hT6oThfmIGecdqyZZ5DKGVnKg52noR9Kv2qi7ozWEclaR6Mup2l5C0nyISSpBNUWvLZPNQOXmYfIO2O/NcdHdkhg6+WT69P/rUrapsnRu/QsecAjrWyrJo5Z4JxbsdZDCxiQrwCowADRXPi+dwG84888Gir512/Ez+rz7nyZcyYzg+lXNEl3wEE8g84rGupRg/ezVrw5KTPMh6EZrNx9250Uqv75I6ZOvb196bJksOTj0pVOccdOpNNbrWZ6Rq2JIVRlvrnpXQWUhUqNw4HHr9a57TWU5zkNt+XjjPH5V0ljCCsbKxRu39cUGrsbti7vG0cIwAC3HUEc/jWo8pCKhbEDHcfLOeehz/AI1mWoVUDty3bjqfrUxKifCHMzchR9xf/wBVBmrXLrF9hEYO0sSir0Zun5CqF7CHjjcsN7DiT1Pbp2q1FKy5IHK4OE6N9fWollVpI2IDLgHaVyCvQcdRUoTbRHp0ewZumAZ2zvU8j1/HjP1NS6jauGXzHG0soRmOep4z+Rz7mrlsqlgrHL424HPp0Hrx/OqesqsVqyzPsUZwQM464H5n9aZle8jHt0ZUleNipklIDZwAOQVz2zz09auLaxrYclFkzgApyoz1zVWCfFmItpBUDcG657Ee/b8asJcStIIShAdR5gzyy9eo+lM1d+gxbWR7aOVAqITtUjgnA6//AF6taRauqTTcFXfYCfvE96uWlrLcwzTMrbYxzs4AB/lV62iiICwK7SPJlOPugev1pW1M5VNGivPpSXlzEvKKdoJJ6t3NasNjDa3wGnMWjtlIklkHDMDzj39KsJH+5ljhWPdEC7sx5JHv9MVagtZnPlStGVZN/AwOfai2pg6jtuLc2ablkiZtjDzGZjzn3oIh+zszqCFwoXOCfc1Z09ElmCS5WIYDZHYen6UXVvHcXj7VYwp0A43AdB+lU1daGan71mPsLYXKxs3y4U4GeQB3qWUJEruoJyAFX+9UlnE8dk0ikkynarMcbB/FgflUVxdDB2gHaNq+v1FCskRrKTKYTZbHk7+u7GMCrNo/lusjwiZBgAEkZP8AhSGS3SNPN3KkwIX5atLZ7VdrRvPhhAeVHIyg/rSS7Gsl7uvUpTiZ43lMRSISHayj5Sc9B+FX7Db5RmliGCMK/TgdatSX/nRRQbBHbhsiNUA+b8Bmo5/tJwnK/wAW1RkKPpVKKjtqZSm2rPQntr5WmMjEwxF8YHJA9RU41JZZ3lVCRHnD93Pb8awjZvN5r2yOXwGG3p9T6VbsdN81ifNEQjIMh3ZJ9gKcZyeiMnTgtbircFTvuVcGZuink5/rTLwCOMzwqVVn2xrnJxjnNS3dnarc/uXZ8HzDuBG3/ZxT1iE8m2Y7R8pAB6f4ClZ7A5JamfaTyQSB1J39ASOB7e1T6nHIzSyysGkuHwrhtwxnkmrBSKG7kdUwkXCqDnn/APXWZqMqRrCs+XfkhCeAT64p2sgT5pKxnXpkikKI+QjAg4xx61n3VyZbgHYTjg49PpRqNyzXSh12tsGVB9v85qO2ZPP3Hk9h6e5rmm9bHs0I2jdl6DEkjFeVwMBu9TbQ3AYlQMfSooXHKkbmz1xxTw4J685xx2rK/c2fkK0G1iPMGT29R71WeM54OQef8irLSqnyx5Yg8dgarGVd5DDJJ7d6ZKT6kXlE7hJwQc8VXnG1SsgynQEDkZq4sgbGDz2war3DedHjgkDJIOKuKMZvUz/IH/PRP++6KcYRnlefbFFWVzeZ8sXEuWq94fJW857rWcil24rR05tl7FgjA9TXe17rPnKUv3ql5nVpncTnn1pXBD/yqOI5QEGpWBdlxzjpiuQ+gNHTdwKg5xnt3rq7DGBtwpPIJ5A+np3rkbJxGQD8yk5/D2roLS5Ox+crjA+nQfzoNGnY6JdpbywzNhs56ZwR0Gf0zVrepwYvmIB+UDOPUZ+npWRbyh33D7xAKjbgA+vX/wCtWmDsgVh9xchQePlzx9f0oJ2J45MqiHDOvKAnsOvb/PtRaPuu2MkmHLHJVfm+maihypkljUjOef7v0OeKF/dyBkJjkEeQPU5wcGkTJJm0MJCzKWRU6EEgknOcD2/rXNeI7lmigjIALYOBkZAOPzrakvAVZFJkIwCewz3z07dfeufuY/NnYEb3IYlew/HNNsVNWd2CRq6xgkRcH74+UcZ7D2H51KI/LUvGSJMZkbud3G0fhnNKvmhE+RGwuCA3Ge3X9asRQqzoRggEFlUZCk/560i72NfTYruWyuEEoNuGDSP2LgZAzV/TIp4mEjjlV3cds+tQ6cDcwpDAB5ZYdMncfpWugJka3ePaAd7lc856D6UzjnLVomtYgloWZGZ5jgsw4GavyiOKdI88KOMDr6fnTnxJFEi5/cjP3uOO1R2zJvMrMCedq/3RTatoc976jnIURx7BuH3gerE0y7ZUkdcEFccDgZqZXRPLBIMRbe+etTRW7XRaWRtkYOSxXPHYUWb0Qcyi7sqo+NPkJkfa5wFA64qBZ40lVss2RjkcL6nFW7q3FtCsjyKofOPz7UxPs4aEyMoTbyRyef8A61JvXUqLT1Rh6vJLLeidpoYrfy22J2+Xt7E03SLiQIHuABjOAevPqfSt1bFL2d/s6IYwAUknAH4kd6pTW01hqAkjljQuoVgUyPyOeKm2tzuhUjy8rNO4ncC3nilyjL6jdkdSB6Ukd6+JGjDsFGWct7c1n3UElpMJm/1gIO3GBz6fhirkcce4B5d6Ow3BB1GBmm2zncIWLMV7dQqQjfLKAOOOKksdSm0+R5LdV3BhwQGwce4q0LeB7ad4CkSpH+7TJ3MQeMn8azVXMaeYpVmbDex7ZqruOxz+7O+hWmnuLi5d5nbezFyzcbqWS+ZmJWNmkddpGTwB396dcQtKHO0jacgr0xU8cTpLF8hO1crjkioTbLly2J7XU4ra1k8sFZpBtD44x7iqqG1NqXEg+0tk8oQA3c1E8Q6ZPDE8j0p08bPCFBGFPze/vVqTZjypbGDqsaSy8DAzgMecYFVEhKEFWw5I98Cta6h2sclSFG4j+VQQgR8scKWzjtmspRu7npUqlo2IYmYDBAG3jPPNT+YAvHJx94nk1DgGZm2Fvr+PFPU/I+84Xr9axeh2bojlPzbVIYA/exULxY+bBZlOQwNWhECUG7PPGOBSuMZ+XOAOtHKS59EUw4LfIwJJwOM/zqNdp3buWwOv09KliUfNxjJ4HBNTeWJG+VlG3Abn9KtXMajRAFyAQoI9SRmirbWqliSozmiteVnP7Q+QYhtXJqaF9k8Ttxh+aY5HYcetNY4dTwcGvRa0seGnZnXQMSvI681bgJMi8c+1UbYkxKeCev51dhHzdeB3zXAfRR2LapzyMA89elXRLsKByNuTwOoqtAAck8kdAKcseXBHHrnpSN4nSaPPvyrHJ2kbT9OK6GWAsjMq8DgDPP69M9K5vS7fPIA8wEA4PrXWojQwZMjMesmBnOO1MwnK0tCq8geTYB8h4I2ngH269PrSpuk8qMFGLD5Hc7ccZJP+FMizgllyobdnnLfSrLtkMxwoZsjHPX3/AC5pIdyM3Ci1YSKwQ4wR0Dd8/pVNyCCyAGOMZ+Vxnkj8xnFXbhsxqB8zDjaFI3e3T8ay5VjZwwL9R90Yxz6fWgS11LVuxl3B2JLZyQOPzq3APJDKhVcnbIRkKv4dSO/FU7WBVJWMtycHBBGetacal4lQMXB/hI6D60mVdFjRNRSNELbmljO1MfKDzxnvXS28qmOcKN7vJhpBwo9h/KuaggRHRnVd25eBwXHpn1rVsbpdkUcigeWSxGep7U4u+5jWgt4nULIWjTzNqRkYyFyoqFlidwkEW/y15Y/xHHX6VU+1POY3nYkRqFRFXGanlmNvE7/KskmcY4wDVuzOJRsP2kpHl1YuMMCvQe2O9SwzBSsQdh3Zdxxj0+tQaflH8zyS6kbVJPQ45Iq5MLaMK0XzSMcMhGdwx1NK3Ucn9kmuWYXWZAgIXkFcqgPQD3qrptpC/nvIu9OqnJBJ9fpT/tgi01o18tnds/NyS3t9KclwI/LiiDIPLwxK549f6UNK92Qm1GyII13MPKbYoO0jJ5PtxVgRRy24QHdM+RLJJ1x7UlvGRB5h6KMcf3iasvAEbzAcx7MHvn/JpqOgOqloJrcUsi24lA3tGrIgHb1+p9KGtXhNtAgD5GDkgbSeTU1i7ol1dTFnlVQELdQB6UkMiKhuWLNNI2VVume5qnZ69xc7St2LUSQrG1tPGsojB2ybsZYdPpWGbhijARh+dzZ59v610F55TQx3EgWOVm+eIDrx1/lVGztVa+xbqEQDA3HkmlJXdkKMkk2ytCHktvKXCRk5cnt9anhSWOUqJVTy+N+evtVmeaG0uTHavuP8bsMjJ9KymkZm8veCpPDDrTVo+ZDblrsS3sMWxmDbmLcc9aoNuhEu/dlhsQDtzV2+Gwxq4KsRkDocVmXN5iRfLXdj8lqZtJl0k2Vn2qFSRh8pJJxkmmMqiM3DKfMxtVB2/wAetNkkjJbzW/ePjI64qncXQj3FCdw6Z6Cs20j0acHIaGHmHG7ceDn/AAqWIqGBbkYOMntWWhYySbjhj83PU+1TxiRcrlSM8f8A6utc71dzvasrGnhgVZQMYz7U5JFyVYEg56joaSD96u1R05xmi6CoRhhu29AT+oq3Hqc1+jI5Fy6jq2cfj/hRtdEIGAM8nb29/Wp1QNGCBtccjgkmmMGdckEHHX0FCMZMqY9wfwoqby3PIbj6H/CiizHc+QyeTTVG+RVA5JxSSkk9AKfZ5+1wn/ar1pOyPn1q0jr4QBHgduKsI2Bkd+tQRE7ecYxUyZOOec/lXAfRRNfTU3uC2cdMA96vRwyxTGMY3Dk4OcDrVPSj++RWUBcZPbIrq0jBTzn2nBwNx9sjNFinKzJ9HhkgXAciUnawQYyMdMfp+NaMrmUtGrkAj5yB0PXbjt71RgkEQYgAkD5BnqexP402SQq7qWk3uR5gDcknnJB7/wA6bsQotu5ZBRN0nmKyJghsnjttAParHmLv3I0alOuWx9enpVLfH5iIrEyPk4XBJ9ST2qZ1R4Y9gbOeEx1B7Uhvcdd4ji+/uBO4MGGT68fl+tYX2lvPaNkKp1461r6hIIbTbwkbDGBzk/5xWBaxiS5DEgegA/nUlw21Nu2CuQg3jjnYvJ+n4Vt2xLhRGW2gEfezwe1ZNraS5BypUjIX2+n+etbEWdgwN4x8uT96kyZPsOeJ2j4ZR7bqW3Dxk8ttxwRipghygKAEHAJHT6etO2bpEw5AA7nj/wDXUbbFp6WZfgugpJkI5XB464qW4vo3QNJ8zADHP5CsyRRtyuTjgn1pmxSMuByeVBGPy+tP2j2IVCL1NyzuCQv7zCueeenrVuKcqwdB/uHOBgVjbmeRRH94rzxgD1q5Yzy3EUxQL8iA5bpt5/8Ar1pFnLVhbU1oVRwCpGwHDerGrFrbol35GeS4BY88Dmsi1kEMEe6Rt0hGQ4wMe1b+mp50V1P1yML2yPWtYJSaRwVpOF9SS98u1uBApBh+/n+8feojKXZoc7AADg9W9BUU8kbywg/MyqOcc5qveMsQDLncflbngU5JK7Ji72RcuL5Yz5Y8v5osEe1Q211EVUou0BcMR3rO3Rs7uzBQB6ZxT4JY2LsSFPQHp+lZuTvc6FTVjasXE0m5s+WrfMf4aug/ZpJGhDMEUkbhwcmseTUB9nSCIfuk+Zhx/k1sXGqRQaRgRRu7odm459OcVpGz67GMk00u5VhtJpY45iu4M5AAHPqeKrTl7dvniIDZKbxwcelUIrmTy18tmDrgZBxjNSre3luiy7POj2+Wpfovc1nzX20NHBpivc5umluN0zkDgnFVriGNLZ5iOM7tvfiqGozyJqEolkAJG5gp4BPaq0l7MYxucrDjPTPIqXPVpm1Oi3Zozb6WZbhwvzIxILAdKrZDNhjjngipARPcSFvmYjIJq4sIVcsSx6Ddngelczep7MbRVgtE8xcucADG4nGKaY8dNztyQBxx/hU8f3Qcqc9+1ObdIAysAoO0ZNNGcpDYWKRH59rA5xjGPb8qlAKyEu7EZ6j+dQSE4G0Ng9TSp8q5c+2OgosZSkjQyfKQLKSScAH61WnBJJRvu8Eg96ejqVBXhl6Y70yTAAKkKTxz1z6Voct9Svn/AK6iik8/HGR+dFPUqyPkZ+vH1p9sD9pixz8w6U0nIP8AOpLZczx/73Nem9jw4/Ejrougwc1ZUHjaDxmq0OcDJ561chAwAeRnPNcCPoo7Gvpy7MOFJPXH971+hroILjzXRirBSoO4885HPP6+2a560mddioSMnjntW4weKyaMjZKQRkHPPFMqS2NGCRJZJBIqlUwCu7+I+nfFTpG/nZXJ6b1JGSPf3qpp4e3t3ZSdwX5gw5YEfzq/JA8TIwTDHkkk8nvj8aTFezsUvLK6ikhUqWUBAAc+3P8AOtKGNooSZHViRjpnH+BzmmOnmMuWPB4xxtPYU9pNy8t93nb6kk80hO7KN2oActtZU4AfAJP4f1qrp6ATblQJz8pHRRnmrLlCJMSDsdzcZ47e+aWzijUhiTlcsRng5x/nFKxS2NeNzGy/IAVzyCeR/k/pV62KmQEjyiG/iXkge/pWRaZ8wMrgLu7jr+FbUXIQzcEDIODwKTJatoTCMnkcAnG0DpT40ZyGkXk/n+dPQkKrbsc9T0JpN5Ei7mBUdcdSKgabJ9rGPD5wTgEngVXliG4n5iO+OtTGcMF2k4PakkPLddp57VFy43uQBmjJUcMRgk1E10VLxHzFVuWIHAA/+vT5MhsEEj69Ka8WOvLE8Z/wqlIUop7lzT7qOdI/PcpsGMnPI962bG+b7PKkAYovIO719q5hJpYjsIzz35/Cp/ORlAVjEwP31PNbxnbY4KtByZ1Cyq0ca42qFLElTnNU7qZ9j5AAzjJ6+9YkN1MgULfOgBzknPA96R7m5mlIZy0JBZpCRyc9Nvb65pSq3CnhWnqTXl4zqEi2hSTnuRVdLuZJACAVXttqa3iDgluST6Yqd4wqggAn7o45/GseZt3PQjGKXLYdbakhwtxbhhnGV4zWpFqEDTqVcggfKjqBkVieScYwOD096gWH7xKHbnq3c/WmqjTM54eEjpopIwpMwbaxyQOB1qhqV/JNOj4EcYG0Ln9azQZo02wTMAR0JzioZ5ZXTy5QF291H3verdRWMY4a0rlqS6WOOR3PmF+R6+5NZ8jPcbQmQiLjkYzSwwF3BBBXruB7/SpIdwcg5A6ZP9azlK5004KGw63h+cb0bcOQCeAKuyR7lBGDxwDwKrqwZSBjPXnPIpHb92AhwCeT2qDR3epIjbQAwxnsDyKaVxJvByB7dqhDAOCR8h9f58UPMVVYyxK84xxTijKoyRmxFluM9MDgimy/vFHBDkYLZ7+tNJO4F+APvUkqELvGMEfKM9K0SMWx1qvlYZWYEDkk9aS4kAwAd3PJHFORNyBkYBhzgHioyzSY8xMHHPoTTIvd3FEgAA8wflRTCBn5g+e+Gop3XcuzPlMr03Dr14zV6wi+YZTPT8KSCHew469/StOCHYV2nj3616M3aLPFpRvNI0IBwe1W4h82T1xgelV4AOOMe1WolJkUKPuj61xHvxNG2wqLuHI6c549P0rpbIbFRt6+YfvFuSRiufsQS2/CqARg+h6f1z3rbtJMu7yxAQoM7VOPxB5/L3oKkjStdsrQsQViBwqMO3fIq3cl5pCpYBYj0BwGHr+IqqrFYgfkw33ADjP1PtTnIMskZL7eOQuTkfrSMutx7v8APt24AX14PsKJZsFHQFWA2tg02QAtGEbeedwPAX/9fWmxJv3LsYApu6Yx70FqxGVzCUKBsjgYyMc+/wDnFOtDsXBJZ8ZUY4/GoUIlCsm7Ocksen0/X9asCNOCNy7c/dbJ/wDrd/zpWKLlgXE6hdrKTuAOOfbmtuOZWxudi559QPb1xWLbwzJbxuD8ucjoeK07Rd0okkj2MOgBAAqCXq7mizrtXapHqDjr7UsKncQ+3aecHvTEP7ss3B/hOOMVNH5ki8bSPpUBsI8ZcgqBvByMDj8u9Ode+BnGQBTm3Kx2Z3ZxwKZcm7Nqfs/kmUsBlxwozz06n2pWBu2pGseGYgAluS2f5flTpEPylB9eeKUowLcZz+YpMOwJUHd02jj8aEXLUSIGXA6MOPcU9rZBGVz+AFSQwF8OUIbPY8+9W1jypHDH9aoyehli0BUBxkAjOB1qdFXIAGBjkkYqzIAGA+ZAD1Hp/hTZAjdemenaoLTuLC4D8KM/SpCEkUl8k8npTcAgBc7Rz704SFgcHJxgHHSmDRE0iIw3r+AX9aY+AwK89+eOaGGJcP8AMfXPGaeqb3Cq21uxxSvfQtqyuRAEIxxyagw2SD95ehJ61ZSIrleeT1981EQJJMSLkDrinbuZc2pQaCQSl1f27YqVlYYUs4I5JBzuq4qIsZCKevAxQ0JXpgY4Ppig0UyGPeTtBbGO5pWxjnAyOg71PvEYJzz2OKaMSAHyxtI6Z60utiW3uVJAXyADjrwelQ5wcfxDjpzVp4xggnGOw7VTuQwfK8ADIBrWJzynrYsQ4JBZSwHbr+lPZdmduMHtTbd1EYYglsY4qaXbgsWbJ6A9/wDCgzvqRJGBEVT7/cE9vp6Uk6O0eUwp7etQB5PMIkUEjqQaezFNpKmQjAOCD+NFzSMbO5L5MvcOT34H+FFONyxJ4Y++DzRTvEdpnzVFEFb3HpVmMHzORip4YdxGcHnJNR4IuZQR0PWvQrq0Dy8Ir1C3BknPJq5CvDcckdc9KpxAbAOetX4v3hQPlduckL2/zmuM9qJpWzhoWBUbwMYzxjH/ANer0RdBCWPDcKh5z7/nTNNiQs8rKdmMJGASTjGfrnr/AJFXtsj3ABbZI4A+7jAPH4dqY+YsghbrYrAB/lZj9xc+gqyp8sERofNyQWJzx7++KqgpDwNplA2svUAdO3c+1WLWIwxESlmLcr79+aRHQe24KodAxABJzz+dMaQseX+Yep46n9KWaVdrY3MUbouDu981HsYIVlj3TY7N05pFR2E4EojdANvIGeMfhT1YGUYICsfm55+n6VRuJPLcGQFvkwuG6Hr+NS2qiQqNy7W+7zkg96TL5banR2gUoTvyQCcAcD/P9K0YvlXy3JcgZJXBxmsuwBWM7xgNwMHn/PFa0C5BKKwPXJP86hmTdtyaFSgw+DjofarKLjJHbke1RxowVk25Uc5qROjAZ57j+VTsPcSTPBGA47Dt71Y8oCLIyWxyf8KhgBYnC5HpnmrPmkL8zkH1xxQlcU3bRFWQPG205B68rRBuLNuAIPcjJApZXLZGcgc4GP1FTKSxB2hBjsetFik3YswxBV3E5b0qxEgYYVQOwI6moLcAbQCCe/tV1VAViWJxwf8A61GplLQpyxofkfA759KhaH+5uJ6E9MVbMRMm4/P79c1IBlTnAPce9RbuWnbYoIzxmNVYYP3sjrTirMDlVAHOQcdKl8oO4Ug46Yx0+tSgJsAxjHXNNIHO2qMuVyVYHYp6H/GmxTMjHLKBjg9P1qS+Cq+QD/hVQg45JyDzjpU31N0k4liRyzAvnHrnrUMrcFlyw60xGIzgfOe+f0qYIZE2spx344/Cq3MrJMbG+5hsPbI9/wAamjfIIbGPTOP/ANdMjREGOnGfu1YyNoL7SxHQ+ntSsDasRSxEj5cZHPrg0ioTjBPI4A6VJHsOWLJg8nntTyFYBVPHU7e9Ul1JlLSxT8rP8eWzUc652kKw5645rSZAgyu0vjHFVLhWI2Y+fO7DGtYrQ4qj1M1ZSshZySPYelLITKV2ZOTkmkuY2YgoOR1/wFPVCqZKZHQc9aTRUZpajMN5gDHKjrzz9KkdFZuVKZ65/nQBunXng9aH/dsSq7iTjNJGykMMPJwDj/roP8aKd5MZ5PB7iilYvnPE7GInbkge9ULldt/KBjg4rp4rVY03nkgcn2rlQ/mSyScjexP616uL0ikeTgFebkWIx0/w61pQBW2J8q7SSX9sdOKo24CkM4worRgBYAuMqmcnOSB2z71wI9pGkl0UwQi7SvAPRRWtAjxELHu81xy55O3HcelYkLFUDSZ3sRtjUcEHoc9BzWpbNOLQliSsjY6dfXPt/wDWphJaaE0Z8qYqxYiMkKcY/HFWUlL3W9mP+zhcheeBz1qukZln2RMAGXktwxx2+lSKqttRtyqOQOvHqQKRN7slwoVMudmN5ye/+eaqSy+Xt4DxliCFTbn05PQVPM6s20rsVuc8nj0qjdsw2MEJ67fr70GkddyOcMxwsi7j156Vr2NvtixKquMggnufT+dZduNrZYM7DBGT+dbNqj43fMx/iA/pSHN6WNu1YBMbVYDjPoPTNW4nRXCSsctg/M2azYJC0WBEwPQDP3avW/3yGGTyBu7VLMbI1FkYjcWbkdAeMe1NQsAqAIM+h6fnUccZQKAdqnjA5zilYhdi9BnODUWCNi5EcfMylgT0HAA9fenuSUOCBkZHPX6VDERn5XynX5jkClllJGDHhemQeKZL1ZEFDSh2YbcYCj19TVuIrtJyrkds8kelNi2unI4HQ9yaZJAzFQDknnPrSZsrPRmhbpzyuAe/XHFW2+5hTuweCDWZbEjaBkc9SK0Yo1EfJwByB2xSsZTWopiGzcSBnHWnFcKeV9gB3pSC7KVJEfTGOlRuob+I5UketJ6EpiOWfaD+eaqtkPhfv/zq/kgAFOB6d6rOQHOF6HH0+tFhxkVJItzMCMf0qlPHgZbHPqeta+QOGVtvsKo3QDsQofPHGOKLFRqO5RiC/eBKjoeM1ZQkEhW4H61IqqEyoK896jkOGxgLgdSaLJMalzD4grFt0oORnNQOSqAvg8cjPIqZZADjk8cg0yZN8bAphe5B/ShlRdmOiK7CVUcdO5pV+V9r/XpVLLqQ3JA4xnnHtT1dt2MjGcg+vpTj5kyNBiuOpBBzmqzI0iDGNvXkf4VA5fAKqW56damSVtuDzx6dKuL6HNUjZEEhGDhFIAz1x+NQbeQMED86tSKA5IbnrionZD0HB6fSrZz3tsQhWMmwBcjkcdKlIbflsZHPtmmRSBZvmHBHY0p3KzkEEHn2zU2NeYk8snnKc80VGAxAPm49s0UWZXMeX6u4ttDuZD97ZtH1NcXAMBV6AV0/i6XZpkUI43yDj6c1zEQ79S3JrvxsrzS7HNlsbQb7mhboXUYGccjFaNiodgzbtitlvrVCNf3SjIDMpxz/AJ9KtwF/LWFApLnd6cY//XXIesloa1rGss7CUr5a8cnGfb/9VTbt84ijydhySeMDtVaPNtbrbh2LsdxG0fL/AI9BVuxhDOrTEKFILEZ5/wDr0WE3bUv7XS2yxOMkDdkjnr9TQjBl2pxz88nPPHIFQzyecoRBtQZC7iSCP8advXccM4UgttbqTmhkxVlcWd9sLgY288A9c+lZ6Yck7yi/3e/X1p1zKZZOQAo7Y5FTwRoAFJPTJJWkaR0HQ4iyrqPMJCjJ4P8AjWjDNIjGMIemNqHqapWdubm4LNBIxClYkQfeI6nntWvaNE0Ac/68YCeiDufc5qox7mdSdi7ACjsJiQvHHqQOnv8AjV5JQzAcRKeVCj7vfOe9VLaBZLhij+eEG4vyMMePXnvU8cX7wJuJLngDJAHvRKOhlCV3ZmjG4KqGzjruJNDsC/RiGO3K0sW0YIGV6fMep+lSxRIzKFJ5bk4xmsWmaqyVxscigEqpKKcnJp/mBgA3T27D0p80YWQkqAOmB3qFIiCg2rznH0pDVmrllITIy7QFHucZ96kO4ORjKjjDd6RQFI3Btx455A/xq6oCI2zggdM4P1oBtohjcRyIcqpHY8/56VZDqclmy3UAdqhSEOAzLkbc8mkaNzhsYGeMdxStcltXLSSMpyy/KePY04TDzBJs6jqfSqyNuba5G3pwOlKX3OU2P8vG49/oaLENItefG8ZKgg9fpVV5Pn3tgD9T/wDWqIymMfMpBPB5ycU2YhlVnyuOQMUbjUbaDxLvLEgEc8+hqKUKBl269MetQvMqcRYBJ4JGc1KGYsSSQOoyKpRIluQ72kdtx49CKibCMGKd/vD/AD0qbIZjsb5gO44psq5Kq+NxHTr+NKxqpWKcjAyYGcnv0zUoVtuEyM8kNS+VtbI2kdfWkZxsXd8re5xn2FJRCU+wKBIzoAEwN2M8GlkHzKVKj5e1QxTIxyVIPIPrStJyDhQvcDqfwqkmZSnqSxnHy7zuHIPSh3+Zt3DDn0yapTK5EihiADkEVZiyEUFsNtwe/wCtNJmcpK1yOVnYggFCfvHuBUETE3LDIYYPzE8j8KsvvVMZIHXnk1UjmEaMT1z1xTehCV9iwsfzEuANo4I5qK63KCTjYeevBqSKVXC8ADp60yco7qTghQfYZNCY7NMqibjlOfpRT2KZP7wUUzS55V474msUH3cMawI+QPriiiunFfxWYZf/AAYmhYYuFiaQA5YpjtitSyCMl1IyKWAKjOeMED+n6miisVueg37pb0dRdEF/l+YKAvYZrSnkKxpCoAjDdPXmiigU/iI9+yOXao+UjBpqszecdxHQjHYk9aKKOpSIrOMPdMhztHP41eyUQqpI4yD3FFFR1KW5O0jwwIYnZMRH7p9etbZkC+VGIovLggV1Xb1Y9SaKK1huclfb7zRs7OIadDMNwMjEsAeDzVuQCaZ+AgU4GzjGKKKvoYw+IWyZmdUzgE8kdTVyIkDI7ZH5GiiuZbnXIfMN0RY8kc06yAxv752/5/OiikStmWYVBMpIztOPypEVX2yEfOwwTk9M9KKKllEwjGcgkfMBxRIfLgLqBkHHNFFMlleHAjZsAtUsMZ4kWRwEB+QY2n3PGf1oopMb6iAeazq/THWs9+MYoooW4kJGimVhjlQpB785qRiSucnrge1FFW9xdQSFVDct75PX/OKbMpG19xyX2/h6UUVAN6jc7mAOO/NV5cFFyAdwB5GcHPUelFFaR2MpDAi7V474qK4ACjHXoD6Ciin0M2/eIwNysSTkcZ/z9anjQMiKSeuKKKpIzY66jWMOUyM8nnrWaMH5CBhmIP4DNFFZyNqOxIMqZFUkBDgflTZGJjY5IKtt49M0UUka9jHlBErgO3DGiiiqsda2P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White atrophic plaque with a violaceous border that is characteristic of lichen sclerosis et atrophicus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7762=[""].join("\n");
var outline_f7_37_7762=null;
var title_f7_37_7763="Annular pancreas CT";
var content_f7_37_7763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial image from an abdominal CT scan showing the annulus encircling the duodenum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Darren Brennan, Department of Radiology, Beth Israel Deaconess Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7763=[""].join("\n");
var outline_f7_37_7763=null;
var title_f7_37_7764="Becaplermin: Patient drug information";
var content_f7_37_7764=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Becaplermin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/61/30675?source=see_link\">",
"     see \"Becaplermin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Regranex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Becaplermin may raise your chance of cancer and death. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin ulcers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to becaplermin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Infection or tumor where the drug is being used.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694467",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use once a day on the ulcer(s). Keep using until fully healed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Squeeze the gel needed on a piece of wax paper.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on the ulcer using a clean cotton swab.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spread gel over the ulcer in a thin layer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cover the ulcer with a clean saline dressing for 12 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off the dressing after 12 hours and rinse with saline or water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Recover with a clean saline dressing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11153 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7764=[""].join("\n");
var outline_f7_37_7764=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139209\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012173\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012175\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012174\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012179\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012180\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012182\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012177\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012178\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012183\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012184\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/61/30675?source=related_link\">",
"      Becaplermin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_37_7765="Tinea corporis 3";
var content_f7_37_7765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This annular lesion with a raised erythematous border, central clearing, and slight scale was consistent with tinea corporis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7765=[""].join("\n");
var outline_f7_37_7765=null;
var title_f7_37_7766="Triazolam: Pediatric drug information";
var content_f7_37_7766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triazolam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"    see \"Triazolam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38068?source=see_link\">",
"    see \"Triazolam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halcion&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Triazo&reg;;",
"     </li>",
"     <li>",
"      Gen-Triazolam;",
"     </li>",
"     <li>",
"      Halcion&reg;;",
"     </li>",
"     <li>",
"      Mylan-Triazolam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"      see \"Triazolam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;18 years: Dosage not established; investigational doses of 0.02 mg/kg given as an elixir have been used in children (n=20) for sedation prior to dental procedures; further studies are needed before this dose can be recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults: Usual: 0.125-0.25 mg at bedtime; dose may be increased to 0.5 mg at bedtime in patients who do not respond to lower doses; maximum dose: 0.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.125 mg, 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Halcion&reg;: 0.25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F230811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088610.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088610.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer dose in bed, since onset of hypnotic effect is rapid; do not administer with grapefruit juice",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triazolam may be confused with alPRAZolam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Halcion&reg; may be confused with halcinonide, Haldol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F230817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, drowsiness, headache, lightheadedness, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, anterograde amnesia; complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls); confusion, cramps, depression, dermatitis, dreaming/nightmares, dysesthesia, euphoria, fatigue, hepatic failure (fulminant), memory impairment, pain, paresthesia, tachycardia, violent acts, visual disturbance, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In addition, the following have been reported in association with triazolam and other benzodiazepines: Burning tongue/glossitis/stomatitis, chest pain, dysarthria, jaundice, libido changes, menstrual irregularities; paradoxical reactions (eg, aggressiveness, agitational state, delusions, falling, hallucination, mania, sleep disturbances, syncope); pruritus, sedation, slurred speech, urinary incontinence, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triazolam or any component; cross-sensitivity with other benzodiazepines may occur; severe uncontrolled pain; pre-existing CNS depression; narrow-angle glaucoma; pregnancy; concomitant use with ketoconazole, itraconazole, or nefazodone",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with depression, renal or hepatic dysfunction, chronic pulmonary insufficiency, or sleep apnea; use in lactating women is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patient carefully for medical or psychiatric causes of insomnia prior to initiation of drug treatment; failure of triazolam to treat insomnia (after 7-10 days of therapy), a worsening of insomnia, or the emergence of behavioral changes or thinking abnormalities, may indicate a medical or psychiatric illness requiring evaluation; these effects also have been reported with triazolam use. Due to possible adverse effects, use lowest effective dose. Abrupt discontinuation after prolonged use may result in withdrawal symptoms or rebound insomnia. Triazolam is a substrate of cytochrome P450 isoenzyme CYP3A4; serious drug interactions may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity reactions including anaphylaxis and angioedema may occur. Hazardous sleep-related activities, such as sleep-driving (driving while not fully awake without any recollection of driving), preparing and eating food, and making phone calls while asleep have also been reported. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate, but not the extent of absorption; grapefruit juice significantly increases the bioavailability of oral triazolam",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triazolam was found to cross the placenta in animals. A case report describes placental transfer of triazolam following a maternal overdose. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines. Use of triazolam is contraindicated in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypnotic effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-7 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Drug and metabolites distribute into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.8-1.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver; primary metabolites are conjugated glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 1.5-5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as unchanged drug (minor amounts) and metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38068?source=see_link\">",
"      see \"Triazolam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of triazolam. Avoid alcohol, other CNS depressants, and grapefruit juice. May be habit-forming; avoid abrupt discontinuation with prolonged use. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Take dose in bed at bedtime. May also cause daytime drowsiness. May cause dry mouth. May cause hypersensitivity reactions. May cause hazardous sleep-related activities (ie, driving, preparing and eating foods, and making phone calls while not fully awake).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Meyer ML, Mourino AP, and Farrington FH, &ldquo;Comparison of Triazolam to a Chloral Hydrate/Hydroxyzine Combination in the Sedation of Pediatric Dental Patients,&rdquo;",
"      <i>",
"       Pediatr Dent",
"      </i>",
"      , 1990, 12(5):283-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/37/7766/abstract-text/ 2095538 /pubmed\" id=\" 2095538 \" target=\"_blank\">",
"        2095538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12860 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7766=[""].join("\n");
var outline_f7_37_7766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055871\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055865\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230749\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230734\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230811\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874925\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055876\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055875\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230817\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055880\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055864\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055863\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230743\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055883\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230744\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230759\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055870\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055862\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055878\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055879\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055869\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=related_link\">",
"      Triazolam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38068?source=related_link\">",
"      Triazolam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_37_7767="Scabies axilla";
var content_f7_37_7767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60849%7EDERM%2F75169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60849%7EDERM%2F75169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules are present in the axilla of this child with scabies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules are present on the buttocks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7767=[""].join("\n");
var outline_f7_37_7767=null;
var title_f7_37_7768="Endobronchial lung cancer";
var content_f7_37_7768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54311%7EPULM%2F57883%7EPULM%2F68408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54311%7EPULM%2F57883%7EPULM%2F68408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endobronchial squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopic image of the left upper lobe orafice in an 85-year-old male with hemoptysis. The lesion proved to be squamous cell cancer without evidence of invasion or metastasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Armin Ernst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photodynamic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The same patient photographed during the delivery of photodynamic therapy. The field appears diffusely red to orange, and the tip of the cylindrical diffuser is embedded in the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Armin Ernst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Results of photodynamic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 337px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFRAUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uoq5o4LatZKOpnQf+PCvW4oO2M5wBz1rKpU5DpoYZ1k3ex4xRXuUduwb7pAz1/pVyC2+c5BAI5BP8qy+s+R1LLX/ADfh/wAE8Bor6PjtywUgMOM/LyPar1tZsCAwJYdc4H+fpS+teRf9lf3vw/4J8xUV9WQWiBfugHoBnrUy2BdAqqNrc7iSPrTWJ8geV/3vw/4J8m0V9axWbqDhRtA42/MBT1h3sfvDJxjGPXngUfWfIP7L/v8A4f8ABPkeivq2dNqNuA25xkdfrUbgLGd4xggjBx2/Sn9Y8hf2Z/e/D/gnytRX0xKhlkygAK/L6ULaSNtVVzk8Arj8qf1jyF/Zv978P+CfM9FfU8qCDO5SWK4U5/zzVa5O7iPDDAPIxzVe28iP7P8A734f8E+YaK+l7fTbm4BlELLg8kA8H2/DNTm3VFIcMBjPIp+18hfUf734HzDRX0wVVCABx9O57e9QyANwVOU46nH40vbeQLAf3vwPm2ivoeUqBsxyWJAx/OqkiqV+U4xxgij23kH1H+9+B4HRXvOPn3bQRjj/AOv605fuhflHGOD2/Gl7byD6j/e/A8Eor6H8vfC+9TkEAAfoc00Qb2C9cdCOo96ftfIX1L+9+B89UV9GR2jOQZUHJ6lj8op81rCifKqqNpyAeMU/a+Qvqf8Ae/A+cKK9/dYii4yMDOfbtk/jVKVQh+7wB3PWj2ovqfmeG0V7LcqMkjrjkA1A0IAUtuYcjin7Qh4a3U8hor1WdDv+UFgeDiqskZVgX3dKfOQ6Fup5pRXobxkk/KQDweKz7q2WNVaINnuCOlUnczlTcTjKK6foe9LQZ3OXorqhXN3f/H3N/vt/OhMZY0MZ1rTx/wBPEf8A6EK9nto/lJwx+teNeH/+Q9puf+fmL/0MV7paKXZSM88den0rkxLs0evlseZMfbQBiGYMSD+nrWja2iM+7adntz+Ip9lbgOrEEAN68j3rXtbfd0BC+/A/GuS57CiloQWdpGACMkkHPTkZ6VcWBd2AjFgOMd/b61dhi2PnrjJ4J/Sp/KWMITuyOpz+n1qoiZXWJODs5xkYxUioqtwWO09d2R0q1sUjALEk4Y5/n7VHJC5MmEAx8xBbp+tXoTZlV9p+XAI5IGeD7fT3qNtiMSCpJHPGKmTYxO5OoyChxk+/+e1NLgANtbg45xgGgLFe+VYwSyrxxWRKW4AAGOoz0+nrV68l3DamSewJ5z6VDDFvI3Z65bj/AOtQDRXgt8RqxKkZ/hGf1/PirsRijUs5Ytg88DPof8+lI8iIg+ZRKoJbaDn61WJMoA3EBMDA/i/+tVJWM5O4kkU1xGmdzLnggdT/AJ7U6C1CIS7BTkhec5HrnsauR4WPbJknBKc4Ib8RVQb5HYoCFzjpnnuelaIyaSEivXjykHO7JO7v6nFQy7mB34I68HjHpVxVjXaQSNw6HHI9Prms66nOX2YYgHJJOCe9ErvYSslqQMAVO5WHYdu/SoJHID7UPLZ5OAKAxJOQQeWx7+tVJpXY5TleAd1KxN7DXdN7F/l5yOaYTnoMAjA9CKcsW1gHI25O4EDp/jU0EDswJJ6Ek/560w8yoU/dgFsjGetKe54OB6+vX8auLayyl3c4G0sQBjAqPydpJJblcnPb0pDsCMpHzsQSegH8qup5YUeWRkDkdDVKWBcjuOM+xpF4YbSeTyCOlFwsWnuG43FM9j7e9Mup8qQjdeh6ZPrVdlwTyxG4jqR+dIV/dHHPcEUrj5SvIxJLEZ3e+f8AJqN0yBzjuN38qsBGGBkKcYx6H0pPLB4JAPXBHX86aZm4lVkDR9Tuz3PQ9qruhT5SRu9DWkYljA2/eIyCDxVdxlW6dMAc0KVxOBmyJk7gTkfp7VUmiyrN1GMge1azxoASdwwvHPeqM6c4BOO+McVakYSgZcgZgQe/NQOu0nYx69a1fLBTLb8kZAHeqxRcEk7frWiZzyiYl1aglpEOPbHWqXtn8K3po+Ac/wD6qpXVqrAmMNu7jHGKtM5p0+qKA965q7/4+5v99v511GwiNn7A7eveuXvP+Puf/fb+dUjIt+HAD4h0sHp9qi/9DFfQlnAxIAB4PXPI/D+tfP3hcbvEukD1u4R/4+K+mbGFQxKoD8qk55FcWL3R7eVfDL1JbODPHYEcjuPT9K2re2UKdhGWGMYBwfSm2sWcMoQ5OOMD889KvxRMMp0Gdo46CuZHrehHg5b5yoK4xtHzAen+e1NBO7ghgcZxH15/lVwwDhgDwccml8lVJLquMYb6dKsLEYZQd7yAnIOWXr+VPZAE7Dk5O3tU6IZSn3QF9QM//r96V/nI+TkZOegPvjtV6WJszNfCt/rBgHk+g/z2rMvwgA+YZ7fL1rVuNqGONgu4nOSvIqhIFk27yMk8DeMn35qdOgWZmbtoJJUDoWC9aryXToQEb5gemcH8KsajKsUDsMfJzwM5/D1rn4p2mkBQd85xTS6kSl0LrTOWYqB8xwe2ff3q5EVQqePMYZAx+hFV4lGQ0h4+6f8A61W02oG8xuMYHUYHU1okZSZJCrTRrJIBtUYAOSc/SkuZ4rUYidhz+JPr9KytQ1VEBWJhu4rGvNRedVO5i6/dwOKsylJI0p7/AHM2FLZydwHU9qqh/MUluv8AFlcZqtbxs+cn5ehG4nBrQWKNMNMykEY6daajczc7kYic7zvOMfxAc81NBaZl3nAGeDgU5tRtEC8rkYyccGqrarF5rDd8ucfKOv8AhVKFhcy7mqYI/LIcqQD6E5NPiWNDuzz9Mf8A6qxf7VVlCqdxJIOTjNJ/aWG2l0cYwN3WpehaaZvSyIkYUsijb2Xt71XdI23BCDk9sc+/Ssl70yKVBwpGARUttd5fMhGAMDHAFZs0Vi89upZ9rjLMC2OCcelRy2q4QsVBJ6nOAaIrjcGbPC8j1pfPSTjIOON3B/H61L2KViu0UZIGf4ucjkn0+tIY1Uh0J245Pfp09qludohYHO7tg/zqorMVCBmIXjp1+tJXG7EbMCq4Bx9ehpVRiVBYZ6g/5+tJtz8o3EehHf0q7ZxjKvjgnv6elMzKckLEFivBGBx0x2qrcIgx8oz1wB26Vt3CgMvmcjGD71REO935xt5AxxTTE4sypF3MqMSB16VDLAF+ZMZHbHWtqW0Cc7d3HGeSD71BNaPsyWZs88DimmZyiYMkQDn7vA9evNQXMKANxgY7GtqS1LDI78Djr/8AWqKW0wuWXI7EA9K0TMJxMJo8gZyzY9KrTptYnaQCOBjpW09pIvQOPTis+aA7gCASOo96tM55RMa7gEzlgV3kdelcNfAre3APUSMP1r0mVOCAuAc54rznVONTux/02f8A9CNaxdzlqxsy54SG7xVoq+t7CP8AyIK+q9OgCoMIcdTkdq+VvBwz4u0P/r+g/wDRi19b2yiNZPNJ2/LnaenoRXJileSPWyr4ZF22QMPlCkfdXPr6n/GpER87oyV64IPPvVizLFCACR5nU54x/k1ZSPKs20bsngHGT6Cufpc9ZIpsh2jKjAByCeAaiWNsZKnB+Y4xw1aoBwCvGF5z/I1QdABtKMMck56UDsMiXy1k2xkcg4PY+xp9w7lSTyvcgccD9aiVsFmwUZT2Ixz/AEppKiEBWbocnONo9Paqv0CxnXMgkmZmAPAB25BBqm7gHB4zwcZ5GetOumIfLEgNkEelY2p3kSQvlgecMc8+wFFybGZrd273OwE4OT06celN0393EvAY9eDWfEVln3Dcw5Bzjn2rRS4S2AJXocAHtVpXOdu2pcLosR87G3bjDc571m32q+ZtjQYIyeOSx+tZWr6ojnYuQFJOMd6xri7VTndz15NbJdjmnUSNN5DJlt3UVE1zHbqrEg4HJzzj865++1dBuEZPPA4/WsW7vDJ0d/xrSEOrOKriEtjrpfEaxIQgwMYwDWbN4immY445z1/lXKlye5+tKr4AweK25UcjxEmdAupSsSSw9qlS8dnAJ4FYEb461cglGc5P51LiVCq2bKXTMxxnk/SrMcrsdpOM9CDWbAwO3sM5zV2AbpMLkHIz6msWjrg7l3zznCgjI7dqnjmm3EKccfjVaMhn2qcnHHYk1ftsE5JG3jjOKzudCLX2h0BBYANjr2p8d2eyknrgDp/nNJt80NtOWHJIPWolhY5y3BOB65pW0NLu+haMwYlSCMnnsPWrMbKZAvV8DGD2+lZJOJT0weef5VYWVQB8x6ZxnGf/AK1KxXObNukbLjH3ieF4/wAirSx7V25HH5iseKcBPvEcYYA54/wq9BclnCl2G49T7UrIL6k9xGzAElcg5Jx19h9KiRSrMVyGJ/h/z0qyi7hhwPmOc8mo+pbduOeODU2LuPCjYvDcZ/8A1CojbtnMJABPA7j3x6VLjd1BGACSamjcgspDEZ55HHvmqjuZyVyhLZOQxbIG3GQcZ/8ArV1vgzwTJrkyYdfK28ktnAxWJ13Lwp6HB7V7b8NIY7DQWu7hxDbn+OQgD6+1dFKHM7HLWlyRcjw74h+G30DV5LU4ZgFfch4NcFewHzSW+YkZJPc17d8V9W0zUPEBktpY5kSIIZEIIY49a8j1L53Ji5APGOcVU48r0IV2k2c1LEdpLAYPYeleZ6sMareD0mcf+PGvW54z85xg9RXkus/8hi+/67yf+hGnBnJXVrF3wZ/yOGhf9f8AB2/6aLX2BaRtsGTtYDndxn3H+FfIXgZd/jXw+vrqFuP/ACItfaVnCqqo6McZPp/+uubFfEj1MoV4SCBWj3kkjjdz6+v+easiHBJG3OQSPQ9z+tWYoFU4wBhsrx0NRsQshHG3PXGPwNc6XVnr3uQNEFBygxg/hTHhRsMVJLDkDofr+XWp4j5ucYOMgkDO0elRySiOPAYen3Tx6mjdXGUriPAyGAPYlTx/hVeUtIGUByCP73K+px/k1LPI5CkBSuSVz+lUZpSARjI288np6+/1oQpbmdfnarZUA9QQO2PWuJ1SR3cgBuRx2HHrXV65dRJbsQRnpw2SDXBXl5uOOd2Dj/62f61UVqYVZ2RNE6Qr8w5PHLCsrVdQLnCHCn3zj/Gq9/f7Ub7qYOAfbFcxe35ZztP610wgzzK1dIv3V2EJwQe3FZk908pbB49PSqvmFuvNPRSemAcVuopHnyquZE5JPOTTGHPSrG3IORgUwoQAc1VzFxKxXGTilH/6jUrDAwetMAx1qkQ0M/lUiPtb0ppoHUUCWhoWk3zruI9627E+YRyo4JrmYMhxg1p2cpRhgH2rKcTroztudFax4GSNxb0q5CSM4BA7jHX/AD/SqVnNuQKBkAc5rUhCsrKwYZx05rBnoQ8iaNThdp44yRxmrEUTyZIBIbr+HemxIWAznaMAk8c1ZgkCsFx8zdT1xUs1RXmsn8zeVOemCM1BNASOV6cAlTW2NryELu9tvH40xrcOwyMFT35H/wBalcbWhhIJIiAc7cYHFWY522lQ2CT6ZOKs3dqNqc8rx781Bs2SZK4x1oBGtaM3lHczDJ+Ujj8qsgMy4I3Dr97tWZbSyEDGMr8oJPX61ZikDO5/hxnaO35VNir9C6Aysqjdxkg55x7e1AQIu5mJXHQ1G0wUFFBGRxuNQq8u4lm2g9FyMGmtCX2LSu0cRBLjPHB6/X0p41zWlsnsopytk/VCeR7fyqhtZ2DBwV5HXqfU1ZTKK+0HjkkjtVRnKOzJlFPcoXBecNk8txjt/wDWrOaH5zhWPBGTwK27lcktyoIA5PSs+4Vo2c7myeMEdvrV3vqzFq2hgzx7WJzkYPfk145rQA1i+A6CeT/0I17hdIXj2/3ec+1eI66Cut6gDnIuJBz/ALxramcOJVki/wCAhnx14dHT/iZW3/o1a+4LOIEEKACxycZxn0r4i+Hn/I/+Gecf8TO15/7arX3jEB5DMQcdeDisqyvJHdlkuWEvUqlcZBBPrk1UbOTtzwc8Hqf89qvvH8gUFm59earxoEckDOR1PH5VzSXQ9eEupGURYz5gOMHv1rNlLy5U52jnJOCPpVu+lONp2AtwBwKoq20gsOSQRx1JqW+iNUurIZYyA7O2cgAKABn2rIv5dkcjN/CvQVbvLpdrYkfdknA759PeuO8SalIgMcb8bSAc/p9KSsKTsYOtXZkkZtx2nOcnt+FctPcBA7EgjqT61dvpd2QzcnsT/WuU1G6IJVcYrppQPIxVfqQaleGQso6ZzxWcD81K5LMe/wBelIvt2rrSSPGlJyd2SJkZNTJyMHpjpUCjNTxc4PvSY4lgISMHn0pAvHb15qeELtI7HkYNBQdj9KVzXlKske05wMdqhePIB/Sr5TIPc+gprIAMd+3PWi4nC5mbTjvSFM9elXXhA5zz9KhaMZBFWmYuDQkGNwOcVdj4IIz7GqAXn2q7B0Gf1pMuBr2E5XAHBPHTtXRWsgON3PQYyTg1ytscHJYZ64PpW/prMqjoVH6VzzVj0aMrm5CecKDjPQ561YHTLBeGznOOarWo3SYPAPJz2q8jgOFOCCc9OvtWbZ0pD41Bbawxk7Rg1et7VfvHhhyMc/5+lVYV53cY79OeOlaVkQRlgmMfM2RUstNFC+tF+Z1j3E4JX/8AV/Ks2aERkqM+/Pb3roJlLEEEYzk54NZ1xbsrMy5wTyvc0kNlNAoBxwe4yeR/jTo/3Uo/gVgOfWopGKsQxPy9OOM05Ji0nIUkHB70yWrGgFXcATknqRx709wWkO3KgNnb9BUK5KDcc8cg9/ep7fOCCQCuPqKQxoiKlgDnPOBjmps71ZQcnjIGe1IGweCCfVecD29adG38RyAScUIT2IZdsW4buvfHU1XIW4GAW3kd/T8KmkTzGKDeMEE47H2qrLG0D5LZUnB44q4voZTTRJ9mt4o2kuFMrnmOI8Bj/tn09hya+ePEn/Ixap0H+ly9P9819B3N0nlbcFgAQD3z3r578Rf8jBqfX/j6l6/75rqhsediuho/Dn/koXhfv/xNLX/0atfescJ8kggn6np718F/Df8A5KJ4W6/8hW16c/8ALZa+8nnRYiEKqTkY/pUVbX1OnL78rS7leUAvyAGPvUErYXPHqcfyqQuVILbc9MnvVGSUnkuMc964pSR7UItmffOZFaNT8+OMjPNUL+Zo0VsEHkE5x261a1KRYgSxU8dSP8/4Vx+paiUh+WU53EZ2/pWSN20itqWqJEpVgTkZBJzgVxmq3rSkgAjPOO1alxKJFJlY5HOehFc1eMSkkmeOTW9ON2cGIqtIyNVuvKDJxk85B4rm5WLMSTnJzzVzUbgzTH5t3vVD1P6V3RVkeBWnzMb1FPHSkA55/KngZOByau5kkKg45qVMjocmm8ADFPj79RUvUuJbhGenOPerCwMRlsdMDHeq8DKIyxPJ6DFaFm4CDecjHAIqWbxsyBQOAMngA9s0ojOeTn196kuApbKfd7c9akQB1Hr7mpuWo3KbRk4I78gVHLD0PQH171pGMMTgZA7UTQrxhQTj1zQpCdMxGiC4qa2TkDjNWZIgQMY/wp1vCQ/pkZGOcVXMQoak0ScjgBa2tPXaBnp05/Ss+BAy4Izx/n8a1bOPcuGx/Lis5O51U1ZmtCpGCpHDfePr2rSiXaQc4Jb9frVWyQMoRgSc54XoK0IgJI1Ge/J9vzrGWh2RGwjcxGAPm4wOnvWjaZQjgADkgdv/ANdVrZV3kNyTyO2Pb2rREexEc56HPy+vFJal2tqTBdxywH4L+Qpr2Us+TApJzj0/KrFuiOpEhAGNpH8h711Phaz0+SYJflcZO0bwvGO5rSEOd8pLdtTz3V/Duoxx7/JOw853dhXMDMEjK2Ov4mvbvGOyG1QQ52Ffk7nH+TXjGoKPOO0nG/I9/pRUh7OXLuLfUvW8rSHBAx1HbNXI2Bx2xwcHoKoaYodFywJJ4HcYrQWMEndjaeckECsnuNaC/KSTwXI4OfyprEFsduMnPelL5/iHPAIGcinN6hcgcEk/pRYljFGG5yBjr1x9RUzokkfBJ9P97096ibeOU7HI6YNMDFMgkAHgYNVFkyMS9j2kq3ABzjPINeF+If8AkP6n/wBfUv8A6Ga+gr6MTD5mQkcjcccV8++Iv+Rg1Pt/pUv/AKGa6KZ5uLWiNH4dcfEHwx/2FLXp/wBdVr7lWOSRw4Ybcc818NfDr/koPhj/ALClr/6NWvva2iIiBXgZHGKiurtI68tnyQk/MqzRhYQCRk+tZE553AtgA456/Wtm+YlCgU7QenpWHft5MZ569WA6Vx1dz2aD0uzkfEl7Iq8sAxGSM9fYg1w9000isr44JIPXk9q1dXuDPczfe4Y4GKwtQucooXO3+92NEVYipK7uVr2c+Wq54P61zWu3HlRmEHO4ZGa1HkJt3YsML6jrXIandefMxPPPFdlKFtTx8VWuUmyT/hSADb605nXbg8fSoy3X0rpPMbHgdcdqcDyc/l0qJWHr/wDWqRRxn+dA0PB6Z796UZ9ulNOAgx37U+MHPHPYUmUi0m0KT3A6/wBKsRAFMHPSqsIGAe5q3E/3eOMfTNQzeI8Kc4PpViLO0D1/Ko4yWbkjpzk8Vet48+p78Cs2zeMbiLExONvPbvTHiJYcH2PAq7Em4gn8805ogFHGST2FFyuUy2iGFxxjkfWnxRlPv9xxV1bbpuBAbocVYt7YlstgYFJyGqZWihzzuY4H5VrWsZUcH5eOCM9/altbNhGxA2qRg/1+lXIo9rjDEscDPYfSp5rmsYWLsCnBLtgk4IxWzp9q0xGzkE4Jzj8DWVAGaTc20rnoDjn+lenfDO2txqMX2sqytzjg/j9KUY875Ua35VzHGHT2t3AwBzkkHO7jtSQuWVQwZuvPT8DXqvxFvNEitmt4YlN0RwUTAHfr9K8oiZfmYnjAHJ7ZqZx9nK1y6cvaQ5rWJhIU5jLFl4zjGR2/CrMNy5K5wzA5Gf5VUVlDYY5B6M/OfrV2OMF1bcM9Mjtx/P60k7lWHalfzXVqqTk4QY+n0rlNQt/3jMcjoeldPcAbAfkIYcL6jvWbcBNhIIJzgEng1NxtGPYfumIYkYOSMda03AcBsjJOOuQvviqxgEjCUdSMKM+//wBep0BEbKcc8gHmkSQPlgwUrx/F70QqXVVwMtxjFOm/iKgk4HA7eppbYHeoOB+Hb1qkSy2lnkDGxQeOe3t9ap3yhBtLfLjsoyP8a2IGBJK42DqKo3sTSjGVLDnB9PSqsQzmbiUqzfKR29j7V4X4jyfEOpk9ftUuf++zXv11aqv3nVdoJ5Xv2FeCeKMf8JNq+BgfbJuP+Bmt6LuedjFZIv8Aw4GfiH4XHrqtqP8AyMtfeqSmKHGckY4ya+CvhucfETwsfTVbX/0ctfergsSvOOvJHFFbRpm2X6xafcgmXefMXnPJwf8APNcr4puha2w+YhsEHJ6CutZMZPy5Hpjn3rzTx3d/dRQwwxHB9TXJPzPXpvRnEXMqrJO4zhuD7Vg3cnTBYjtx3rUvXAjbAwVHHPWubv7nCIflIzRBXMa87IqapdGC2kUAgSdQe1cnJId2eM1reILkyOvbjNYJfOTXfBaHgV53lYcXJPp+NGc0wU5PpmtDAkU8VICffNRqakHagpEvoCuD6U9OcDGOKiTsMdqmj4PQ4/WoZpEsRggHrnGatQg7APy9KggUsCccHnNW4hjaCBjIzxUM3gh8QxuUjr6dcVehDAkcZPSqyLn7uCavQIWKjaMk+vFZM6ooljLkjnkHp61bEYbaSSQR0zTYImBJwpLdPrWhbR7QGO3BPT09qls2jHuVhGMKOcAZAA7f0qzFEWU/KMbeSavRoI9pyzAen8qfHblghK4GOcnFTc0USGOLah24yQD7n3qeOLkNhs9AR0Iqbyvl2jaWxjPr6CplRVzvBGQO46+lA7CpH5b8L3wDk8f5xXTaBfTWk0ckQCNGcZ7D3rGijDPESCUyAeCB+nUVsWuwYRcLg847dad2tSopMt6nIL0CSc5kYkjd3Hqawivy7V2r1xx/KtZ3LYU42n7xP+Pr7VV2Ayu0uMDqEBOPTispNt3ZtFW0KMyBFDZO4jseKtxyAncWChWAJB5NNm2FflUY75PSo0LAgEFXY8jPb6VNyuUkmZmVf4sHIyMcVRu8BmJwM4BB+tWlkGMAnJyc4zg1WvELJkEsOwweKL6itoUC4Ay+WOcj0+tTwyr8p2g5OWHPFUnQnJGAG5JHFPRirZByDyeadyHEmyGBbDHJyMH+dPixvUDgjI98VXYkE5xjOc45xU0R2OMk9c4A4NUjOSNGCIhCWVcjAIGcexqO4Ji3dNx44yc//WpzSh4htbnHP+f61WuGWRY1JGAMc8/jVkNGTqspZ8JlVOccZINfP3iL/kYdU/6+pf8A0M19E3cPyt/CSNp5xuFfPHicY8S6sB2u5f8A0M1tR3PPxuyND4bsV+Ifhdh1Gq2p/wDIy194K2RwB69MV8G/Dz/kf/DP/YTtv/Rq193wAeWg7nI60q26NsuXuSfmJcOFQhiCMZ+teO+KZftF1Kqk8HIyRzXqWtTFLQkNhsleV6Y9q8i1iX/SJDkZbPAHX6VyTlqevGNonOag6bWwP4cc9zXKXXzo2F+7+f1rotTl3EuSvzDn2P0rDeLzI58jJ9a2pKyPOxDbbOV1Eky8n8ap9R0/Crd8MS4HSqpB4rujseJP4mIPrn3pwoHegew96okeDz71IvbvTFA9AaeBz0qSkTRkY5649KkUZxkDPaoY854P61YiGcg+napZpEtQLkdBn1q5Gu4KB834daitYsx5br061bSJUAxkH881nJnVCJNEAQxYbiBwa0baNQQdo4qjBke2R/ke1aVqWaMHj0AxWMmdlNFyBU3biPlz165rVgiVTjaFOOe4FUrZGVVxz3wK1LVCRGwBAz0xj8azudKiWY1jYbSBtHHT2p2zyxlQBkAABeaLaIOAHYjBKk9s1bMakqAG4Hf+ePxpXsWo3Vyv8rAg5xnjirP2bYGbZ8oIB3HmhozsJAw2Nw56VdgiOWbcuAd3HbnrTv2Fy23HQxbEwQck5PB/l2FXIMZAffgnJOcfhQsO2JXIO4HjAPcVJbuxAiEZKOx5x6en+FVshJ2YzHybixyOw5OPpUSbiBliqAZGQB+PHStr7KrRDLlWA9O9VhGiy4yzr0yT2+nrWT3Nb2MxoWw3yh2wCfQioSjFsAHj5QRWubZV3Ycjbz8ufyzUf2XDD5j35HUZ/CpY7mKR0CMR7E5qFo3ZlBQkk7VNaz2iqPnB2gY5PHNNCblKqnzHPBzSHcxp7UHkKwOeBjIHtiqSxOqYKEKOOa6QwHaGAUDPAII/H3qqQSw5PoR6/nVakN9DHWNh/CO+cj9anWB1Ugqw9Qc8e1XhEu0q7EsDwVJyKWdVEQyMc45bv6mmmQ7FSNDkDA/LOBSrGCBuAI6f/qqzleOn17f/AK6DgBc8nuM7T/8ArrSKMZMzpxkAZBOSMHrivm/xXx4o1gDH/H5N0GP4zX0nfDG4/KMDAIP6V82eK/8AkaNYzwftk3/oZropbnnYz4UXfh1/yUHwx/2FLX/0atfd8beXtZTgn/ZFfCPw4/5KH4Xzx/xNLX/0atfdE8mFdui9c1Nd2aOjLFeMl5nP+KLlkil2nIxyMdf8K8v1mVw7MwI4OeK7rXZzPM65OD93nj61xmtR4i5OTnJyOpriTu7nsTXKrI43UGMxXLZ3DIwtRDMcV1tBICgntmr9xBvYSLnDcnAwR9KdfWaw21w5C/dHHtiuiL1SPMmnqzzK/J8081VA9KnuiTIcnJB61D26V3LY8OT1Gn8MU4HsaQmlXk1QiRT6fyp4x+NRYOKlVf50hokTBAA4NW4hnsTVRMdRj8auwDJHsahm0DQt3K4HbHpVqMklQRyBUEcIVT29vSrtsoyvIwvTvmsZM7YJkkKNgDB5z1FatkpMg7r06dqqRJ8wYAbeetatkhEaYIwTkVg2dtOJftk5+b5lHTjr7VoWC7+ARxnGD/Kq0L5XBJ3DgqO1W7bKPGx3YbJ+7ipbOiKL5J6rgc/KuCMUkgXYRuUKFx0wfXj1qS1G8AnJ9AvJ9quCByisVODxjd/npUpXNGUbCAyKWdTuzxxnPvWtDEAWwQTuBxjjI70ltKsCOoVdwxg56/TtVq0XzcbuhOSR09q0Rk9CQQgxquATyeeM/X0rU0mxBdXOevGOR9RVYxjC5DZU8k5/A81btLhoHVRnIOPmwR/n/GtLLqSmX7pHjCsCPXaoHA+tZc2FZkIYY56YzWgT5+CCCMlvugZP+fWmJamTlCeccggdqlx6IuLsZqgs/wB4YB6kfdNSqgEKNnIUbyB1JPerUli/SRjkjnnP40R2wVuAwA6LkfpWdmUZs1uS5xnkbiQAB+NZ5hO5mw2z73cE49DW1efIA2CVK5xgjB/x9qy3vGQlj5a9/pj+VJx1E5diCchVkywO0Z6Hn/D+tVpv3kcZB7dlwasyT+Yq5KIOueajYbVI3Z4BIK5x/nmlbqJlUocjAwB83Heqzszbwc5xljjgj0qxdPklQvPbsT9KrlHYAFBk9j0xVIzasImCdxAzz3GKfKxCqowc4OMdakRMYbIGOeDnP0qZogY1EgU92YDkZ+n860TRlJGLe5Icg5HOMDivmzxX/wAjRrH/AF+Tf+hmvpK6QgFVCjtnqRXzb4s/5GnWf+v2bp/vmtqW552M+FF74cDPxD8Lj11S1/8ARq19z6mgS1JO4Y5IHHIr4a+GmB8R/CpPQataf+jlr7u8QNGLKSGM/P2A+lTiI3VzoyuTvZdzgbyEyF3ADBh1GP8AP41zOsruyCM9ue/sK6/EzqrZbB9COeOn/wBaueubfdIWfP3SfmGSD68VwU+57ddOxyToDLl9zDOeB/nmjVoi1nMvJGwBien/ANatOa3VJI1Kd88ck/hTZ4la3lT5OQMjfkE+1bQetzinHSx4bfx+XOy+nrVbAP4dK3fFluYdRYBVVR2HSsM4wa9GLurnztWPLNobjnnrSjg+3rRSg9P51ZmKOvTmpEPpkVGD1yacuSRSZSJk6jmtO0j6c/8A16o26lm9u/tXQWdvhDkKTWcmdFKIsKfISSMfrV2GAgckHI57flToIfkA+XA9O9XYbZsHbjO3PJ6fhWEmd9OJLaw5j+Ujp6cGtOyiZUABOQePzqvAjLHtxgnoAfXua04f3e0FlzjGQT+NYSZ3QRdsoxlmbIYk9B/nNWVhT5DlupHXBptsDg/MG5446irEab9uACy9SR196g3RowWQR1kbIzyc/qMetX1RQoO3IGTyvPPpUFhM7KiE4VVJx1p7T4cJswF6A89f61pGwpXJ4reN243DGBjb+h9/frVtIthIVmzkEZGOM88/56UWsakDcUDDC/KevvVxArITxz1yc9PbH5VtFGDepWJfzeeQeV3c5x2//XVlIk2Rkff6dOc1XQhSpcoFzwWPQe5q9YIXYcHjsfrjJx0p2uIdGuIVBfIB4xnn8vpWlZxMqjaMu3zHIOf1+lAt95wMcZIOMcVr2FnhAdmDjgKc1aptsbmorUzTatLN8pHJGMcY/wDrVG9m5JGACTgEgcdefaukSzQL9w8jB9qWW2z8uOWHA+lU6DMvrC2OB1O2aNz0UZxlQSP171gXcCBt67SV6ErgDPeu51eEKGIxgepHX0H4VyV/DsVk+UAjB9/rWEo2LcrmHJgEeW4AHOMc1ag5i3NIoPoD/n8qrBFjyjhie2TnHv8AX2qzCN0P91gc85zz7/jWRdyvKg37nYAMc9COfakO4s4DgqDnkYyakuFUHEnAzjHcf41ASuMqwYjpg/0pWE2TQxdPun1wKfMFIHzhQOhIxVizTe/Crz0HYn1q3dQKIACFJz/Cf0rSCM5s5XUDuUgkEKcE5zivmfxaAPFWsgdBezf+hmvpy+VtznDD2I/mK+ZPF4x4s1sf9Ps//oxq3pbnm4zZF34bEj4i+FsYz/atr/6OWvtzxFOWmnRnzj5sCviH4c8fELwvk4/4mlrz/wBtVr7Wvlaadzv4PIx6VhjHokd2TRTbkzHnYeQGzgLyQR396ytqieTdyAMcDHX9K6C9tybRCsgByec96yLqNkY7DhSmTnP5n/61c0VZo9Srqmc3eJ/pK7eUXPOBgf4UsdvuwoACnue30omj/ftwSfds/j9a0NOiDhhtOB6seKqO5hLY8g+IdkFvzsBCjIHHXnrXCspBNe7+PdFS4g83JyFOe+DXjd/aGOVs8dq76UtLHh4yi+bmRldx0FL+NTtAcjAzxmomjOeP0rY4bNDBU0ILHAGe9CQs3fr+laVtYsMFs7fSk2XCDbJ9OtwwIbPqK3rdRwqkc4FZ9rEFZVGAegPXNaSIFOCeMjjHSsW7ndTjZGta2zOWyBk9OOBWrbW2Dy3HQZOaj05Bsj3ffOM7R1HrWmEUqXYKFCjcOvPtWL1OyOhnEGIqQCWAPXipVBZFyATn5RS3C7mYkAsMDHYio1XKAE/QjrisnodMHdGrZhnPlgnBOR6itWKB/lyo4Hc8EVmWMYhXfnbuwePT1/8Ar1fadiE2YODkjH6DNQdCLCEo2FAIxxt46j9TU8KkSxrtA54bFU4EkZkJVSxGOvH+ferotpFkj4AHGTngiqiKVuhtWhdk35JbcBxxgdM1ekBLMpX5mYKCTgEf5A4qnZxoVGAAr++MEVeijO7IcuSR1bgfjW8bmLQ6CyLO0hRueDxnnjnPrzWpY2W1F+8pHHTJpdNUyFV+UgHHXkityGERLt2fXJxW8YX1MnJRGW1opRQ2AvUgdBjtWrbQKqliMk889RVdGVDkOCc5/wD1ZqVZ2bB9epBrqikjkqOUi1lFHGPeoZCPm4yCMHNQecRg7R+pqF2IJIVQfQtRKSIjTZm6uFkjJ3KduRkcj/65rjtVjjDjI+Yc5xmus1MlEcbhj27H/DiuP1WR2YDIYgZJHt/MVwzXc7OljCfBlJMec8ADkipYnIjw2TjI+n40tsrn5gOvfBGKfJ8gHIA9c5wPQ1gzRGbeEmVgVGC2Dz/KmW1uZbg45YHoO/09qdMztLtGDj5hgZx74rQtI8EEnaM9SOB+VSldjbsjWsE8qKM7QrdefT1qvq2PJTbtIXPIXr7Gr0LjamHBwMgZ7f8A16yNRZmc4HBPY5x7Vvaxg9TFuFKo2FCgg7sf0r5h8Yjb4u1xfS+nH/kRq+pLsBgcKMdvevl3xr/yOWvY6fb5/wD0Y1a09zgxeyJfh+cePPDZ/wColbf+jVr7UiLPOCc4IyDnjHrXxV4Dz/wnPh3HX+0bfH/f1a+1IVGNx7jGc1yYz4onpZN/Dn6klyhFsB8uSeenT1qkbV/LDFclYiRt+YfQVqxpub5jweCD0q1qEX7hcKDkZwfT0PvSpR5tTtqytoed3VqXkJxgnkgcgUmn5UsgA6555APtn/8AVWvd2YhkYNDy+SCWxz6Gs+CMsRlckHAyOSf61NrO5nfSxbu7M3VrIqqp3DjA/SvGvF+jtBdsuzAA+9mvoHTrCSWMcMXY4yOAB6/SuP8AiJ4fBMhVAxKjbx1/+vXQnb3jmqU+eNjwKW2aMfNxntmodgPJAPrXRahbBGeMqMdc9/pWW0JWTJ/QCtlI82VKzsV0KISQozmrkcjY4wo7cVEIc8NjH86mSIDHUL0OaTZUYskiycEZ4NaFryM7gCfT19apxpkqADyMdauRwso6HI4+lZtm0Ym1BdCCHJwXz16Z9qDq8kjEBhge1UrdGOWIxkcj1rQsokEqDaSMZyBnIqbm1my3bK8se4DnGCAMZHStm0tC+AxGFbB56VFbWoByoIx7dK1rRDEzKoDYbHPpWTOiC6Atv5bYCkAHgZHFWIowSrLHuycEk5J/w+tWI7QyFiRkgAgA9c1qabpZyWCnbnnH8hQos15iO2t0n2CGEYUfN1wD9atSW7RoqmPAwCSM5/WtqHT44Fw65+TLc456A0+eyERy754BHXB/I9fpXTycqM3K7MeLdyV3YZgScA5+lbNrGzknMjZAAz6f171XijjRSGCNnBcgfkfrWhG8YyArMMYHy8nPQn0oQPY07SLy9hIBZOnHI9c1dVjgYyADgD6/zrNjfaqBgwA+UYHT6etSG4OOrKegAHA9TXTGSMJRuWriTacyMc5wSxxTBOqqwQLtJ59vrVK6m3ybQVAzkYGc/n3qOMlUVQxzgkYHX8aXM09BqCtqa+9MdPTnuPfFMdwuBhsjuf5ms2TUCq4yuR1z39xUK3rcDJwRnO4YHtx/Ks3NIFTGazcxskiqy52/xDt7/wCFcjc7pHRiwPOTj9K0tQkDOxZcZ5AB/wA8VnSyjP8AEpPXAHPH06dawlNs05SunyHG0jjPX/PNQXDEgfOVzyVPIHufenXbHczZYEjg8jj6VmXlwroVQDGOhPGfU1nJjS6gJFaZtr/dPU9M1rwgAEKfvHJwMfl7Vg2znzcgqGXjpnPvWrbzANubduI+UjP6+ppRdyZaF0O2GAyRjjb0/XrVaXh97Bi3TnGP8+9RmcIRyW28sD3rPmvCQ2M47Hpn2HvV3M7D7tyA+185755NfLnjP/kcNdz1+3z/APoxq+lriUSueCucYHXBr5o8Y/8AI365/wBf0/8A6MatqTODGbIn8ADPjvw2D31K2H/kVa+3Fi2oM9QMDjofwr4j8A/8j34c/wCwlbf+jVr7W8wHksCRxgnqfxNc+L+JHfk6fs5epaiG3AXcxHPI/TmrdzJ/o8Z+RSV7tVCEZbIAJHr0J/yaW/eRokTcR2yBj8KzhKyPQqRuzK1RdgKbR83Jb09+vArLt/l5wxUtwfQdyKtasrtcxYXrx97hfrmnWaH5kdvmLZYEdKV25WIsuU7Pwyq+WCxTjgH0H+cUzxdZpNbsGY8rnGcj/wDXUeguIo2BOCTwd3X6Voagv2mLajBlxjHX8a646w5epytWqX6Hzn430fyXMsSH5sE/LjI/rXF7VQkPkHpya+gPFOhCdDH5ZcquPr714vruh3NhcuHjYLnIJ9M1EbrRkVqf2kY6jcwGDzmljTceCoxweaRPlHPU+9SwyLjHBY8HNU2YxSHxx5ZSMYHPPGR61pwKApKkYPTv6iqULEkYHf8Azir0QKgoQRjgjHP0qNTVJFqOPIQDK88DPQ1bWAwjKnJP4YNMUFyeenOfWpVYmMZB55wBzU3NLGnaTBiRs6jHU4//AFVv6bFkKxbr975R1965+0jyiqufp1yevH5966PTsBRhgCD0PapNYnRaXab4wrHIPB4HB9f/AK1bsEPkorZ4IwfY/wBO1ZFlMlvCpXZgfwk5A/r/AJ4rp/DenR6nblxJ7r8/WuilG+xE5qCu2VY7Sa+IEULkouOBgDp+VR6gJUj3zYRh0XnI/D/Irp/Ds8Nkt2koCKmSpYnLAVyHiDWbfUrkrABtjYjI6ZHr/wDXrSbio67kQlKU2raLqU3Jdtm1y3Gdw5Iz7/0q7bHgF1wd3OOM4qlZOhY8Lgc5J61ptJG6YBOGOTtbqfU1iu5ux6PukQcjdkfL/L8eKdIdqHjaqqCQe3+FRQoFw2WLgAcHnmpnk8n+Hhe2SMfWtUyGtR4mKAkEEZIweD+P4DtVaW6KjbGW4Pv+mKhXLsfLcAD7pLA1WllcuAxyevK/zpc3QLD5LwozliVXG48rz+FUjdxAsNpUK2TgcLn0pl5IrZzwTyO2KzXkCrkyMozg4/rWcmCJbmdmc7uWGcADBHp1qMOigEleM9PWml22scAhOQOv48/lVG4n+duxyCce9Z3XQbK99L5hKIG6dQBzWamA7c4JGOfX6U66ZlYNkkrwSQORUaTEr1x15A7VD1DYmZuWbCs390dRUkUnl85YMD1P+c1FHGzy5WQfMAcYxTmj3NkBvc+lCuiXruI8rO3JZmwTtAxn/GqxRiyhtxPdsnFWgMEdefQU3cEB3DIzg7j+lUldmbIvLCxEiRgp7E/dPtXzd4zx/wAJhruDkfb5+f8Ato1fRV7OwRuOem0mvnLxdz4r1o/9Ps3/AKMNdVI87GbItfD7/kffDeOv9pW3/o1a+zmXc+0YDE5GeSD9K+Mfh7/yP3hr/sJ23/o1a+2jG3m7kUZx1HWubGRu0ejk0rQl6kNiWUjnAyc5PT6+lT3TI6qDtGB164Priobh/JIbqSfukZyPalH7zBwCpGN3U596wjpoepU194zNTEIlBIGcAlieDxVe0Kzy7t4B7/X25q7f2+4tkMxUZJxwKoWkbIwJHCnrtyTnp9RTktTFNWZ0WnzbWwZDgEFh159K2A42BWYEEZJHr7Z/lXN6axF0gAxg5+XnB9vXrXULHviy2ct1z/Wumm9DCdupTubf7Qu4ffzwN361znibwrHqVuSiqrDoQM1120iPaM49+M+9WoQrKduxQw6qP51cYqTsyZSsfMOueH5rO6mXaDg8E8ZrGFqyMSV56gkdq+lPFHhqC+tQ8YXe2SRtHA9jXlGsaAYXl+VcA4zgj8KmpFwIUVLVHCxfKwJbBHTpVmPPmAglt/IJ7D/GrM1psyg2lj2x1FRIjIAWBGfwrK5SjYtITsUepwOcZqaLbkMHGcZOTVYSfKF6gjJOPT0qVCMbgxz0HHX2oKsa9tchWwjDB4P0/wA4rb0+6AbccBcY71yce4L8wYEd+Rjmr9vdMFAyFIOM9x7H86kvZHWvqKMqjIAAPyrx+P6U2y1qe1kR4pVw646kZ78Vzkwm2KFU5DbvpketOSGYhfMj3HHJ471opW2M22d1qniS61mC0S3Vbdo1AlBJwxHdfWphJshLKeMbmwBxXOaR5cKNu+XK/L/9etJ7pXiZVJYkADdx/n60+Zy1Y0rKyNKObD/u2xjA5OPwNb1pvK5+ct0ySB74zXJaVIzvuyOuMNzn6118EZ+zg/uypbPC9sfzoUimhXYBtyAjJwvzdDjoP8az72VyVw5weMZzg1YuWjVSqtwPcDcP6VmTyGQFuu44PGSnpjHf39qu7ZLROJHAYb+dvOVGSfwqrPPvJx95McKcfr+NQrMxI2lASTgqnH5elQ7g3DygrnruwPx96TkJIimnLsAxAA6YJ4PtUMpbemQCVBG0Hj64qS6QIGwqDjDAHkfj2rNurza20hu3Ge/1rJvQvdjZpAqtGoXJOQc8e/FZt5OfnBxk9s5zUdzPvYll29txOM1nzy7nbOCT6VFxtEjzFsYzz2xnNWbZi6AljkfeyKht4WkIIxg4A9K1I4AAu0Im0Yz79x61VjNjIzI7naFJ9M8/jSkvuwwwCecc49KuxWsZb5ivPG0nH+frUksKRgkBecLluw96pRIbM9gRjLSH3449s1TkYqASSV69MirswHKp0XqMVUlwqDcuSOQRzWiiZORmX/y8EKrDvjpXz54rJPijWCeT9sm/9DNe/X0+13BCjjd1zj2rwDxQc+JtXPreTH/x81vBWPOxTukXPh7/AMj94a5x/wATO25/7arX29GuJwcKBj045r4h+H52+PfDZ9NTtj/5FWvuSz+d1yq4z2/nXPiVeSPQyp2pzZDc24lXGM7juxyenf8A+tUlouxTvG5gODgD86tBSqcH1HHvVG4ZwwC8DuTXPazueopcysPuocKQUOAOgHaqT2wSElEAGcAFeSf8KvgtODucf7pPAHqailBCMGzk/dPfFXvqZN2I7KGRH2qfm/vYwfoB/Wuig3Mih8kj0rnRLIsoDAbWXHzLWzazbQCBtwMDJyR9KqFkzOacloWLi3cZ7Z9TxUMFyqShWySOCCQDVuUZj34J47c5rFdW+1MXVRwCCRWs/daaJp++rM3QzMqhVXaM55GK5TxBpiSRnyzGHY7jk+9dHZgAZwQCD36U7UbcmJCFJyOSB19setay9+FyIvklY8f1TQ1DMdq5IyoHP6+lYN3puImCqMnnIFeuS2/mAkomc4YlcH8KyNU0lDvyQBjG3HXp1rjcex0+p5WbKTjH97sKYLV0J3KM4zt9vUetdtNpexxglyvJIzWdJaKGJJUgkk4HJPtU3Y+W5hiMdGA3ADBOcD2p8cZLjaoO0cYx+dX57VTlshgO2Ov/ANeoYLVg27YSM9f89KdyXFl+1lhcqsnQdR3xWldS2reX5G3gEYzz9MVhpbkMSh79l/rnmrsMbKpB+Xkn3FNS6EtPclRyvmsDxt2gAnIPvnrUMrSEAE4IA6k8/X/61Xok2x8heBuB9PrUUhbzF2OxUewHWpuUl0LmmNJE6BCmT8ozkf5FdKL12jjQbcEnL85x6e9c1GV5V8tgjGT96rk16zJtCA7Tt6D8vamnbcdm9i8XcybkLBSM4yMH6j1pJZSqAJIxB7AdPrVKOZiY/wB2ilQcnnkVZkZsgMVCp1KjqPb/AOvVp3RLWohbG7bjOeM5z7HFMNwIzuyRkEE+/pUT3LRZDIBxyN2RjtjNZs8zSk7egGRzyD6fSlewrDrm9LfMwUODg5HJrImuTkKoAy2flOAvtS3Ez7TlRnbkNjA/Cs6RmZ8queMjnHP9KzepWxLdMSj5RBnrz/Oi1hDoWcEkcKR1qCNHZR8q/eOCOa1LNMH92Qd3XNOwm9S5bQbUHy428tk55q1FwSOmDkcVKG8uFSWAOepx/nFIDkDY4GQSecc+nuK1S7GUmPUHdk/KTkDnikmt5nVSMbRwPTHpTI2HmEOFwVJ5/wA/yq9LqcKWyouFkXHbk/hW0IXvqYSlYrW1jbHLSy8gfN0x+dY2seREwEZyBzyevvUFzfyu7kgMq9ien+NclrursocDcMjtzj86002RhOVtyp4h1BY3OwgH1HBNeL605k1m/c8lriQ/+PGu+u52mcsR155Nee6l/wAhG6/66v8AzNWlY8+rPmNb4f4/4Tzw3nGP7Stuo/6arX23av8AvCCFx1AVv1/+tXxF4Dz/AMJx4dx1/tG3/wDRq19rGUo6kqFPsB/jXHit0exk6vCSNeR/kwQRxnIA4rJmKtOPvK2flxj/AD+NSrcqxYbjtVCQRgY98/0rPeVjLyzZY8nOMj1+lcspJrQ9aEHE6C1LEkE4OBnI4FSXUeY9u0kvzzjFU9OkzEzb+TgDI5X6Vab548v8wz8zAZz7VtF+6c817xlXIBRvmGGO0M3Y+1T28ipOU4Q5AIGRk+9Q3+1CQg2twQWAwPb2/wDrdagt2Y5ZSMr36kev+TSS1YM7CCRXsxgkg9OP8azpkDylsEYPIA5pYLoGBI/MIA6ZXrUJb5z0Oep5ronK6RlThZtl/T9oXGXIAIBP9a05SpjCZUnGBxnFZFvIU2shIbsDxx/StOKUvtzhgOx4/EVtRaSsc9aLvczLjTzbS5LBt394kEVXmiPl7ztC5wen610VwglHKg8ckc1nNbg5GB8vOcVNSkk9Niqde694wJbGOZVyyl8kdMY/wqhd6QVVjtjUdzniuomtQp3hCQD8pPIHv71mX7Om4bThBlcLj05HrWEoJbnRCfM9Dgry0NvKyEAkHAO3oahSDzFBCKerdO1b1zChnKkvhhu4GQR/T6VeisYhCpCMBg9Ryv4elcyV9je9jjoom3/u1GeoAHFXl2RDL5IUckjuavRWW12ByxIzkLnJ9arXkTSAZA3Mcn5OelUk0S33M+VwQFy2ByRgcj29/alZN3IIbjOSD0FW1s22lgFQgAjJ+971Uut0bKCRuzgAn07U0tCWyGcFV8wFMNzk54H9aSGQjaGHHbH6U9FSQksrbsnPH8qYQuOMZ6bcnmoLtoaELxiIBg4YNkHPCmkudQVCeoGTngHP+NV4mbEXIPXvVG83GVkVl55z6VXNYnlFuLtWjbewIY8e3tioLifIwpPbGD96kAByWOc9AB1PtUcyqGBTeqs2MqP1zSQNDicAhsg4+UdOPeqyxmRjkNt6AgnH4VZeAMg3FmbOc4AqaC3HmbCGHy8cHA9/rTRLTG29lsLFkIJxgHrn+laMUBZtwTPbIHf+tPsoy08caqMMcAc8/h2r1Pwx4LtX05JrzdufoB2H41tTpupsc9aqqUeaR5jHDIFYgEsDzg5/Pmld0ztjIBbg55I+ldl430i0026aGDJ3R71Vh298da4nUCscStgbv7o7Vo48rsZqpzrmIbiQqnyiT5enPDe1ZkygnPJO77vQE0Xd3lcBlOCTg8fpWBqWqYZiuOOMHvVJXMpzsiPWbtYAyKfXbnr+PrXF6hcvLL98nJ5xVrVL2SZjuxnpjPT2rIYgtyDzW8InBVqX0Bk+facZrgtU/wCQnd45/fP/AOhGu8JLNxnH+eK4PVP+Qld/9dn/AJmrZys0/ApK+NvDxHbUbc/+RVr64vLspsA8sMc5J7H/AA+lfIngogeMtBJ6C/g6/wDXRa+pbtmkKsxITPy/N0rzcdukfQ5J8Mn5nR2tzmPcWUgjgr1A+neqiSbbgnDY3ZHpUOkOG3ALggHO3IxV6aAEKyqx2jqOp989K41do9qTSZoWV1guB9xsHdnnPvWuX6ljtx1HrXOWb/vVLcKuDnIwPrWuk4bGdwwOAW6e1bU5aHLVjqRX5ZFOc8AjGAcf4Vni5ePIZCT3bt19O1Xr0GSFiTv/AI8B+SD6etYrPmdlI2EcBgensa1MJG/aXTgBm3KSMHtzVpJmkcBQ+B/DnkH1I9PauegucgAjnoVLj+dbdnMEDYGduATu6e1aRd1YnY045OmeeMgk9f8AAVetzjBBUD0ByKzhw2SVAxknkk/QVbO1o1+5gDGcYA+tXFsiaua6zq8LEbugwCO/SqYmBI5IOeQ3X60sD/uypyfb0FRSxATBcgcck9/xrecm0mc0YJNovlo3hHA5Pbk1k6jaK44xnPBAzirNuNrBQysoP3SMfjUl3cqseCPm5x1GaUuWavIcLwl7px11GsTBWADLk5J4FQ3NwuxQqtgHPU8/X1rUuwkrHZwWOVGM84rGu4o94Ugjvk9Ccc1wu6eh6K1I9NmAVi3B6e6/X2ouCC4I25xyB0J/madbxhmXYAUPB7ZH9KuX+k7Iw8Qj3bTjYeAM+5oWxLVjNZkEJJPJUYPfNYV/KsrD+90+vvWrNYy7guCuD8u5vz71j3NkwkU7vlZuMDGPUUm2NJEUYJID8EdQD0/wNWmhdULsQF4+mKgaJlJbYQ2c4A4qYHEJAIVTz0JP5VBTWhArKVXaBkEgHGDx/OopxIAGK4PTkYqUYYBiCc9OOmPWnGD5SzFgvXAxj8vShMTSMwKAG27lHuMc08bgC2TkEDGatXgSNNyqwJ4INUFWSVuGy3TgZGP8imInZY2ACksP4vxPQmprWNslVDZOASRyfTmpLa3B2sT343Y/Or9jEHnjQsAzMOQSfx+tXFNmbO1+GWkJcNHqNzErJC7bSwPB6V2Hibxbp+jo0IlMl4yny0QZ5x1z0p3gXTzZeH0STIaQliM9s8V5j8UfJXxPAI3Z1KnJDDj2x6V2TvCCjHRnme5iMQ+fVL7jN1fxBc6nItxfE+cF2HIGTz7dqw9UvQIvmLFQMckDIqK7nEROGIUc88nBrmNbuw45wABjCkjHvWS7G85dVoQ6jfc8OcE9+9c1e3W8tt4OcYqPULzLMMnBPes6SQZI4GK6oR0PNq1LsV3yeQwH86iJ3EY69DUTyAnPPWnoU8ssc7hxitkjkbuSqMnBA9q4LVht1W9B7TOP/HjXevcLbrub537L7+9cDqkhm1K7kYAM8zsQPdjSnYVy/wCDP+Rw0LjP+nwcf9tFr6ku12x5bbtJ/vZP0r5c8FHHjLQSen2+Dvj/AJaLX1BL5bEM2zCngkk15uLV2j3snlaMvU09CRp5pNxBHJIU4FbeohYU2KxPGQfTPb6VzmnZXIVlGR1yea1bkkRseA2Fxjk4/pXNFOzPWnL3iO2KkpvQBwTkZwG9607YGMZygJzg5yMdCR69RWBuVpWG4EEdVHJ98d60baYqvzAg/TtSgmFRo0ZsSRLGV4A5BOPxNZF6PLOUXadvy5Pymrdxc7IWU5J4HzL/AC9BWVqEnBGAMnke/v3rZHLIckwEibUTy85+p781u2E5cRg7A2eNw4/GuNSbEjHccgAYLdK1rO4A2bCpyM889+9aQbM2zt0cOhyF2ggLn7x9cfnUkT4by/lJycgDGKytKuJHALOPu/NnGfy7Vro+5GDL/DnhiSo9q1iuYbdizC4H3WH0xnBqxIcIDhDu/Q1n28hEmWf5j6gbR3p17MOoUgHktxz+FNPQTV2F1OF3/dZ8849qEjadJD8+9+mG/wA4rOWeTduVcKT8vHOc/wAulaVrcEF1faAOCSeM/wCf1qYpN6lPRaENxCyAkbsNx+PtWPepnblJA3TOMn6GujuXizJvwVHHr9KxpSIyGZmJBOVPPP8AWpnBFwn3KdvbHar7nHsOxq6X2KfNxtIwQxq3azeYQpxnb1C9TV28smngwDtG0g/Lz/8AXpKi+gSqrqYTwrmUHaw75PXmqDWsawMsqsWY8E9T6/Sp7uGWA4PzA425GOPT/wCtWXctsJCoEO7cxYnI74qXdD0ZnXcSxSGIHcGPXdzVYMY0ZgcEdwcmrTgFWUEkk8Bj09yaqupLk7sv0OM9qytcd7CAkxt8qkHjBPb605epIwxIwee3t/8AXpVVQSAkjZH8OBzTV2lSDH8w4K55/wD10+Vi5iv5I3b3OfXJwMfSlhQR8q2Poex9PemM3yv3Hpkj86rMGY/efg5+8P5UgRoNdhI8OWyOBg9RUtlceVeW0+zeEIJBON/tVeK0leIsvK9c7s44601hsUeZnA53E/mBWkUzOTSZ2niLxfcsoitYTDGEAfL5zxXD6lfPcSebN97oCeuKr3lwkqYUtux0PIP4+tc9qN+Qpw2S3PSrd5y5nq2Yymox5VohmrajyFRQy5zkHmuW1DUDKx/vHj6inX12HkO1yAPT+VZLsWYtu6+p6V004dzza1bsNlcliTxz0zVOVzuYf5FPnlG7gg/SoVUkknvXSkcEmCDLVdsNXutEuGnsJAkzxPCSUDfKwwRhge1UJJ1VWUH5qqlj82Scmhy5diR24k7vzrlb3/j8n/66N/OupUHpXLXv/H5P/wBdG/nWQy/4TOPFOjH0vIf/AEMV9L28nnAj5t5PJB5x6AV8qxSPFIkkTskiEMrKcFSOhB7VpL4i1tcbdY1EY6Yun4/WsatL2jTud2Exiw8Wmr3PqzTWGSG4IzgEZ7VclvFWHYflKjgr2r5KXxNrynK63qgPtdyf40h8Ta8Rg63qZ/7e5P8AGs/q7Ssmdf8Aakb35T6mjuIzKQnzHAKoBnPvW1ZSr8isApHQkDn9Oa+Ph4k1wHI1nUwfUXUn+NSDxV4hAwNd1UD/AK/JP8alYVp3uOWaxf2T7FuirjActjpheh9/UVg3khMWQFC5ydozj86+Wv8AhLfEf/Qwav6f8fsn/wAVUR8Ta8QQdb1Qg9c3cn+NX7C/Uz/tGPY+kWlPmNwWJ9McCtK0uN4+Z3ZgeDnmvlk+IdZJOdX1E59bl/8AGlXxHrajC6zqQHtdOP601Rt1IePV72PsfSJhuxs+UgE8849631uBsYnarDgc/Lj1/wDrV8PL4q8QqAF13VQB6Xkn+NPHjDxKOniLWf8AwOl/+KqlSa6lf2jF7o+3nuVM67SSO555x2/+tSSyrKreWhYnJxyCPYf4V8RHxf4lJJPiHWCTxn7bL/8AFU7/AITLxP8A9DHrX/gdL/8AFU/Z6h/aMf5T7TBzkhFAPBIJP4Uy2vVQsNyRsDjGCQM+hr4uPjHxN/0MWs8f9P0v/wAVSHxf4lOc+IdYOev+my8/+PUvZFf2lH+U+0pNSVN7F+vGeOeOgqk2qRSsN0mVOeo+6a+OH8WeInAD6/qzAcDN5If60z/hJ9f/AOg5qnr/AMfcn+NJ0m+oLMor7J9m2l+wkBUhZDwdvYZ7eldNYNeywPJ5UroM4w1fByeK/EKE7Ne1ZfpeSD+tXI/H3jCKPZF4s19EP8K6jMB+W6qhTtuyZZintE+99Bh0/VdHu57kJMUJBOSOR6+9ef6q1u11iBlKbyC4zgEHHPvXyHD428VQRskHibXI0fllS/lAb6gNUH/CV+If+g9q3XP/AB+Sf40pU3JJCjj4xlKVnr+B9ZXeApVeEU4AP3s/jVAGOOUSMQdo5AOBn0NfLZ8U+ID113VT/wBvkn+NNbxLrrfe1rUzj1u5P8az+r+Zp/acf5T6eaUu7Rh0+Xuc9+2ajWSTLZyhxnOOv418yHxJrh66zqWP+vp/8aUeJddAAGtamAOg+1Sf40fV33F/aUf5T6dV8/vGBJxkEdf/ANdWrfy3BDDaOCQf4f8ACvlc+I9cPXWdSP8A29P/AI0q+JteUYXW9TA6cXcn+NNUBf2lHsfVDz7IsDq3XHGR/n0rKvrlFJCE+WRxk9K+bD4l10nJ1rU8/wDX1J/jTX8Q606hX1jUWUdAblyB+tV7HzI+vrse93l8Pmw2Tt5BOM+9ctqF8WJAcY6YJzmvJm1fUn+9qF431mY/1qM6henrd3H/AH9b/GrjTsY1MXz9D0kq8h3DJB4yRVS5KgDBGOmK4H+0L3GPtlxj/rq3+NNN5dHrczH6ua2TSOWU7nZE/NyOPXFRzS4b9309a5A3Vwes8p/4Gab583/PWT/vo03PsZ2Op+YnpzShSeMH8q5Tzpf+er/99GjzZP8Ano//AH0agZ1wVj2P0Fcpff8AH7cf9dG/nUfmv/fb86aTk5PWgBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image obtained during bronchoscopy from the same patient, four months after the application of 200J of photodynamic therapy. Scar tissue is visible, and biopsies and brushings were negative for malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Armin Ernst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7768=[""].join("\n");
var outline_f7_37_7768=null;
var title_f7_37_7769="Inotropic agents in heart failure due to systolic dysfunction";
var content_f7_37_7769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inotropic agents in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7769/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/37/7769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The positive inotropic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , inamrinone (formerly known as amrinone),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , and the beta adrenergic receptor agonists (",
"    <a class=\"graphic graphic_table graphicRef63265 \" href=\"UTD.htm?28/22/29035\">",
"     table 1",
"    </a>",
"    ), have beneficial hemodynamic effects in patients with systolic heart failure (HF) due primarily to a direct increase in cardiac output and, to a lesser extent, the ensuing reduction in neurohumoral activation, which causes an unloading of the heart via a reduction in the plasma levels of vasoconstrictors such as angiotensin II and norepinephrine. Inotropic therapy is of potential value only in patients with decreased cardiac contractility. Those with HF due to diastolic dysfunction or mitral stenosis do not need inotropic support.",
"   </p>",
"   <p>",
"    The efficacy of acute intravenous inotropic support is well established in patients with severe myocardial systolic dysfunction. However, the benefit of chronic administration of oral inotropic agents in ambulatory patients, with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , remains unproven. On the contrary, available data suggest that the chronic use of many of these drugs may increase mortality. Digoxin is the only oral positive inotropic agent available for long-term ambulatory use.",
"   </p>",
"   <p>",
"    An overview of therapy of heart failure (HF) with systolic dysfunction is presented separately (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIGOXIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is the only safe and effective oral positive inotropic agent. Data supporting the efficacy of digoxin therapy in patients with HF are presented in detail elsewhere. An important finding is that the safety of digoxin is related to the serum digoxin level (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"UTD.htm?24/42/25262\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition to symptomatic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/4\">",
"     4",
"    </a>",
"    ], digoxin appears to be safe at optimal serum concentrations of 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in men and 0.5 to 0.9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in women, but to reduce survival at concentrations &ge;1.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in both sexes (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"UTD.htm?24/42/25262\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. It should also be recognized that digoxin has other actions, most importantly to modify autonomic tone, that may be as important, or even more important, than its effects on myocardial contractility in determining the drug's clinical effects during chronic administration.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is discussed separately. Our approach is consistent with the 2009 update of the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline suggestion that digoxin may be considered for symptom relief in patients with left ventricular systolic dysfunction with symptoms of HF to reduce hospitalization (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHOSPHODIESTERASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterase (PD) inhibitors, such as inamrinone (formerly known as amrinone),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , and enoximone, decrease the rate of cyclic AMP degradation. The ensuing increase in cyclic AMP concentration leads to enhanced calcium influx into the cell, a rise in cell calcium concentration, and increased contractility. These drugs also cause systemic arterial and venous dilation via inhibition of peripheral PD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of an intravenous PD inhibitor, such as inamrinone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , can provide acute hemodynamic and symptomatic benefit in patients with advanced heart failure (New York Heart Association [NYHA] functional class III or IV) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 3",
"    </a>",
"    ). Initial uncontrolled observations suggested that prolonged outpatient therapy with intravenous milrinone, either continuous or weekly, could improve functional status and reduce hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the possible benefit of such therapy was not confirmed in the OPTIME CHF, a controlled trial in 949 patients admitted to the hospital with an acute exacerbation of chronic HF and a mean LVEF of 23 percent; patients requiring inotropic support were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/9\">",
"     9",
"    </a>",
"    ]. The patients were randomly assigned to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    or placebo for 48 to 72 hours and then followed for 60 days. Milrinone therapy was associated with significant increases in hypotension requiring intervention and atrial arrhythmias and with nonsignificant increases in mortality in-hospital (3.8 versus 2.3 percent) and at 60 days (10.3 versus 8.9 percent).",
"   </p>",
"   <p>",
"    In a post hoc analysis, patients with ischemic cardiomyopathy did significantly worse with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    in terms of the primary end point of days of hospitalization and the combined end point of hospitalization plus death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, milrinone had a neutral to modestly beneficial effect in patients with a nonischemic cardiomyopathy.",
"   </p>",
"   <p>",
"    An adverse mortality effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    was also suggested in a retrospective analysis from the Acute Decompensated Heart Failure (ADHERE) national registry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/11\">",
"     11",
"    </a>",
"    ]. After attempted adjustment for differences in risk, milrinone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    were associated with increased mortality compared to patients who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    . However, since sicker patients were treated with the inotropes, one cannot know if the adjustments were sufficient. Use of these agents is discussed below. (See",
"    <a class=\"local\" href=\"#H24038082\">",
"     'Use of dobutamine or milrinone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of an oral PD inhibitor, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    or enoximone, has been associated with",
"    <strong>",
"     increased mortality",
"    </strong>",
"    compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A meta-analysis from the Cochrane Database included 21 randomized trials with a total of 8408 patients treated with a PD inhibitor or placebo with greater than three months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/14\">",
"     14",
"    </a>",
"    ]. The largest included trials were the VEST trial, which studied vesnarinone (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Vesnarinone'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/15\">",
"     15",
"    </a>",
"    ], and the PROMISE trial which studied milrinone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to placebo, use of a PD inhibitor was associated with a significant 17 percent increase in mortality (relative risk 1.17, 95% CI 1.06-1.30). PD inhibitors increased cardiac death, sudden death, arrhythmias, and vertigo. These adverse effects were seen with or without concurrent vasodilator therapy.",
"   </p>",
"   <p>",
"    In the PROMISE trial in which 1088 patients with NYHA class III or IV heart failure were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/12\">",
"     12",
"    </a>",
"    ]. At six months, milrinone therapy was associated with a significant 28 percent increase in all-cause mortality (30 versus 24 percent with placebo) and a 34 percent increase in cardiovascular mortality. Patients treated with milrinone had a greater incidence of hospitalizations, more adverse cardiovascular side effects (syncope and hypotension), and higher drug discontinuation rate. Although there was no subgroup in which milrinone was associated with a survival benefit, the large majority of excess mortality was observed in patients with class IV symptoms.",
"   </p>",
"   <p>",
"    Why the oral use of PD inhibitors worsens long-term outcome is not clear, but likely is due at least in part to increased ventricular and atrial arrhythmias. It is possible that the chronic use of PD inhibitors in lower doses may be safer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/16\">",
"     16",
"    </a>",
"    ], but the long-term efficacy and safety of this approach remains to be demonstrated in controlled trials.",
"   </p>",
"   <p>",
"    It has been proposed that the use of a PD inhibitor may permit the successful initiation and upward titration of beta blockade. Such an approach might be effective in medically refractory patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .) It has also been proposed that a PD inhibitor and beta blocker might be used together long term. In a randomized short-term study, the hemodynamic responses to enoximone were maintained or enhanced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/17\">",
"     17",
"    </a>",
"    ], and in a series of 30 patients with refractory NYHA class IV HF who were treated with the combination of enoximone and metoprolol, this regimen was well tolerated by 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/18\">",
"     18",
"    </a>",
"    ]. While the short- or long-term use of a PD inhibitor with beta-blockade may be useful in selected circumstances (eg, to stabilize hemodynamics in a patient with decompensation in the setting of new beta blockade), the safety and efficacy of the routine use of this combination has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BETA ADRENERGIC RECEPTOR AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic stimulation of the beta adrenergic receptor has been considered a therapeutic option in patients with advanced HF. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    and selective beta blockers with intrinsic sympathomimetic activity (ISA) have been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dobutamine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24037881\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic improvement has been demonstrated in patients with advanced HF after treatment with a continuous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    (at a rate of 5 to 7.5",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min) for three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. It has been suggested that the benefit can last for 30 days or more in selected cases, a phenomenon that has been called a \"dobutamine holiday\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/21\">",
"     21",
"    </a>",
"    ]. Possible mechanisms include a sustained improvement in myocardial contractility and left ventricular performance, a training-like effect on skeletal muscles, and an improvement in vascular endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"     \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, no placebo-controlled data documenting improved survival from either intermittent or continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. A small study randomly assigned 38 patients to ambulatory, intermittent, low-dose dobutamine (2.5",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min administered for 48 hours per week for six months) or to optimal standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/24\">",
"     24",
"    </a>",
"    ]. Dobutamine did not affect mortality or improve functional status; it did, however, reduce hospitalization for all-causes and for worsening of HF. Another controlled trial, the results of which have never been published, evaluated intermittent ambulatory dobutamine infusion in 60 patients; the trial was stopped prematurely because of",
"    <strong>",
"     excess mortality",
"    </strong>",
"    in the dobutamine group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the potentially increased mortality risk, the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    has been limited to the in-patient management of patients with severe decompensated HF. In this setting, dobutamine appears to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    may increase mortality compared to placebo in patients who do not require inotropic support at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, a nonrandomized retrospective study from ADHERE suggested that, after attempted adjustment for differences in risk, milrinone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    were associated with increased mortality compared to patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/11\">",
"     11",
"    </a>",
"    ]. Since sicker patients were treated with the inotropes, one cannot know if the adjustments were sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Effect of beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral beta blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , are part of the standard management of HF due to systolic dysfunction. In a randomized, short-term study, pretreatment with carvedilol markedly reduced the inotropic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , whereas metoprolol had only a slight inhibitory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/17\">",
"     17",
"    </a>",
"    ]. The reason for this difference is not fully understood, but likely relates to different effects of the two agents on beta-adrenergic receptor regulation. Metoprolol leads to upregulation of beta-1 receptors, which are down-regulated in patients with HF, whereas carvedilol does not cause upregulation of the beta-1 receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypersensitivity myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An eosinophilic hypersensitivity myocarditis has been reported in 2.4 to 23 percent of patients treated with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    infusion, particularly if prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Hypersensitivity myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24038202\">",
"    <span class=\"h2\">",
"     Beta blockers with ISA",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that beta blockers that also have significant intrinsic sympathomimetic activity (ISA) may offer a safer way of providing chronic inotropic support to the failing heart. However, a prospective, multicenter study of 512 patients demonstrated a significant excess mortality in patients treated with one such agent, xamoterol, as compared with placebo (9.1 versus 3.7 percent within 100 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24038082\">",
"    <span class=\"h1\">",
"     USE OF DOBUTAMINE OR MILRINONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given concerns about increased mortality with short-term intravenous therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in patients with acute decompensated HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/9,11,31\">",
"     9,11,31",
"    </a>",
"    ], we suggest that these drugs",
"    <strong>",
"     not",
"    </strong>",
"    be used in the routine management of such patients. However, administration of an inotrope should be considered in patients with severe hemodynamic compromise that is not adequately managed by diuretics and vasodilators, or cardiogenic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Inotropic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to long-term intravenous therapy with a positive inotropic agent, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that long-term infusion of an inotropic agent may be harmful and was not recommended in patients with current or prior symptoms of HF, except as palliation in patients with, end-stage HF refractory to standard medical therapy (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CALCIUM-SENSITIZING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents described above act through a common pathway involving beta receptors, cyclic AMP, protein kinase A, and increased calcium influx to the cardiomyocyte. However, increased calcium influx leading to calcium loading may increase arrhythmic risks and result in worse outcomes.",
"   </p>",
"   <p>",
"    An alternative approach is to enhance myocardial response to a given concentration of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Several compounds have been identified that increase the sensitivity of the myocardial contractile apparatus to calcium, causing an increase in tension development and myocardial contractility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One concern regarding such compounds is the possible impairment of myocardial relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/35\">",
"     35",
"    </a>",
"    ]. However, at least one of these compounds, levosimendan, appears to have a favorable effect on relaxation properties in failing hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most calcium-sensitizing agents have additional pharmacologic properties, such as phosphodiesterase inhibition, which may increase inotropy and vasodilation and contribute significantly to their clinical profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pimobendan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pimobendan is an inotropic agent with phosphodiesterase-inhibiting and calcium-sensitizing effects. Acute intravenous administration of pimobendan to patients with HF results in increases in stroke volume and cardiac index and reductions in left ventricular end-diastolic pressure, systemic vascular resistance, and mean arterial pressure with associated small elevation in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/36\">",
"     36",
"    </a>",
"    ]. In two randomized, placebo-controlled trials (PMRG and PICO) of patients with heart failure, 12- to 24-week administration of oral pimobendan resulted in improvements in exercise duration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], although in the larger study there was a nonsignificant trend toward greater mortality (hazard ratio 1.8, 95% CI 0.9 to 3.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term efficacy and safety of pimobendan for treatment of heart failure has not been established. In the EPOCH study, 306 patients with NYHA functional class II or III HF and LVEF &le;45 percent despite conventional therapy were randomly assigned to 52 weeks of treatment with pimobendan or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/39\">",
"     39",
"    </a>",
"    ]. The primary combined end point of sudden cardiac death, hospitalization for HF, or death from HF was less frequent in the pimobendan group (10.1 versus 15.3 percent) but this difference was not statistically significant. The combined adverse cardiac event rate in the pimobendan group was significantly lower than in the placebo group (15.9 versus 26.3 percent) but this end point included addition or increase in doses of background medications and decrease in specific activity scale.",
"   </p>",
"   <p>",
"    Pimobendan is currently approved for use only in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Levosimendan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the efficacy of levosimendan in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/33,40-43\">",
"     33,40-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Short-term benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term hemodynamic effects of intravenous administration of levosimendan include reduction in cardiac filling pressures and an increase in cardiac index.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report consisted of 146 patients with NYHA class III or IV HF, an elevated pulmonary capillary wedge pressure (PCWP), and a reduced cardiac index [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/40,44\">",
"       40,44",
"      </a>",
"      ]. Compared to placebo, an intravenous infusion of levosimendan for six hours produced an increase in stroke volume and cardiac index of 28 and 39 percent, respectively, and a dose-dependent reduction in PCWP, right atrial and pulmonary artery pressures, and symptoms of dyspnea and fatigue; there was no significant increase in adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These hemodynamic effects were maintained during infusion for 48 hours. In addition, discontinuing the infusion at 24 hours did not appear to attenuate the benefit seen at 48 hours, probably as a consequence of the persistence of an active metabolite [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A dose ranging study found that the effects of levosimendan on cardiac output, stroke volume, and PCWP are dose-dependent, at doses ranging from 0.05 to 0.6",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per minute [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/41\">",
"       41",
"      </a>",
"      ]. The higher doses (above 0.2",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per minute) were associated with a higher incidence of side effects including headache, nausea and hypotension.",
"     </li>",
"     <li>",
"      The LIDO trial compared the short-term hemodynamic effects of a 24-hour intravenous infusion of levosimendan with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      in 203 patients with severe, deteriorating heart failure, acute heart failure, or heart failure after coronary artery bypass grafting; patients with cardiogenic shock were excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/42\">",
"       42",
"      </a>",
"      ]. The hemodynamic end point (35 percent increase in cardiac index and &ge;25 percent reduction in PCWP at 24 hours) was more frequently achieved with levosimendan than dobutamine (28 versus 15 percent). The effects of levosimendan were not attenuated by concurrent therapy with a beta blocker in contrast to dobutamine.",
"     </li>",
"     <li>",
"      The SURVIVE trial randomly assigned 1327 patients with acute decompensated HF and an LVEF &le;30 percent to intravenous levosimendan or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/45\">",
"       45",
"      </a>",
"      ]. After the 24 hours of therapy, there was no difference between the groups assigned to levosimendan or dobutamine in the percentage of patients who reported more than a mild improvement in dyspnea (82 versus 83 percent) or a global assessment (80 versus 81 percent). Patients assigned to levosimendan did have a significantly greater reduction in plasma BNP compared to patients assigned to dobutamine (631 versus 397",
"      <span class=\"nowrap\">",
"       pg/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, levosimendan therapy improves indices of cardiac performance and HF, but does not appear to have a greater impact on symptoms than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Long-term benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term effects of levosimendan are less well established, but recent studies do not support a survival benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the LIDO trial cited above, levosimendan was associated with a significant mortality benefit at both one and six months (8 versus 17 percent and 26 versus 38 percent, respectively).",
"     </li>",
"     <li>",
"      A similar effect was noted in the RUSSLAN trial of 504 patients with left ventricular failure within two days of an acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared to placebo, a six-hour infusion of levosimendan did not affect the primary end point of hypotension or clinically significant myocardial ischemia, but significantly improved the secondary end point of death or worsening heart failure at one day and two weeks (12 versus 20 percent), with a strong trend toward improvement at six months (23 versus 31 percent).",
"     </li>",
"     <li>",
"      In the SURVIVE trial described above, in patients with acute decompensated HF and systolic dysfunction, a 24-hour infusion of levosimendan, compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      , did not reduce all-cause mortality, cardiovascular mortality, or days out of the hospital at 180 days [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The REVIVE trial (not yet published) was not powered to assess mortality. However, a secondary endpoint of 90 day mortality showed a trend toward more deaths in the levosimendan arm than in the control arm (45 versus 35 deaths, not statistically significant).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24037752\">",
"    <span class=\"h3\">",
"     Use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the above results, we conclude that the efficacy and safety of levosimendan have not been established. Levosimendan is currently approved for intravenous use in some countries in Europe and South America, but remains investigational in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The 2012 European Society of Cardiology (ESC) heart failure guidelines note that the efficacy and safety of levosimendan are still uncertain, though they suggest a potential pharmacologic rationale for intravenous levosimendan (or a phosphodiesterase inhibitor) to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VESNARINONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesnarinone is a quinolone derivative with multiple mechanisms of action, including inhibition of the outward delayed rectifying potassium current, an increase in the fast sodium inward current, and phosphodiesterase inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies suggested that chronic oral therapy was associated with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/48\">",
"     48",
"    </a>",
"    ]. However, these benefits were not confirmed in a subsequent, much larger prospective mortality trial (VEST) that compared vesnarinone (30 or 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with placebo in 3833 patients with NYHA class III and IV HF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/15\">",
"     15",
"    </a>",
"    ]. The trial was terminated prematurely due to a dose-dependent increase in mortality (12 and 23 percent in patients receiving 30 and 60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively), primarily due to sudden cardiac death. The increase in mortality was seen in all subgroups (",
"    <a class=\"graphic graphic_figure graphicRef67401 \" href=\"UTD.htm?24/61/25566\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based on these data, there does not appear to be a role for vesnarinone in the treatment of patients with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IBOPAMINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ibopamine is a dopamine agonist that stimulates the dopaminergic-1 and dopaminergic-2 receptors, causing peripheral and renal vasodilation that may result in mild inotropic activity. Ibopamine improves symptoms during short-term use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/49\">",
"     49",
"    </a>",
"    ], but is not effective during long-term use. The PRIME-II trial, which evaluated 1906 patients with severe (NYHA class III and IV) HF who were already receiving maximal medical therapy, was stopped prematurely because of excess mortality in the ibopamine group (25 versus 20 percent for placebo at approximately one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/50\">",
"     50",
"    </a>",
"    ]. The increase in mortality primarily occurred in patients treated with antiarrhythmic drugs at baseline;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was the most common agent used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INOTROPES IN PATIENTS AWAITING HEART TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe HF who are awaiting heart transplantation constitute a unique population with respect to the role of therapy for hemodynamic support. In this setting, the goal of HF management is to maintain the patient's clinical stability long enough to enable the patient to undergo transplantation when a donor heart becomes available. A variety of approaches have been used to \"bridge\" a patient to heart transplantation, including the use of mechanical ventricular assist devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link&amp;anchor=H15#H15\">",
"     \"Indications and contraindications for cardiac transplantation\", section on 'Major society guidelines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous inotropic agents are another option for the temporary hemodynamic support of a heart transplant candidate. The clinical improvements seen with inotropes (reduced hospitalization, less frequent worsening of HF) are beneficial because the patient is maintained in an optimal clinical condition prior to surgery. Such patients can be discharged from the hospital if clinically stable and managed on an outpatient basis with the assistance of a visiting nurse and a home infusion therapy program. The increased risk of sudden death associated with these agents can be mitigated with the use of an implantable cardioverter-defibrillator (ICD) and, if appropriate, pharmacotherapy (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) for the suppression of ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Use of an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of outpatient intravenous inotropic therapy as a bridge to heart transplantation was illustrated in a report of 21 patients with severe HF who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    (12 patients),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    (eight patients), or dopamine (one patient) for a mean duration of 146 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7769/abstract/51\">",
"     51",
"    </a>",
"    ]. All but one of the patients received an ICD prior to hospital discharge. Intravenous inotropic therapy resulted in significant improvements in functional capacity, renal function, and hemodynamics as well as a decrease in the number of hospitalizations. Fifteen patients underwent heart transplantation, three died, and three were still awaiting transplantation at the end of follow-up. There were five episodes of catheter infection or thrombosis during home infusion therapy, one resulting in fatal septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only safe and effective oral positive inotropic agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      but it has a relatively narrow therapeutic window. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Digoxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious questions have been raised about the long-term safety of other oral positive inotropic agents, including phosphodiesterase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      , enoximone, and vesnarinone, as well as other agents such xamoterol, and ibopamine. When added to conventional therapy with digitalis, diuretics, and ACE inhibitors, each of these agents has been associated with an increase in mortality. The adverse outcomes with these agents may result in part from proarrhythmic effects leading to sudden death. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24038202\">",
"       'Beta blockers with ISA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Vesnarinone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Ibopamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given concerns about increased mortality with short-term intravenous therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      in patients with acute decompensated HF, we suggest that these drugs",
"      <strong>",
"       not",
"      </strong>",
"      be used in the routine management of such patients. However, administration of an inotrope should be considered in patients with severe hemodynamic compromise that is not adequately managed by diuretics and vasodilators, or cardiogenic shock. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intravenous therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Dobutamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With respect to long-term intravenous therapy with a positive inotropic agent, long-term infusion of an inotropic agent may be harmful and is not generally recommended in patients with current or prior symptoms of HF, except as palliation in patients with end-stage HF refractory to standard medical therapy (",
"      <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24038082\">",
"       'Use of dobutamine or milrinone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous intravenous inotropic therapy and mechanical ventricular assist device support are options for the hemodynamic support of patients awaiting heart transplantation. With appropriate protection against the risks of sudden death and catheter infection, selected patients may receive inotropic therapy on an outpatient basis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Inotropes in patients awaiting heart transplant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/2\">",
"      Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/3\">",
"      Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/4\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/5\">",
"      Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986; 73:III175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/6\">",
"      Mehra MR, Ventura HO, Kapoor C, et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997; 80:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/7\">",
"      Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996; 132:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/8\">",
"      Milfred-LaForest SK, Shubert J, Mendoza B, et al. Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. Am J Cardiol 1999; 84:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/9\">",
"      Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/10\">",
"      Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/11\">",
"      Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/12\">",
"      Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/13\">",
"      Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990; 82:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/14\">",
"      Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005; :CD002230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/15\">",
"      Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998; 339:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/16\">",
"      Lowes BD, Higginbotham M, Petrovich L, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000; 36:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/17\">",
"      Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/18\">",
"      Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/19\">",
"      Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980; 100:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/20\">",
"      Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977; 56:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/21\">",
"      Liang CS, Sherman LG, Doherty JU, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 1984; 69:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/22\">",
"      Patel MB, Kaplan IV, Patni RN, et al. Sustained improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure. Circulation 1999; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/23\">",
"      Sindone AP, Keogh AM, Macdonald PS, et al. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997; 134:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/24\">",
"      Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/25\">",
"      Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/26\">",
"      Dies, F, Krell, MJ, Whitlow, P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure (abstract). Circulation 1986; 74 (Suppl II):38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/27\">",
"      Yamani MH, Haji SA, Starling RC, et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J 2001; 142:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/28\">",
"      Takkenberg JJ, Czer LS, Fishbein MC, et al. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit Care Med 2004; 32:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/29\">",
"      Johnson MR. Eosinophilic myocarditis in the explanted hearts of cardiac transplant recipients: Interesting pathologic finding or pathophysiologic entity of clinical significance? Crit Care Med 2004; 32:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/30\">",
"      Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 1990; 336:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/31\">",
"      Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy. J Am Coll Cardiol 2005; 46:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/32\">",
"      Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/33\">",
"      De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006; 27:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/34\">",
"      Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 2007; 115:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/35\">",
"      Hajjar RJ, Gwathmey JK. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovasc Drugs Ther 1991; 5:961.",
"     </a>",
"    </li>",
"    <li>",
"     Hassenfuss G, Holubarsch C, Heiss JW, et al. Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside. In: Inotropic Stimulation and Myocardial Energetics, Just HJ (Ed), Springer-Verlag, New York 1989. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/37\">",
"      Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992; 85:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/38\">",
"      Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/39\">",
"      Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002; 66:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/40\">",
"      Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/41\">",
"      Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/42\">",
"      Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/43\">",
"      Moiseyev VS, P&otilde;der P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/44\">",
"      Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/45\">",
"      Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/46\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/47\">",
"      Focaccio A, Peeters G, Movsesian M, et al. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation 1996; 93:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/48\">",
"      Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993; 329:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/49\">",
"      Dohmen HJ, Dunselman PH, Poole-Wilson PA. Comparison of captopril and ibopamine in mild to moderate heart failure. Heart 1997; 78:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/50\">",
"      Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7769/abstract/51\">",
"      Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant 2004; 23:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3488 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7769=[""].join("\n");
var outline_f7_37_7769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIGOXIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHOSPHODIESTERASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BETA ADRENERGIC RECEPTOR AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dobutamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24037881\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Effect of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypersensitivity myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24038202\">",
"      Beta blockers with ISA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24038082\">",
"      USE OF DOBUTAMINE OR MILRINONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CALCIUM-SENSITIZING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pimobendan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Levosimendan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Short-term benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Long-term benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24037752\">",
"      - Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VESNARINONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IBOPAMINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INOTROPES IN PATIENTS AWAITING HEART TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3488|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/42/25262\" title=\"figure 1\">",
"      Digoxin level and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/61/25566\" title=\"figure 2\">",
"      Outcome subgroups vesnarinone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/22/29035\" title=\"table 1\">",
"      Chronic inotropic agents HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 2\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 3\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_37_7770="Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors";
var content_f7_37_7770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Francis J Hornicek, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Stephen L Lessnick, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Henry J Mankin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/37/7770/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/37/7770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET) were originally described as distinct clinicopathologic entities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1918, Stout described a tumor of the ulnar nerve with the gross features of a sarcoma, but composed of small round cells focally arranged as rosettes; this entity was subsequently designated neuroepithelioma, and then PNET [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ES was described by James Ewing in 1921 as an undifferentiated tumor involving the diaphysis of long bones that, in contrast to osteosarcoma, was radiation-sensitive. Although most often a primary bone tumor, ES was also reported to arise in soft tissue (extraosseous Ewing sarcoma [EES]) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, over the last several decades, it has become clear that these entities comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes malignant small-cell tumor of the chest wall (Askin tumor) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/3\">",
"     3",
"    </a>",
"    ], and atypical ES [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Because of their similar histologic and immunohistochemical characteristics and shared nonrandom chromosomal translocations, these tumors are considered to be derived from a common cell of origin, although the histogenic origin of this cell is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Histogenesis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H44#H44\">",
"     \"Diseases of the chest wall\", section on 'Malignant neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EFT can develop in almost any bone or soft tissue, but the most common site is in a flat or long bone, and patients typically present with localized pain and swelling. Although overt metastatic disease is found in fewer than 25 percent at the time of diagnosis, subclinical metastatic disease is assumed to be present in nearly all patients because of the 80 to 90 percent relapse rate in patients undergoing local therapy alone. As a result, systemic chemotherapy has evolved as an important component of treatment.",
"   </p>",
"   <p>",
"    Advances in multidisciplinary management of EFT over the past 30 years have resulted in a marked improvement in survival and a greater likelihood of limb-sparing surgery rather than amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .) In data derived from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, five-year survival rates for patients with ES rose between 1975 and 2000 in all age groups, although the improvements were most marked in younger individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/14\">",
"     14",
"    </a>",
"    ]. Five-year survival rates in those treated between 1993 and 2000 were &gt;65 percent, whereas for those over the age of 15, they were below 50 percent. Among young patients presenting with nonmetastatic disease who receive modern multidisciplinary treatment, long-term survival can be achieved in 70 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will discuss the epidemiology, pathology, and molecular genetics of",
"    <span class=\"nowrap\">",
"     EFT/peripheral",
"    </span>",
"    PNET. The clinical features, diagnosis, and treatment of these tumors, principles underlying the performance of a diagnostic bone biopsy, and central PNET tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=see_link&amp;anchor=H20#H20\">",
"     \"Uncommon brain tumors\", section on 'Supratentorial primitive neuroectodermal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary bone tumors are responsible for 6 percent of all childhood cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/17\">",
"     17",
"    </a>",
"    ]. Although rare, the EFT represent the second most common primary bone malignancy (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"UTD.htm?41/39/42620\">",
"     table 1",
"    </a>",
"    ) affecting children and adolescents, after osteosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Despite this, EFT is responsible for only 3.5 percent of cancers in American children 10 to 14 years old, and 2.3 percent of those arising among 15 to 19 year olds. A similar incidence (2.8 percent of all tumors in children aged 15 to 19 years old) is described in adolescents in England [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, 650 to 700 children and adolescents younger than 20 years old are diagnosed with bone tumors every year, of which only 200 are EFT and the remainder osteosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/20\">",
"     20",
"    </a>",
"    ]. The peak incidence is between 10 to 15 years of age. However, 30 percent of cases arise in children under the age of 10, and another 30 percent are in adults over the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. As with many pediatric tumors, there is a slight male predominance.",
"   </p>",
"   <p>",
"    Racial and ethnic factors are of epidemiologic importance. For unclear reasons, the EFT affect mainly Caucasians and are extremely uncommon among blacks (both in the United States and Africa) and Asians (",
"    <a class=\"graphic graphic_figure graphicRef81715 \" href=\"UTD.htm?27/47/28415\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The reason for this striking ethnic distribution is not known. However, interethnic differences exist for certain alleles of the Ewing sarcoma gene (the EWSR1 gene, MIM#133450), which is consistently disrupted in these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/26\">",
"     26",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H9\">",
"     'EWSR1 translocations in EFT'",
"    </a>",
"    below). Furthermore, genome-wide association studies have raised the possibility that genetic susceptibility factors may contribute to the observed",
"    <span class=\"nowrap\">",
"     geographical/ethnic",
"    </span>",
"    differences in Ewing sarcoma incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;EFT have not been consistently associated with any familial or congenital syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], although at least one series reports an excess of congenital mesenchymal defects in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/30\">",
"     30",
"    </a>",
"    ], and another suggests an increase in neuroectodermal tumors and stomach cancer in the families of patients with ES [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific environmental exposures have",
"    <strong>",
"     not",
"    </strong>",
"    been identified as risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. EFT develop rarely after treatment of a primary cancer during childhood, but most cases do not appear to be related to radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. An association has been suggested between a parental occupation of farming (particularly if the mother farmed) and the development of Ewing sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ewing sarcoma may be more common in children who have hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. A meta-analysis of three case-control studies (totaling 357 patients with Ewing sarcoma and 745 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]) showed that affected children were more likely to have had a hernia in childhood (odds ratio 3.2, 95% CI 1.9 to 5.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/35\">",
"     35",
"    </a>",
"    ]. The association was strongest for umbilical hernias. The mechanism underlying a possible association between hernias and Ewing sarcoma is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HISTOGENESIS AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the EFT represent a spectrum of tumors that range from the undifferentiated ES to atypical poorly differentiated ES and the differentiated PNET.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histogenic origin of EFTs has been debated over the years. A neuroectodermal origin had been proposed based upon variable expression of neuronal immunohistochemical markers, cytogenetic, and ultrastructural features, as well as the ability of ES cell lines to differentiate along neural pathways in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/10-12,40,41\">",
"     10-12,40,41",
"    </a>",
"    ]. Because of the resemblance of the PNET to classic neuroblastoma, the neural crest was regarded as the most likely progenitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although ES is typically described as an undifferentiated tumor whose primitive cells lack neural differentiation, some tumors contain Homer-Wright rosettes, which are indicative of neural differentiation. Furthermore, ES can express neural antigens (eg, gastrin releasing peptide, a protein which is normally expressed by the brain and neuroendocrine cells) on their surface [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/40\">",
"     40",
"    </a>",
"    ], and both ES and PNET synthesize choline acetyltransferase, a marker suggesting a common neural origin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Histologic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based upon these features, and the lack of precursor synthesis for the adrenergic pathway, some investigators believe that EFT are derived from postganglionic parasympathetic primordial cells, which are located throughout the parasympathetic nervous system, accounting for their widespread distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/10,12,42\">",
"     10,12,42",
"    </a>",
"    ]. In contrast, neuroblastomas synthesize neurotransmitters that are associated with the sympathetic autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/10,42\">",
"     10,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to this \"neural crest hypothesis\", an alternative theory is emerging that suggests that EFT arise from mesenchymal progenitor or mesenchymal stem cells (MSC). MSCs isolated from bone marrow can differentiate into osteogenic, chondrogenic, or adipogenic lineages. Expression of the ES-specific oncoprotein EWS-FLI (see below) blocks MSC differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/43\">",
"     43",
"    </a>",
"    ], while removal of EWS-FLI from patient-derived ES cell lines allows the cells to gain the ability to differentiate into multiple lineages and adapt a gene expression profile that resembles that of MSCs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional data will be required to draw a final conclusion as to the cell of origin in ES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphologic appearance of classic ES is that of a primitive, undifferentiated neoplasm. On hematoxylin and eosin-stained sections, there are monotonous sheets of small round blue cells with hyperchromatic nuclei and scant cytoplasm that is clear because of the presence of abundant glycogen (",
"    <a class=\"graphic graphic_picture graphicRef63471 \" href=\"UTD.htm?12/34/12837\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/44\">",
"     44",
"    </a>",
"    ]. There is usually extensive necrosis with preservation of viable tumor around blood vessels. Nuclear atypia, palisading, and formation of rosettes (where the tumor cells are arranged in a circle about a central fibrillary space, indicative of neural differentiation) or pseudorosettes are typically absent. Invasion of blood vessels can be seen, although the tumors are not characteristically highly vascular. Mitotic figures are rare, and aneuploidy is uncommon on flow cytometry studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atypical ES are usually described as poorly differentiated rather than undifferentiated tumors. They contain larger cells, a greater degree of cellular pleomorphism, and have a higher mitotic rate (generally more than two mitoses per high power field). Spindle cells may be present at the periphery, and these tumor cells invade the adjacent tissue in an infiltrative manner. The cells can be arranged in sheets, or there may be an organoid, lobular, or alveolar architectural pattern. As in the typical ES, evidence of neural differentiation is usually absent.",
"   </p>",
"   <p>",
"    The histopathologic features of a peripheral PNET may resemble the typical undifferentiated ES or atypical ES; however, a neural immunophenotype or evidence of neural differentiation on light microscopic (ie, Flexner-type rosettes or Homer-Wright-type pseudorosettes) or ultrastructural examination is present in about one-half of cases. However, mature neural elements (ie, ganglion cells, nerve fascicles, or a neuropil background) are absent. The neoplastic cells are typically arranged into an organoid, alveolar, or lobular pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologically, the appearance of EFT and PNET tumors is similar to that of other small round blue cell tumors involving bone and soft tissue, including lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, medulloblastoma, dedifferentiated synovial sarcoma, desmoplastic small round cell tumors, and rhabdomyosarcoma. As a group, these tumors often pose difficult diagnostic problems when examined by light microscopy alone. There is little in the routine histologic appearance of an EFT to relate it to a component of normal bone or other tissue from which it might have arisen. Even the determination of bone versus soft tissue origin can be challenging, because EFT involving bone often have an extensive soft tissue component, while extraosseous tumors may invade bone secondarily.",
"   </p>",
"   <p>",
"    Although ES can exhibit a variable degree of neural differentiation, this is usually subtle and often only detected by immunohistochemical staining for markers of neural differentiation (",
"    <a class=\"graphic graphic_table graphicRef78518 \" href=\"UTD.htm?12/39/12925\">",
"     table 2",
"    </a>",
"    ) or by ultrastructural examination. Although no routinely used histochemical or immunohistochemical stain can positively distinguish EFT from other undifferentiated tumors of childhood, the vast majority of EFT express high levels of a cell surface glycoprotein (designated CD99, MIC2 surface antigen or",
"    <span class=\"nowrap\">",
"     p30/32MIC2)",
"    </span>",
"    that is encoded by the CD99 (MIC2X) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/6,46\">",
"     6,46",
"    </a>",
"    ]. The finding of membrane-localized MIC2 expression is a sensitive diagnostic marker for the EFT; however, it lacks specificity since other tumors (eg, rhabdomyosarcoma, which is often in the differential diagnosis) and normal tissues are also immunoreactive with anti-MIC2 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/47\">",
"     47",
"    </a>",
"    ]. Another new potential immunohistochemical marker for EFT is NKX2.2, the protein product of the NKX2-2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/48\">",
"     48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Cytogenetic or molecular genetic studies looking for particular chromosomal translocations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their fusion transcripts are usually required to secure the diagnosis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular diagnostics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remarkable progress has been made in defining and classifying bone and soft tissue tumors on the basis of characteristic chromosomal abnormalities (",
"    <a class=\"graphic graphic_table graphicRef64666 \" href=\"UTD.htm?23/27/23997\">",
"     table 3",
"    </a>",
"    ). Because of their unique shared chromosomal translocations, the EFT have become a model system for nonmorphologic approaches to diagnosis and subclassification using both cytogenetic and molecular techniques. These translocations interrupt specific genes and recombine them to create novel fusion genes, whose products are tumor-specific and present in virtually all cases of an individual tumor category. Thus, their characterization not only yields profound insights into tumor biology, but also holds great promise for diagnostic and therapeutic approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Chromosomal translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     EWSR1 translocations in EFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unique shared pattern of nonrandom chromosomal translocations in the EFT provides one of the most compelling arguments for a common cellular origin. Virtually all cases express one of several different reciprocal translocations, most of which involve breakpoints that are clustered within a single gene locus designated the EWSR1 gene on chromosome 22q12 (",
"    <a class=\"graphic graphic_table graphicRef64666 \" href=\"UTD.htm?23/27/23997\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/7,8,44,49-52\">",
"     7,8,44,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EWSR1 gene normally encodes a widely expressed protein, the EWS protein, whose amino terminal domain shares some homology with eukaryotic RNA polymerase II and whose carboxy terminus (which is replaced by tumor-specific translocations) contains an RNA recognition motif. The EWS protein is a member of a family of highly conserved RNA-binding proteins that are believed to mediate interaction with RNA or single-stranded DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 85 to 90 percent of cases of EFT, a recurrent chromosomal translocation, t(11;22)(q24;q12), fuses the 5' portion of the EWSR1 gene on chromosome 22 to the 3' portion of the FLI1 (friend leukemia integration locus-1) gene on chromosome 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This can be detected using fluorescence in situ hybridization (FISH, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62731 \" href=\"UTD.htm?19/9/19615\">",
"     image 1",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    FLI1 encodes the FLI protein, a member of the ETS family of transcription factors, and is involved in the control of cellular proliferation, development, and tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/55\">",
"     55",
"    </a>",
"    ]. Members of the ETS family are defined by the presence of a highly conserved 85-amino acid domain termed the erythroblastosis virus-transforming sequence (ETS) domain, which mediates specific binding to purine-rich DNA sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/56\">",
"     56",
"    </a>",
"    ]. As a result of the t(11;22), the EWS-FLI fusion protein is expressed. EWS-FLI binds DNA via its FLI-derived ETS domain, and regulates gene expression through the EWS portion of the fusion.",
"   </p>",
"   <p>",
"    In EFT that lack the EWSR1-FLI1 translocation, analogous translocations fuse the EWSR1 gene to other genes of the ETS family (ie, ERG, ETV1, ETV4, or FEV) that have structural homology to FLI1, forming t(21;22)(q22;q12), t(7;22)(p22;q12), t(17;22)(q12;q12), or t(2;22)(q35;q12) translocations, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. The EWSR1-ERG translocation [t(21;22) (q22;q12)] is present in 5 to 10 percent of EFT, while the others are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/42,60-62\">",
"     42,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to EWSR1-based translocations, rare cases of EFT are associated with translocations involving a related gene, FUS (also called TLS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Tumors exhibiting t(16;21)(p11;q24) or t(2;16)(q35;p11) translocations express FUS-ERG or FUS-FEV fusions, respectively. Because EWS and FUS proteins are highly similar, it is believed that FUS-based fusion proteins function similarly to EWS-based fusions. It is important to note that tumors with these translocations can be a source of diagnostic confusion. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular diagnostics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ultimately, specific translocations are important diagnostic features of the EFT, and the protein products of the fusion genes are believed to play an important role in tumor development and biology. A growing body of evidence suggests that these proteins function as transcriptional regulators, although their transcriptional targets are just beginning to be identified. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     EWSR1 translocations in other soft tissue tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although translocations involving the EWSR1 and ETS families of genes are specific for EFT, translocations that involve fusion of the EWSR1 gene to other genes have been observed in many other tumors (eg, clear cell",
"    <span class=\"nowrap\">",
"     sarcoma/malignant",
"    </span>",
"    melanoma of soft parts, myxoid liposarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]). The structure of these resultant fusion genes is analogous to that of EWSR1-FLI1 (ie, all result in the fusion of the 5' portions of the EWSR1 gene or an EWSR1-like gene [eg, the FUS gene] to 3' portions of genes encoding transcription factors). The resulting chimeric proteins presumably have a similar function to the EWS-FLI fusion protein, and it is thought that disruption of transcriptional control contributes to their transforming potential [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite these similarities, with few exceptions, a clinicopathologically distinct tumor entity has been consistently associated with each specific translocation involving a unique class of transcription factors. This tumor specificity is most likely related to cell-specific influences on DNA recombination, chimeric gene expression, and intrinsic proteins that are necessary to complement the action of the chimeric protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other genetic changes in EFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the characteristic reciprocal translocations described above, other numerical and structural chromosomal aberrations are occasionally found in EFT. These include a gain of chromosomes 1q, 2, 8 and 12,losses of 9p and 16q, and the non-reciprocal translocation t(1;16)(q12;q11.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In addition, alterations in known tumor suppressor genes have been identified in some cases. As an example, homozygous deletion of the CDKN2A gene has been described in 18 to 30 percent of cases, and TP53 mutations are detected in 5 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/44,71-73\">",
"     44,71-73",
"    </a>",
"    ]. The biologic implications of these findings are incompletely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EFT-associated translocations result in the production of chimeric proteins that contain the amino-terminal domain of the normal EWS protein fused to the nucleic acid-binding domain of the transcription factor translocation partner. Because of their ubiquitous presence in EFT, they are thought to be intimately connected to the biology of these tumors.",
"   </p>",
"   <p>",
"    The available data suggest two possible mechanisms by which these unique chimeric proteins may contribute to neoplastic transformation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell growth:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chimeric proteins such as EWS-FLI may influence transcription of some of the same genes that are normally regulated by native FLI, but because the chimeric molecule is expressed in either a different temporal or quantitative manner, the downstream targets are deregulated, leading to uncontrolled cellular growth.",
"     </li>",
"     <li>",
"      EWS-FLI may affect target genes that are different from those regulated by the native FLI or EWS proteins. This would explain why the chimeric gene product (EWS-FLI) has transforming properties that are not shared by either the EWS or the FLI wild-type counterparts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some chimeric fusion proteins can act as transcriptional activators, deregulating many genes associated with cell signaling, proliferation, apoptosis, tissue invasion and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/44,74-80\">",
"     44,74-80",
"    </a>",
"    ]. It is likely that this ability to regulate transcriptional activity is associated with their oncogenic potential. EWS-FLI and other chimeric fusion proteins are all capable of transforming cell lines equally well. As an example, expression of either the EWS-FLI or EWS-ERG cDNAs can transform mouse NIH3T3 fibroblasts so that they acquire tumor-like properties (eg, growth in soft agar or in immunodeficient mice) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/74,81\">",
"     74,81",
"    </a>",
"    ]. Notably, EWS-FLI can only transform cells in which insulin like growth factor signaling is intact, and thus there is a potential role for IGF1R inhibitors in the treatment of Ewing sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protein products of the fused genes are also important for maintaining the growth characteristics of EFT cell lines, and emerging data suggest the potential for molecularly targeted therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/85\">",
"     85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Introduction of EWS-FLI RNA antisense molecules or short-interfering or short hairpin RNAs (such as RNAi that mediate RNA-interference) into EFT cells decreases the expression of the EWS-FLI fusion protein and results in growth inhibition",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of oncogenic potential, both in vitro and in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/86-90\">",
"       86-90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Likewise, inhibition of the interaction between EWS-FLI and its cellular binding partner RNA helicase A (RHA) by a small peptide or small molecule inhibitor reduces the growth of EFT orthotopic xenografts [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Truncated ETS domain-binding molecules can act as competitive inhibitors and have a dominant negative effect on cell growth [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/92\">",
"       92",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       p21(WAF1/CIP1),",
"      </span>",
"      which is important in cell cycle regulation, might be one of the direct targets of EWS-FLI, suggesting that this molecule could serve as a target for a molecularly based therapy for EFT [",
"      <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because EWS-FLI and related fusions are thought to function primarily as transcriptional regulators, a number of studies have sought to define the genes that are regulated by the fusion proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/88-90,93,94\">",
"     88-90,93,94",
"    </a>",
"    ]. Some of the EWS-FLI regulated genes are involved in the oncogenic phenotype of Ewing's sarcoma model systems (eg, IGFBP3, CAV1, NKX2.2, NR0B1, GSTM4, and others) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/76,88-90,95,96\">",
"     76,88-90,95,96",
"    </a>",
"    ]. While many of the details are still being worked out, some of these gene targets and associated pathways may prove to be future targets for molecularly-targeted therapy.",
"   </p>",
"   <p>",
"    Another mechanism whereby EWS-FLI may exert a tumorigenic effect is via deregulation of programmed cell death (apoptosis). Cancer is believed, in part, to represent an imbalance between cell growth and cell death. Expression of EWS-FLI1 or EWS-ERG in NIH3T3 cells inhibits the apoptosis that would normally occur with serum deprivation or calcium ionophore treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/97\">",
"     97",
"    </a>",
"    ], while antisense inhibition of EWS-FLI increases susceptibility to chemotherapy-induced apoptosis in ES cell lines. Similarly, reduced expression of EWS-FLI using RNAi-based approaches also resulted in increased apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EWS-ETS fusion proteins also activate human telomerase activity in Ewing tumors through upregulation of the telomerase reverse transcriptase gene expression, probably by acting as a transcriptional coactivator [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/98\">",
"     98",
"    </a>",
"    ]. Telomerase is a ribonucleoprotein enzyme that compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. In normal somatic cells, telomerase activity is usually undetectable, with the exception of some cell types such as hematopoietic cells, hair follicles, intestinal crypt cells, and basal cells of the epidermis. Upregulated telomerase activity in cancer cells correlates with the stabilization of telomere length and cellular immortalization (ie, the ability of the cells to divide indefinitely). This raises the possibility of therapeutic approaches using telomerase inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Molecular diagnostics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The translocations that characterize EFT are exquisitely sensitive and specific tumor markers that have rapidly become the standard for confirming the diagnosis, particularly for cases in which morphology is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/7\">",
"     7",
"    </a>",
"    ]. Standard cytogenetic analysis can reveal a wide variety of chromosomal alterations, but technical constraints and variant translocations may complicate the interpretation, and results are often obtained too late to influence therapy. Molecular assays are more attractive because of the small amount of tissue required, rapid results, and higher sensitivity than traditional cytogenetics.",
"   </p>",
"   <p>",
"    Both the fusion genes and their hybrid transcripts can be identified in tumor cells using molecular genetic approaches. Two techniques are in use, fluorescent in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR), and both are more rapid than cytogenetic analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. In particular, RT-PCR to detect the presence of fusion transcripts in tumor cells has become a mainstay in molecular diagnosis of the EFT. It is extremely sensitive and specific and allows detection of very low levels of tumor cells even among large numbers of normal cells (eg, peripheral blood and bone marrow), providing an extremely robust method for molecular staging and monitoring treatment response (see below).",
"   </p>",
"   <p>",
"    In addition to providing diagnostic support for challenging cases, the identification of specific types of transcripts was at one time thought to have prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/68,103,104\">",
"     68,103,104",
"    </a>",
"    ]. As an example, in one report, the presence of type 1 EWS-FLI transcripts (EWSR1 exon 7 fused with FLI1 exon 6) was associated with a threefold reduction in the risk of developing metastatic disease as compared to non-type 1 transcripts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/103\">",
"     103",
"    </a>",
"    ]. However, more recent independent studies from both the United States and Europe do not support the prognostic value of translocation type [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. It appears that current intensive treatment protocols may have eliminated this apparent difference in prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While molecular tests for EFT-associated translocations are important and often useful adjuncts in the diagnostic work-up, in most cases, molecular pathology laboratories do not test for all of the \"alternate\" translocations (such as those that encode EWS-ERG, EWS-ETV1, EWS-ETV4, EWS-FEV, FUS-ERG, and FUS-FEV). Thus, a \"negative\" FISH or RT-PCR result does not necessarily rule out the diagnosis of EFT. Physicians are strongly advised to consult with their molecular diagnostic laboratory to understand exactly what tests are performed, and the sensitivity and specificity of those tests for EFT. Ultimately, the diagnosis of EFT is based upon a combination of histopathology, special stains, and molecular diagnostics that are interpreted in the context of the patient's clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Molecular staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease stage as determined by standard imaging modalities constitutes the most powerful predictor of prognosis for patients with EFT. However, some patients considered to have localized disease have an unfavorable outcome, even with multimodality therapy, and this may be related to the persistence of minimal metastatic disease that is not detected by traditional methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Minimal disease (ie, circulating ES cells) can be detected in peripheral blood and bone marrow using PCR-based methods in up to 30 percent of patients with apparently localized disease and in approximately 50 percent of those with advanced or relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/107-111\">",
"     107-111",
"    </a>",
"    ]. However, the prognostic significance of this finding, particularly in patients with localized disease, is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/108,110,111\">",
"     108,110,111",
"    </a>",
"    ], and the ultimate contribution of this finding to patient management is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/37/7770/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Further prospective studies using molecular methods to detect the presence of minimal residual disease are needed in order to assess its impact on outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684655\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma and peripheral primitive neuroectodermal tumors (PNET) comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes malignant small-cell tumor of the chest wall (Askin tumor). Because of their similar histologic and immunohistochemical characteristics and shared nonrandom chromosomal translocations, these tumors are considered to be derived from a common cell of origin, although its histogenic origin is debated. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although rare, the EFT represent the second most common primary bone malignancy (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"UTD.htm?41/39/42620\">",
"     table 1",
"    </a>",
"    ) affecting children and adolescents. EFT have not been consistently associated with any familial or congenital syndromes, and specific environmental exposures have not been identified as risk factors. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Morphologically, the appearance of EFT is similar to that of other small round blue cell tumors involving bone and soft tissue, including lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, medulloblastoma, dedifferentiated synovial sarcoma, desmoplastic small round cell tumors, and rhabdomyosarcoma. As a group, these tumors often pose difficult diagnostic problems when examined by light microscopy alone. Cytogenetic or molecular genetic studies looking for particular chromosomal translocations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their fusion transcripts are usually required to secure the diagnosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Molecular diagnostics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Virtually all cases express one of several different reciprocal translocations, most of which involve breakpoints that are clustered within a single gene locus designated the EWSR1 gene on chromosome 22q12 EFT-associated translocations result in the production of chimeric proteins that contain the amino-terminal domain of the normal EWS protein fused to the nucleic acid-binding domain of the transcription factor translocation partner. Because of their ubiquitous presence in EFT, these chimeric proteins are thought to be intimately connected to the biology of these tumors. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'EWSR1 translocations in EFT'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/1\">",
"      Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984; 8:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/2\">",
"      Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer 1975; 36:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/3\">",
"      Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/4\">",
"      Llombart-Bosch A, Lacombe MJ, Contesso G, Peydro-Olaya A. Small round blue cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features. An analysis of five cases with immunohistochemical and electron microscopic support. Cancer 1987; 60:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/5\">",
"      Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/6\">",
"      Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/7\">",
"      Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/8\">",
"      Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/9\">",
"      Llombart-Bosch A, Carda C, Peydro-Olaya A, et al. Soft tissue Ewing's sarcoma. Characterization in established cultures and xenografts with evidence of a neuroectodermic phenotype. Cancer 1990; 66:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/10\">",
"      Thiele CJ. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev 1991; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/11\">",
"      O'Regan S, Diebler MF, Meunier FM, Vyas S. A Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron. J Neurochem 1995; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/12\">",
"      Lawlor ER, Lim JF, Tao W, et al. The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res 1998; 58:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/13\">",
"      Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11:421.",
"     </a>",
"    </li>",
"    <li>",
"     Bleyer A, O&rsquo;Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/15\">",
"      J&uuml;rgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/16\">",
"      Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic Ewing's sarcoma (EWS) and PNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), Adriamycin (Ad), cyclophosphamide (C) and actinomycin (A): A Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) report (abstract). Proc Am Soc Clin Oncol 1994; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/publications/childhood/introduction.pdf (Accessed on May 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/18\">",
"      Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/19\">",
"      Birch JM, Alston RD, Kelsey AM, et al. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. Br J Cancer 2002; 87:1267.",
"     </a>",
"    </li>",
"    <li>",
"     Gurney JG, Swensen AR, Bulterys M. Malignant Bone Tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, Ries LA, Smith MA, Gurney JG, et al (Eds), NCI, SEER Program, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/21\">",
"      Glass AG, Fraumeni JF Jr. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970; 44:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/22\">",
"      Miller RW. Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma. Natl Cancer Inst Monogr 1981; :9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/23\">",
"      Fraumeni JF Jr, Glass AG. Rarity of Ewing's sarcoma among U.S. Negro children. Lancet 1970; 1:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/24\">",
"      Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/25\">",
"      Jawad MU, Cheung MC, Min ES, et al. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009; 115:3526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/26\">",
"      Zucman-Rossi J, Batzer MA, Stoneking M, et al. Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Hum Genet 1997; 99:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/27\">",
"      Postel-Vinay S, V&eacute;ron AS, Tirode F, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012; 44:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/28\">",
"      Hartley AL, Birch JM, Blair V, et al. Cancer incidence in the families of children with Ewing's tumor. J Natl Cancer Inst 1991; 83:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/29\">",
"      Buckley JD, Pendergrass TW, Buckley CM, et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998; 83:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/30\">",
"      McKeen EA, Hanson MR, Mulvihill JJ, Glaubiger DL. Birth defects with Ewing's sarcoma. N Engl J Med 1983; 309:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/31\">",
"      Novakovic B, Goldstein AM, Wexler LH, Tucker MA. Increased risk of neuroectodermal tumors and stomach cancer in relatives of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst 1994; 86:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/32\">",
"      Yamamoto T, Wakabayashi T. Bone tumors among the atomic bomb survivors of Hiroshima and Nagasaki. Acta Pathol Jpn 1969; 19:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/33\">",
"      Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/34\">",
"      Spunt SL, Rodriguez-Galindo C, Fuller CE, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer 2006; 107:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/35\">",
"      Valery PC, Williams G, Sleigh AC, et al. Parental occupation and Ewing's sarcoma: pooled and meta-analysis. Int J Cancer 2005; 115:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/36\">",
"      Cope JU, Tsokos M, Helman LJ, et al. Inguinal hernia in patients with Ewing sarcoma: a clue to etiology. Med Pediatr Oncol 2000; 34:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/37\">",
"      Holly EA, Aston DA, Ahn DK, Kristiansen JJ. Ewing's bone sarcoma, paternal occupational exposure, and other factors. Am J Epidemiol 1992; 135:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/38\">",
"      Winn DM, Li FP, Robison LL, et al. A case-control study of the etiology of Ewing's sarcoma. Cancer Epidemiol Biomarkers Prev 1992; 1:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/39\">",
"      Valery PC, McWhirter W, Sleigh A, et al. A national case-control study of Ewing's sarcoma family of tumours in Australia. Int J Cancer 2003; 105:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/40\">",
"      Lipinski M, Braham K, Philip I, et al. Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res 1987; 47:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/41\">",
"      McKeon C, Thiele CJ, Ross RA, et al. Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res 1988; 48:4307.",
"     </a>",
"    </li>",
"    <li>",
"     Ginsberg, JP, Woo, SY, Hicks, MJ, Horowitz, ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Priniciples and Practice of Pediatric Oncology, 4th ed, Pizzo, PA, Poplack, DG (Eds), Lippincott, Williams and Wilkins, Philadelphia, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/43\">",
"      Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003; 63:3464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/44\">",
"      de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204.",
"     </a>",
"    </li>",
"    <li>",
"     Dorfman H, Czerniak B. Bone Tumors, CV Mosby, St. Louis 1997. p.607.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/46\">",
"      Fellinger EJ, Garin-Chesa P, Triche TJ, et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am J Pathol 1991; 139:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/47\">",
"      Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994; 18:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/48\">",
"      Yoshida A, Sekine S, Tsuta K, et al. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. Am J Surg Pathol 2012; 36:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/49\">",
"      Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/50\">",
"      Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992; 5:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/51\">",
"      Meier VS, K&uuml;hne T, Jundt G, Gudat F. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 1998; 7:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/52\">",
"      Dagher R, Pham TA, Sorbara L, et al. Molecular confirmation of Ewing sarcoma. J Pediatr Hematol Oncol 2001; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/53\">",
"      Ohno T, Ouchida M, Lee L, et al. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994; 9:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/54\">",
"      Burd CG, Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science 1994; 265:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/55\">",
"      Hromas R, Klemsz M. The ETS oncogene family in development, proliferation and neoplasia. Int J Hematol 1994; 59:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/56\">",
"      Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993; 211:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/57\">",
"      Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/58\">",
"      Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/59\">",
"      Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/60\">",
"      Urano F, Umezawa A, Yabe H, et al. Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis. Jpn J Cancer Res 1998; 89:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/61\">",
"      Bell RS, Wunder J, Andrulis I. Molecular alterations in bone and soft-tissue sarcoma. Can J Surg 1999; 42:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/62\">",
"      Obata K, Hiraga H, Nojima T, et al. Molecular characterization of the genomic breakpoint junction in a t(11;22) translocation in Ewing sarcoma. Genes Chromosomes Cancer 1999; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/63\">",
"      Ng TL, O'Sullivan MJ, Pallen CJ, et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn 2007; 9:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/64\">",
"      Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 2003; 63:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/65\">",
"      Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 1993; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/66\">",
"      Panagopoulos I, H&ouml;glund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/67\">",
"      Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/68\">",
"      Hattinger CM, Rumpler S, Strehl S, et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999; 24:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/69\">",
"      Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997; 75:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/70\">",
"      Savola S, Klami A, Tripathi A, et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/71\">",
"      Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/72\">",
"      Kovar H, Jug G, Aryee DN, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/73\">",
"      Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/74\">",
"      May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13:7393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/75\">",
"      Herrero-Mart&iacute;n D, Osuna D, Ord&oacute;&ntilde;ez JL, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 2009; 101:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/76\">",
"      Tirado OM, Mateo-Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006; 66:9937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/77\">",
"      Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20:5747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/78\">",
"      Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993; 53:5859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/79\">",
"      Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/80\">",
"      Kinsey M, Smith R, Iyer AK, et al. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009; 69:9047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/81\">",
"      May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90:5752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/82\">",
"      Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/83\">",
"      Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001; 92:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/84\">",
"      Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/85\">",
"      Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003; 278:15105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/86\">",
"      Tanaka K, Iwakuma T, Harimaya K, et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/87\">",
"      Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/88\">",
"      Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006; 4:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/89\">",
"      Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24:7275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/90\">",
"      Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/91\">",
"      Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/92\">",
"      Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/93\">",
"      Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008; 7:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/94\">",
"      Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009; 4:e5415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/95\">",
"      Luo W, Gangwal K, Sankar S, et al. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009; 28:4126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/96\">",
"      Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 2008; 3:e1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/97\">",
"      Yi H, Fujimura Y, Ouchida M, et al. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997; 14:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/98\">",
"      Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003; 63:8338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/99\">",
"      Diffin F, Porter H, Mott MG, et al. Rapid and specific diagnosis of t(11;22) translocation in paediatric Ewing's sarcoma and primitive neuroectodermal tumours using RNA-PCR. J Clin Pathol 1994; 47:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/100\">",
"      Downing JR, Head DR, Parham DM, et al. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol 1993; 143:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/101\">",
"      Taylor C, Patel K, Jones T, et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation. Br J Cancer 1993; 67:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/102\">",
"      Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diagn Mol Pathol 1995; 4:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/103\">",
"      de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/104\">",
"      Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/105\">",
"      van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/106\">",
"      Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/107\">",
"      Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001; 23:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/108\">",
"      West DC, Grier HE, Swallow MM, et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997; 15:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/109\">",
"      de Alava E, Lozano MD, Pati&ntilde;o A, et al. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol 1998; 7:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/110\">",
"      Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998; 79:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/37/7770/abstract/111\">",
"      Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique. J Clin Oncol 1998; 16:1707.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7742 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7770=[""].join("\n");
var outline_f7_37_7770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H684655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HISTOGENESIS AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EWSR1 translocations in EFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EWSR1 translocations in other soft tissue tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other genetic changes in EFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Molecular diagnostics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Molecular staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H684655\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7742|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/9/19615\" title=\"diagnostic image 1\">",
"      Chromosomal transloc Ewing FISH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7742|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28415\" title=\"figure 1\">",
"      Variable incidence of Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7742|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/34/12837\" title=\"picture 1\">",
"      Histology Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/39/42620\" title=\"table 1\">",
"      Classify primary malignant bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/39/12925\" title=\"table 2\">",
"      Ewing tumor immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/27/23997\" title=\"table 3\">",
"      Selected translocations in sarcomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_37_7771="STDs associated with HPV";
var content_f7_37_7771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sexually transmitted infections seen in conjunction with human papillomavirus infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Herpes simplex (HSV I and II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia trachomatis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria gonorrhoeae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis (Treponema pallidum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molluscum contagiosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Genital ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chancroid (Haemophilus ducreyi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granuloma inguinale (Calymmatobacterium granulomatis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphogranuloma venereum (Chlamydia trachmatis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jha PK, Beral V, Peto J, et al. Lancet 1993; 341:1116.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7771=[""].join("\n");
var outline_f7_37_7771=null;
var title_f7_37_7772="Definition of hepatic encephal";
var content_f7_37_7772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consensus statement on the definition of hepatic encephalopathy by the International Working Party at the 11th World Congress of Gastroenterology (Vienna 1998)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       A multiaxial definition of hepatic encephalopathy defines both the type of hepatic abnormality and duration/characteristics of neurological manifestations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       The type of hepatic abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Encephalopathy associated with acute liver failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Encephalopathy associated with portal-systemic bypass without hepatocellular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Encephalopathy associated with cirrhosis and portal hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Duration/characteristics of neurological manifestations in chronic liver disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Episodic hepatic encephalopathy (precipitated or spontaneous): This term describes the development of clinically overt neuropsychiatric symptoms in patients with cirrhosis. In the DMS-IV classification system, this corresponds to a \"Delirium due to a General Medical Condition (code 293.0) defined as \"a disturbance of consciousness that is accompanied by a change in cognition that cannot be better accounted for by a preexisting or evolving dementia,\" that develops over a short period of time and fluctuates in severity. The term \"spontaneous\" requires the exclusion of precipitating factors (GI hemorrhage, uremia, use of psychoactive medication, dietary indiscretion, infection, constipation and fluid/electrolyte disturbance). Episodic hepatic encephalopathy may subside without recurrence or patients may develop several attacks (recurrent hepatic encephalopathy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Persistent hepatic encephalopathy (mild or severe): It includes cognitive deficits that impact negatively on social and occupational functioning and persistent non-cognitive abnormalities (such as extrapyramidal alterations or sleep disturbances)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Minimal hepatic encephalopathy (alternative term: Subclinical encephalopathy [SHE]): The widespread use of the term \"subclinical\" has potential misleading consequences and should therefore be replaced by \"minimal\".",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7772=[""].join("\n");
var outline_f7_37_7772=null;
var title_f7_37_7773="Minor RBC antibodies pregnancy2";
var content_f7_37_7773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minor red blood cell antibodies associated with hemolytic disease of the newborn",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific antigens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity of hemolytic disease of the newborn (HDN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Public antigens",
"       </td>",
"       <td>",
"        Yt(a)",
"       </td>",
"       <td>",
"        Moderate to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yt(b)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lan",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        En(a)",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ge",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jr(a)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Co(a)",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Co(a-b-)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"26\">",
"        Private antigens",
"       </td>",
"       <td>",
"        Batty",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Becker",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berrens",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biles",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ch/RG",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cromer",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dombrock",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evans",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gerbich",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonzales",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heibel",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hunt",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indian",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jobbins",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knops",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LW",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radin",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rm",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scianna",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ven",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wright(a)",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wright(b)",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        XK",
"       </td>",
"       <td>",
"        Not a cause of HDN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zd",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Weinstein L. Clin Obstet Gynecol 1982; 25:327 and Reid ME, Toy PTCY. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia, 1998, p. 1768.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7773=[""].join("\n");
var outline_f7_37_7773=null;
var title_f7_37_7774="Zoonoses";
var content_f7_37_7774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infections associated with animal exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Animal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saliva",
"       </td>",
"       <td>",
"        <em>",
"         Bartonella henselae",
"        </em>",
"        , tularemia,",
"        <em>",
"         Pasteurella multocida",
"        </em>",
"        , rabies,",
"        <em>",
"         Capnocytophaga",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feces",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        ,",
"        <em>",
"         Cryptosporidium",
"        </em>",
"        ,",
"        <em>",
"         Giardia lamblia",
"        </em>",
"        ,",
"        <em>",
"         Toxoplasma gondii",
"        </em>",
"        ,",
"        <em>",
"         Toxocara cati",
"        </em>",
"        ,",
"        <em>",
"         Echinococcus",
"        </em>",
"        ,",
"        <em>",
"         Ancylostoma braziliense",
"        </em>",
"        ,",
"        <em>",
"         Dipylidium caninum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine",
"       </td>",
"       <td>",
"        Leptospirosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tick or flea bites",
"       </td>",
"       <td>",
"        Lyme disease, ehrlichiosis, babesiosis,",
"        <em>",
"         Yersinia pestis",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Direct contact",
"       </td>",
"       <td>",
"        <em>",
"         Sporothrix schenckii",
"        </em>",
"        ,",
"        <em>",
"         Microsporum canis",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Dogs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saliva",
"       </td>",
"       <td>",
"        Rabies,",
"        <em>",
"         Brucella",
"        </em>",
"        ,",
"        <em>",
"         Pasteurella multocida",
"        </em>",
"        ,",
"        <em>",
"         Capnocytophaga",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feces",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        ,",
"        <em>",
"         Giardia lamblia",
"        </em>",
"        ,",
"        <em>",
"         Toxocara canis",
"        </em>",
"        ,",
"        <em>",
"         Ancylostoma caninum",
"        </em>",
"        ,",
"        <em>",
"         Echinococcus",
"        </em>",
"        ,",
"        <em>",
"         Dipylidium caninum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine",
"       </td>",
"       <td>",
"        Leptospirosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Insect bites (fleas, ticks, mosquitoes, sand flies)",
"       </td>",
"       <td>",
"        Tularemia, Lyme disease, Rocky Mountain spotted fever, ehrlichiosis, babesiosis,",
"        <em>",
"         Yersinia pestis",
"        </em>",
"        ,",
"        <em>",
"         Dirofilaria immitis",
"        </em>",
"        ,",
"        <em>",
"         Leishmania",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Direct contact",
"       </td>",
"       <td>",
"        Methicillin-resistant",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Horses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saliva",
"       </td>",
"       <td>",
"        Rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feces",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        ,",
"        <em>",
"         Cryptosporidium",
"        </em>",
"        ,",
"        <em>",
"         Giardia lamblia",
"        </em>",
"        ,",
"        <em>",
"         Clostridium difficile",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mosquito bites",
"       </td>",
"       <td>",
"        Equine encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aerosol",
"       </td>",
"       <td>",
"        <em>",
"         Brucella",
"        </em>",
"        ,",
"        <em>",
"         Rhodococcus equi",
"        </em>",
"        ,",
"        <em>",
"         Coxiella burnetii",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rabbits",
"        </strong>",
"        (domestic or wild)",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        , tularemia,",
"        <em>",
"         Yersinia",
"        </em>",
"        ,",
"        <em>",
"         Cryptosporidium",
"        </em>",
"        ,",
"        <em>",
"         Trichophyton",
"        </em>",
"        ,",
"        <em>",
"         Pasteurella multocida",
"        </em>",
"        , rabies, babesiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pet rodents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saliva",
"       </td>",
"       <td>",
"        Tularemia, rat bite fever, rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feces",
"       </td>",
"       <td>",
"        Salmonellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Direct contact or aerosol",
"       </td>",
"       <td>",
"        Lymphocytic choriomeningitis virus, monkeypox,",
"        <em>",
"         Trichophyton",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Wild rodents",
"        </strong>",
"       </td>",
"       <td>",
"        Hantavirus, tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bird feces",
"        </strong>",
"       </td>",
"       <td>",
"        Psittacosis,",
"        <em>",
"         Cryptococcus",
"        </em>",
"        , Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Wild and pet birds",
"        </strong>",
"       </td>",
"       <td>",
"        Avian influenza, West Nile virus,",
"        <em>",
"         Chlamydophila",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fish",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Mycobacterium marinum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pet reptiles",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Edwardsiella tarda",
"        </em>",
"        ,",
"        <em>",
"         Plesiomonas",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Wild reptiles",
"        </strong>",
"       </td>",
"       <td>",
"        Pentastomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ferrets",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        , cryptosporidiosis, toxocariasis, tuberculosis, leptospirosis, listeriosis, influenza,",
"        <em>",
"         Giardia",
"        </em>",
"        ,",
"        <em>",
"         Mycobacterium microti",
"        </em>",
"        , rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Flying squirrels",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Toxoplasma gondii",
"        </em>",
"        , Staphylococci,",
"        <em>",
"         Rickettsia prowazekii",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Monkeys",
"        </strong>",
"       </td>",
"       <td>",
"        B-virus (Cercopithecine herpesvirus 1) infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cattle, sheep, goats",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Escherichia coli",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter",
"        </em>",
"        ,",
"        <em>",
"         Salmonella",
"        </em>",
"        ,",
"        <em>",
"         Cryptosporidium",
"        </em>",
"        ,",
"        <em>",
"         Brucella",
"        </em>",
"        ,",
"        <em>",
"         Coxiella burnetii",
"        </em>",
"        , tularemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7774=[""].join("\n");
var outline_f7_37_7774=null;
var title_f7_37_7775="Gram stain urine 4 with answer";
var content_f7_37_7775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candiduria: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of unspun urine (x1000) shows Gram positive budding yeasts and large pseudohyphae. Candida albicans grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_37_7775=[""].join("\n");
var outline_f7_37_7775=null;
